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IMPROVING RATIONAL DRUG DESIGN BY INCORPORATING NOVEL 
BIOPHYSICAL INSIGHT 
Matthew Patrick Baumgartner, Ph.D. 
University of Pittsburgh, 2016 
 
Computer-aided drug design is a valuable and effective complement to conventional experimental 
drug discovery methods. In this thesis, we will discuss our contributions to advancing a number of 
outstanding challenges in computational drug discovery: understanding protein flexibility and 
dynamics, the role of water in small molecule binding and using and understanding large amounts 
of data. First, we describe the molecular steps involved in the induced-fit binding mechanism of 
p53 and MDM2. We use molecular dynamics simulations to understand the key chemistry 
responsible for the dynamic transition between the apo and holo structures of MDM2. This 
chemistry involves not only the indole side chain of the anchor residue of p53, Trp23, but 
surprisingly, the beta-carbon as well. We demonstrate that this chemistry plays a key role in 
opening the binding site by coordinating the position and orientation of MDM2 residues, Val93 
and His96, through a previously undescribed transition state. We confirm these findings by 
observing that this chemistry is preserved in all available inhibitor-bound MDM2 co-crystal 
structures. Second, we discuss our advances in understanding water molecules in ligand binding 
sites by data mining the structural information of water molecules found in X-ray crystal structures. 
We examine a large set of paired bound and unbound proteins and compare the water molecules 
found in the binding site of the unbound structure to the functional groups on the ligand that 
displace them upon binding. We identify a number of generalized functional groups that are 
associated with characteristic clusters of water molecules. This information has been utilized in 
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several successful and ongoing virtual screens. Third, we discuss software that we have developed 
that allows for very efficient exploration and selection of virtual screening results. Implemented 
as a PyMOL plugin, ClusterMols clusters compounds based on a user-defined level of chemical 
similarity. The software also provides advanced visualization tools and a number of controls for 
quickly navigating and selecting compounds of interest, as well as the ability to check online for 
available vendors. Finally, we present several published examples of modeling protein-lipid and 
protein-small molecules interactions for a number of important targets including ABL, c-Src and 
5-LOX.  
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1.0 INTRODUCTION 
Rational drug design is the process though which drugs are designed with the intent of targeting a 
specific protein target which is known to be relevant for a disease of interest[1]. Structure-based 
drug design is one facet of rational drug design that uses computational methods to leverage 
information of the 3D structure of proteins to discover potential inhibitors[2-4]. The primary goal 
of structure-based drug design is to computationally predict whether a given compound will bind 
to a protein target before it is tested experimentally, which can be quite costly[5]. Virtual screening 
methods have successfully been used in conjunction with experimental techniques for a number 
of years[6-9]. Successful virtual screening methods require understanding of the protein target at 
a number of levels including: protein flexibility, the role of water in ligand binding and using and 
understanding large amounts of data. In this dissertation we will discuss our advances in these 
areas.  
1.1 OUTLINE 
This dissertation is organized as follows: 
In Chapter 2.0, we present the atomistic induced-fit binding mechanism of MDM2 and 
p53, the so called “guardian of the genome”[10]. We show that the α and β carbons of the Trp23 
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anchor residue of p53 are responsible for opening the binding cleft through hydrophobic 
interactions with MDM2 residues Val93 and His96.  
In Chapter 3.0, we discuss our work in using data mining techniques to identify clusters of 
crystallographic water molecules that are commonly displaced by ligand functional groups. By 
examining pairs of apo and ligand-bound structures we have identified a number of water 
cluster/functional group associations that have useful applications in a fragment-based virtual 
screening approach. 
In Chapter 4.0, we present a virtual screening tool call ClusterMols. Implemented as a 
PyMOL plugin, ClusterMols automatically clusters virtual screening results based on chemical 
similarity. These clusters are visualized in PyMOL in a user-friendly fashion such that the user can 
navigate compounds on the scaffold level using keyboard controls. Compounds of interest can be 
extracted and saved for later analysis or checked for commercial availability with the press of a 
button. 
In Chapter 5.0, we give the main conclusions of the thesis and discuss possible future 
research directions. 
In Appendix A, a number of applications of theory to real-world problems in the realm of 
modeling protein-small molecule interactions will be presented.  
In Appendix B, we will present an application of modeling protein-lipid interactions. 
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2.0 CRITICAL STEPS IN THE INDUCED-FIT BINDING MECHANISM OF MDM2-
P53 
 
2.1 INTRODUCTION 
The tumor suppressor p53, which is transcribed by the TP53 gene, has been shown to play a key 
role in most human cancers[11-19]. Often called the “guardian of the genome,” p53 is a 
transcription factor that plays a central role in the response to cellular stress[10, 20]. It is 
responsible for a number of important cellular functions including cell cycle regulation, DNA 
repair and the initiation of apoptosis[21]. In healthy cells, the transcription factor p53 is activated 
upon cellular stress, leading to cellular arrest or apoptosis[22]. During low stress, it is 
downregulated by mouse double minute 2 (MDM2)[10, 20-22]. MDM2 regulates cellular p53 
activity through two pathways: transcriptional inhibition of the TP53 gene and increased 
ubiquitination and degradation of the p53 protein via direct binding of its N-terminal domain[20]. 
In some cancer cells, p53 activity is often lost either through mutation or inactivation of the TP53 
gene[13]. In other cancer cells with wild-type p53, overexpression of MDM2 can block p53 
function and promote tumor growth, making MDM2 a promising therapeutic target[22, 23]. 
Prior to complexation, the MDM2 binding domain on the N-terminus of p53 is 
unstructured[11]. The MDM2 binding motif of p53 primarily consists of three hydrophobic 
residues (Phe19, Trp23 and Leu26; Figure 2.1B) that become deeply buried upon binding. When 
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MDM2 is in the unbound (apo) state, the binding sites for these p53 residues are mostly occluded 
and direct complexation is not possible. Due to this occlusion, some amount of structural 
rearrangement of MDM2 is required for binding of p53[16, 17, 24-27]. Previous work has 
described the induced-fit binding process of MDM2, but none have determined the critical 
interactions for opening the binding cleft[16, 17]. 
Previous research has suggested that many protein-protein interactions (PPIs) may involve 
the burying of an anchor residue: an exterior residue of the ligand that serves as a structural marker 
and facilitates recognition by sampling its bound state configuration even before encountering the 
binding partner[28]. Docking of this anchor residue marks the formation of the encounter complex 
and provides time for additional triggering interactions to take place that induce structural 
transitions of the receptor and ligand towards the high-affinity complex. Previous work has 
identified Trp23 of p53 to be an anchor residue when binding to MDM2[29]. 
In this work, we use molecular dynamics (MD) simulations to identify the specific 
molecular interactions required to open the p53 binding pocket of MDM2. This approach provides 
direct insight into molecular recognition and how structural flexibility and the induced-fit binding 
process are exploited to regulate critical cellular processes. To determine the role of the anchor 
residue in modifying the structure of the receptor interface, we simulated MDM2 with different 
small fragments of the Trp23 anchor residue of p53. Trajectories were then analyzed to identify 
the receptor interface deformations that occur upon complexation, particularly those that lead to 
the formation of the binding cavity. These findings were verified via MD simulations of the PPI 
and inhibitor-bound crystal structures. 
We were able to map distinct MDM2 interface deformations to specific ligand motifs by 
iteratively modifying peptide ligand mimics and analyzing receptor interface dynamics in the 
  5 
resulting trajectories. We calculated equilibrium free energy differences between the open and 
closed receptor interface states for the apo and fragment-bound receptors, allowing us to quantify 
the energetic contribution of each atom to opening the binding pocket.  
We demonstrate that the binding of the two-ringed indole of Trp23 alone is insufficient for 
opening the binding cavity, specifically the binding pockets for Phe19 and Leu26. However, upon 
the addition of the beta carbon (CB) and, to a greater extent, the alpha carbon (CA) of Trp23, the 
binding cleft is stabilized in the open state, allowing for binding of p53 residues Phe19 and Leu26, 
which initiate the formation of the high-affinity bound-state complex. In particular, we 
demonstrate that the CB and CA atoms are responsible for the induced-fit binding process by 
coordinating the position and orientation of MDM2 residue Val93 (and thereby sheets β3 and β4 
and helix α4; Figure 2.1B), which opens the Phe19 and Leu26 binding sites. Additionally, we 
show that the CB and CA atoms shift the side chain of His96 on helix α4 to an open state observed 
in the apo NMR structures allowing for opening of the binding pocket prior to the formation of 
the final high-affinity bound state. A post hoc examination of publicly available inhibitor-bound 
MDM2 crystal structures indicate that almost all of the known inhibitors share the same features 
as the CB and CA atoms of Trp23.  
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Figure 2.1 Simulated structures of MDM2 and cross pocket distances. Sections of Trp23 from p53 
used in the Ind, IndCB and IndCA simulations for MDM2. B) PPI crystal structure (PDB ID: 
1YCR) of MDM2 (blue cartoon) and the interface residues of p53 (orange lines) overlaid on apo 
NMR structure (PDB ID: 1Z1M) of MDM2 (white cartoon). Three residues on the interface are 
shown as sticks to highlight the closed and open states of the pocket. C) RMSD of backbone atoms 
of binding pocket residues to the bound state for the simulations starting from the first NMR 
structure and fit distributions. The lines are colored (here and throughout) as follows: apo: blue, 
Ind: red, IndCB: green, IndCA: yellow, NMR: grey. The horizontal dashed lines indicate the 
minimum and maximum RMSDs of the 24 NMR structures. Plots of the simulations starting from 
the second and third NMR structures are shown in Figure 2.9. D) Illustration of the distances used 
to measure pocket opening and closing. The PPI bound structure (blue) is shown with the interface 
residues of p53 (orange). The distances (dashed yellow lines) calculated are between of the alpha 
carbons of His96 and Leu54 (Leu pocket; top), His73 and Ile61 (Trp pocket; middle) and Val93 
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and Leu57 (Phe pocket; bottom). The distances measured for the E) Leu, F) Trp and G) Phe pockets 
calculated from the simulations of the first NMR structure. The horizontal dashed lines indicate 
the distances in the bound structure and the minimum and maximum distances observed in the 24 
unbound NMR structures. Plots of the simulations starting from the second and third NMR 
structures are shown in Figure 2.10.  
2.2 METHODS 
 
To determine the atomistic mechanism of opening the binding site, we ran MD simulations using 
the first three NMR structures of the apo form of human MDM2 (PDB ID: 1Z1M[30]). The 
disordered N- and C-termini were discarded and only residues 25 to 109 were simulated[21, 31], 
which are the residues that were crystallized in the bound PPI structure that we used as a reference 
(PDB 1YCR[32]). We conducted simulations under four different conditions: one apo receptor 
simulation with no ligand and three simulations (Ind, IndCB, and IndCA) that included portions of 
the Trp23 indole anchor (Figure 2.1A). Ind includes the double ringed indole portion of the 
tryptophan side chain alone, IndCB includes the atoms from Ind as well as the CB atom and IndCA 
contains the atoms from Ind in addition to both the CB and CA atoms. In a number of the apo 
NMR structures (PDB ID: 1Z1M), the p53 anchor (Trp23) binding site is partially closed and thus 
we could not directly insert the indole into the binding site without significant clashes (Figure 
2.1B). For each of the bound simulations (Ind, IndCB and IndCA), we first ran a short (5 ns) 
simulation wherein we manually position the indole “above” the binding site and then use a Steered 
Molecular Dynamics (SMD) simulation to bring the indole into the binding site using distance 
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constraint between atom CZ2 of the indole and the beta carbon of Leu57. At the end of this 
simulation, the indole is located approximately in the bound position. We then restarted the 
simulation from the final frame (maintaining the velocities) to initiate a 200 ns simulation with 
position restraints on the heavy atoms of the indole and the backbone atoms N, C and O of helix 
α2 (residues 52 to 62, Figure 2.1B) with force constant of 10.0 kcal/(mol•Å2). The indole was 
restrained to its position in 1YCR relative to helix α2. The apo simulation was simulated 
unconstrained for 200 ns.  
2.2.1 Simulation of Inhibitor-Bound Structures 
MD simulations of several inhibitor-bound structure of MDM2 inhibitors were performed as 
described above. Additionally, the backbone atoms of MDM2 and the heavy-atoms of the 
inhibitors were held in place with position restraints. 
 
2.2.2 Simulation Parameters 
MD simulations were carried out using the pmemd.cuda[33] module of AMBER14[34]. The force 
fields AMBER ff12SB and gaff[35] (general amber force fields) were used. Ligand fragments 
were parameterized using antechamber[36] at a neutral charge and default parameters. An 
octahedral TIP3P water box was constructed with 12 Å from the edge of the box to the solute and 
the total system charge was neutralized by adding Cl- ions. The non-bonded cutoff was specified 
at 10 Å.  In the first energy minimization run, the solute was held fixed and the solvent was relaxed 
through 500 cycles of steepest descent followed by 500 cycles of conjugate gradient minimization. 
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Subsequently, the system was minimized while restraining the protein backbone atoms through 
2,000 cycles of steepest descent followed by 3,000 cycles of conjugate gradient minimization. 
Following the energy minimization, a 50,000 step MD equilibration simulation was used to raise 
the system temperature to 300 K while holding the solute fixed with weak (10.0 kcal/(mol•Å2)) 
restraints. Bonds involving hydrogens were held at a fixed length and the integration step was set 
to 2 fs. For the Steered Molecular Dynamics (SMD) simulations, we brought the indole into the 
pocket using a sliding distance constraint starting at ~11 Å and ending at 4.0 Å, the distance 
observed in the PPI crystal structure (PDB ID: 1YCR). The 200 ns MD simulations were held at 
300 K under constant pressure with the constraints as listed above for each system. For all analyses, 
the first 20 ns of the production simulations were discarded as system equilibration. To validate 
the importance of MDM2 Val93 coordination in binding site opening, we ran simulations of the 
apo structure with four distance constraints on the α-carbon of Val93. The restraints were between 
the α-carbon of Val93 and the α-carbons of Met50, Leu57, Gly58 and Ile61, respectively (Figure 
2.8). The distance constraints were set to +/- 0.1 Å of those measured in the bound structure (PDB 
ID: 1YCR). The distance restraint weights were set to 10.0 kcal/(mol•Å2). 
2.2.3  Analysis Tools 
The PyMOL Molecular Graphics System v1.7.4.0 was used for structure preparation and 
analysis[37]. Trajectories were also analyzed using VMD v1.9.2[38]. The LOOS (Lightweight 
Object-Oriented Structure) library v2.1.3[39] was used for root-mean-square deviation (RMSD), 
distance and dihedral calculations.  
The atom overlaps of the p53 binding interface residues were calculated using a custom 
Python script that iterates through the frames of an aligned MD simulation and counts the number 
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of frames where the receptor atoms overlap with these atoms. An atom is considered to be 
overlapped if there is a receptor atom center within its the van der Waals radii[40]. The percent of 
simulation frames for which an atom is overlapped by at least one protein atom is reported as a 
measure of binding pocket occlusion. This script is provided in APPENDIX C. 
2.2.4 Preparation of Known Inhibitor Structures 
We examined the 32 currently available inhibitor-bound structures of MDM2 from the Protein 
Data Bank listed in Table 2.4. We excluded several structures from our analysis, due to the non-
canonical nature of their binding (indicated in the table). These ligands bind to MDM2 such that 
the Leu pocket is vacant. For each co-crystal structure, we first superimposed it on the PPI structure 
(PDB ID: 1YCR) by aligning to helix α2. For structures with more than one ligand, the ligand in 
the PPI binding site was retained and the rest discarded. While there are many more known 
inhibitors of MDM2 and p53[12], we limited ourselves to those that have been co-crystallized in 
order to make direct structural comparisons of the binding mode.  
2.3  RESULTS 
Here we show the molecular binding mechanism of the MDM2-p53 complex. We ran MD 
simulations with different portions of the Trp23 anchor residue from p53 (see Figure 2.1A), Ind 
(indole alone), IndCB (indole + CB), IndCA (indole + CB + CA), as well the apo structure for 
comparison. We then measured the effects of the residue fragments on the MDM2 interface 
structure. 
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2.3.1 RMSD Calculations 
We computed the backbone RMSD of the MDM2 residues in the binding pocket defined as the 
MDM2 residues within 6 Å of the p53 binding residues in the bound structure (PDB ID: 1YCR). 
The simulation results (Figure 2.1C) show that the apo simulation does not closely sample the 
bound state, open-pocket configuration. The Ind simulation is very similar to the apo simulation 
in that the MDM2 structure does not resemble the bound state. In the IndCB simulation we can 
observed that the CB atom is the critical factor in binding-site opening as when it is added to the 
indole, we see that the pocket adopts the open configuration; however, it does not fully stabilize 
the native p53-bound open state. Finally, when we add the CA atom as in the IndCA simulation, the 
simulations adopt a near native state for the duration of the simulation. These observations are 
qualitatively consistent with the simulations started from the second and third NMR structures 
(Figure 2.9).  
2.3.2 Binding Pocket Distance Measurements 
To more directly quantify the extent of opening or closing of the p53 binding site, we measured 
the distance across the binding pocket at the locations of the three p53 interface residues (Phe19, 
Trp23, Leu26). For each simulation, we measured the distances between the α-carbons of three 
pairs of the MDM2 atoms, each pair is representative of the openness of one of the p53 interface 
residue binding sites (Phe pocket: His73-Ile61, Trp pocket: Val93-Leu57, and Leu pocket: His96-
Leu54) shown in Figure 2.1D. As these are measurements of backbone-backbone distances, they 
are designed to capture larger movements of the β-sheets and α-helices of the binding interface as 
opposed to smaller side chain movements. The measurements for the simulations of the first NMR 
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structure are shown in Figure 2.1E-G and for the simulations of the second and third NMR 
structure are shown in Figure 2.10.  
For all three measured distances, those measured in the apo simulation generally fall within 
the range of the NMR structures. The Ind simulation measurements also generally fall into the 
range of the NMR structures, with the exception of the distance across the Trp pocket (Figure 2.1F) 
where the presence of the indole in the simulation stabilizes the central pocket in the open state, 
although it is not sufficient to open the other two pockets. The IndCB simulation is able to stabilize 
the bound state, however when the CA atom is added in the IndCA simulation, the pocket stays 
open with longer dwell times. This indicates that the CB atom and to a greater extent the CA atom 
are responsible for opening the Phe19 and Leu26 binding pockets. In these simulations, the Leu26 
binding site does not achieve the fully open state ("Bound" line in Figure 2.1E), indicating that the 
anchor residue (with CB and CA) is able to partially open the pocket, but further induced fit 
rearrangements will be necessary to achieve the bound-state high-affinity complex, the nature of 
which is beyond the scope of this paper.  
2.3.3 Free Energy Calculations 
By measuring the number of frames that are in the “open” and “closed” state of the pocket, we are 
able to calculate the free energy required to open the binding pocket of MDM2. To calculate the 
free energy difference between the “open” and “closed” pocket in the simulations we used the 
following equation.  
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In each frame, we measured the distance across each pocket (Figure 2.1E-G) to determine 
whether the pocket is in the “open” or “closed” state, based on whether the distance across each 
pocket is above or below a critical threshold, defined for each pocket as the maximum distance 
observed in the 24 apo NMR structures (“NMR max” lines in Figure 2.1E-G). A pocket is 
considered to be in the “open” state if the cross-pocket distance is larger the maximum cross-
pocket distance in the apo NMR ensemble. For all three pockets, the , which is a measurement 
of the energy required to open the pocket, decreases with increasing indole group size (apo →  Ind 
→  IndCB →  IndCA), indicating that the open pocket is being stabilized (Table 2.1). 
 
Table 2.1 Free energy difference between open and closed binding pockets. Values shown are the 
average and standard deviation of the simulations of the first three NMR structures and represent 
. More negative values indicate stabilization of the open pocket. 
 Phe Trp Leu 
apo 0.16 ± 1.41 2.97 ± 4.30 1.68 ± 1.70 
Ind -1.84 ± 2.21 -2.49 ± 1.49 0.04 ± 2.65 
IndCB -2.57 ± 0.74 -3.80 ± 1.25 -0.99 ± 1.82 
IndCA -3.77 ± 1.23 -3.32 ± 2.14 -1.07 ± 1.48 
 
2.3.4 Residue Overlaps 
In order to further quantify the opening of the MDM2 pocket, we computed the fractional overlap 
of the native p53 interface residues with the receptor if they had been in their bound-state positions 
throughout the simulations. Figure 2.2 reports the average fractional overlap from the simulations 
starting from the first three NMR structures. The interaction residues become less overlapped as 
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the size of the indole in the simulation is increased (apo →  Ind →  IndCB →  IndCA). The apo 
simulations show a high degree of overlap and are in general agreement with the overlap produced 
from the 24 apo NMR structures (Figure 2.1F). Likewise, the Ind simulations show high overlap 
on the Phe19 and Leu26 residues. For the Ind simulations (as well as the IndCB and IndCA 
simulations) the presence of the indole in the simulation precludes overlaps with the Trp. The IndCB 
simulations and to a greater extent the IndCA simulations open up both sides of the pocket, as 
evidenced by the decreased amount of clashing observed. 
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Figure 2.2 Fractional overlap of p53 interface residues under different simulation conditions. 
Values are averaged from simulations starting from the first three unbound MDM2 NMR 
structures. Shown are A) apo, B) Ind, C) IndCB, D) IndCA, E) Val93 simulations, F) average of all 
NMR structures. Green colors indicate little or no overlap and red colors indicate high degree of 
overlap. In all overlap plots, average overlap values under 10% are not shown for clarity. 
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All these data show that in the apo simulations, the binding site is occluded and full 
complexation of p53 is not possible. The initiation of binding by the indole of the Trp23 anchor is 
modeled in the Ind simulations. While the presence of the isolated indole group opens the Trp23 
binding pocket, it is not sufficient to open the Phe19 and Leu26 binding sites. It is only when we 
introduce the beta carbon of the Trp23 in the IndCB simulations that the Phe19 and Leu26 pockets 
start to open. The full binding site opens in the IndCB simulations, but it is not fully stabilized in 
the open configuration. The addition of the alpha carbon in the IndCA simulations leads to full 
stabilization the open pocket. The opening of the binding site allows for complexation of the Phe19 
and Leu26 residues, which will lead to further rearrangements as the two proteins form the high-
affinity complex. 
2.3.5 Val93 Rotamer Analysis 
A visual inspection of the simulations indicated that Val93 and His96 often occlude the Trp23 and 
Leu26 binding sites in the apo simulations. This indicates that their dynamics may play important 
roles in opening the binding site in the presence of the CB and CA atoms. To validate these 
observations we first conducted an analysis of the rotamers of the Val70 side chain of MDM2 in 
the PPI crystal and in the NMR structures, which revealed three dominant rotamer states, the PPI 
state and two rotamers that each represent about half of the NMR structures (Figure 2.3B-D and 
Figure 2.11A). We examined the rotamers of Val93 in the MD simulations and found that in the 
IndCB and IndCA simulations the valine is in the bound-state to a much higher degree than in the 
apo and Ind simulations (Figure 2.3A, Table 2.1). The results that we observed in the simulations 
of the first NMR structure shown in Figure 2.3 are consistent with the replicated simulations of 
the second and third NMR structures shown in Figure 2.12.  This indicates that the CB and CA 
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atoms of Trp23 play an important role in controlling the orientation of the Val93 side chain at the 
binding interface. 
 
Figure 2.3 Rotational coordination of MDM2 residue Val93 A) Dihedral angle of Val93 side chain 
in the simulations starting from the first NMR structure. The average dihedral angle of the two 
dominant unbound rotamer states and the rotamer angle of the bound state are shown as dashed 
grey lines. The shaded area indicates ±15˚ of the bound state rotamer. Lines are colored as follows: 
apo: blue, Ind: red, IndCB: green, IndCA: yellow. Corresponding plots for the simulations starting 
from the second and third NMR structure are shown in Figure 2.12. The rotamers of Val93 in the 
B) NMR rot1, C) bound and D) NMR rot2 positions. 
 
 
 
 
α4 α4 α4 
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Table 2.2 Percent of frames within 15 degrees of the bound state rotamer of Val93 (-51˚) 
 NMR 1 NMR 2 NMR 3 Average 
apo 21.4 43.0 24.1 29.5 
Ind 74.7 31.9 55.0 53.9 
IndCB 72.4 72.1 60.3 68.3 
IndCA 99.0 94.0 90.7 94.6 
 
2.3.6 Val93 Position and Orientation 
An examination of the simulations indicates that the CB and CA atoms in the IndCB and IndCA 
simulations also help to coordinate the position of Val93 (Figure 2.1F, Figure 2.3A). We 
hypothesize that pushing Val93 back into the “open” state will also push on helix α4 and sheets 
β3 and β4 thus opening the binding sites for Phe19 and Leu26.  
To computationally validate this hypothesis, we conducted another set of ligand-free 
simulations starting from the closed-pocket, apo state. We used harmonic distance restraints to 
move and hold the position of Val93 in its bound-like position. The purpose of these simulations 
was to determine if the coordination of Val93 is sufficient to open the Phe19 and Leu26 binding 
pockets. The average overlap of the p53 interface residues in the coordinated Val93 simulations 
(Figure 2.2E) and the IndCB simulations (Figure 2.2D), are comparable, although δ-carbons of 
Leu26 in the Val93 simulation has a higher degree of overlap. This may be due to coordination of 
the indole to residues deeper in the binding pocket that is absent in the Val93 simulations. The 
Val93 simulations indicate that the indole + CB help to coordinate Val93, but are not enough to 
fully open the Phe19 and Leu26 pockets. A visual examination of the simulations and the NMR 
structures (Figure 2.1B) indicates that the major contribution to overlapping the Leu pocket comes 
from His96. The simulation data suggests that the added size of the alpha carbon in the IndCA 
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simulations helps to coordinate His96 and guide it, and the rest of helix α4, into the bound 
configuration.  
2.3.7 His96 Rotomer Analysis 
We examined His96 throughout the simulations and concluded that its position and rotamer 
relative to the bound state are important in the opening of the Leu binding pocket. An analysis of 
the rotamers of His96 present in the available crystallographic and NMR structures (Figure 2.11B) 
indicate that His96 is almost always in the same orientation (Figure 2.4B) with one notable 
exception (the fourth NMR structure), which is a rotamer wherein the His96 side chain is flipped 
out of the pocket (the ‘open’ rotomer; Figure 2.4C). We propose that this conformation of His96 
in the non-native, flipped outward pose represents an important transition state in the binding 
process specifically in its role in the movement of helix α4, as discussed below.  
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Figure 2.4 The rotamer of His96 plays a key role in the transition state of p53 binding to MDM2 
A) Dihedral angle of His96 side chain in the 4 simulation types of the first NMR structure. Lines 
are colored as follows, apo: blue, Ind: red, IndCB: green, IndCA: yellow. Corresponding plots for 
the simulations starting from the second and third NMR structure are shown in Figure 2.13. 
Rotamers of His96 side chain in the B) closed state and the C) open state observed in the 4th NMR 
structure (PDB ID: 1Z1M).  
 
Table 2.3 Percent of frames within 15 degrees of the rotated outward rotamer of His96 (62˚) 
 NMR 1 NMR 2 NMR 3 Average 
apo 0.469 0.428 0.548 0.482 
Ind 0.904 0.148 0.839 0.630 
IndCB 0.718 0.758 0.785 0.754 
IndCA 0.821 0.721 0.850 0.797 
 
α4 α4 
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2.3.8 His96 Position and Orientation 
In Figure 2.5, we constructed a heat map of the distance across the Leu binding pocket (as in Figure 
2.1E) and the dihedral angle of the histidine side chain (Figure 2.4A). In the apo and Ind 
simulations, helix α4 moves inward, closing the pocket (dark colors near the “NMR Min” line) 
and the side chain is largely in the flipped out (“NMR open”) state observed in the fourth NMR 
structure. However, as the size of the indole is increased as in the IndCB and IndCA simulations, the 
histidine shifts almost entirely into the “open and out” state where the helix is pushed out further 
than the unbound states (but less than the fully bound state) and the side chain is flipped into the 
open position (Table 2.3). We propose that this “open and out” state is a transition state that is 
required for binding to the Leu26 binding site. As we see here and previously in Figure 2.1E, the 
indole, even with the CA and CB atoms, does not sufficiently fully push the helix into the bound 
state. Therefore, the side chain of His96 must also flip out of the way until Leu26 is able to bind; 
after which His96 will flip back into place.  
  22 
 
Figure 2.5 Heat map of the distance from the helix α2 to the α-carbon of His96 and the His96 
dihedral angle. Data shown for the four simulation types of the first NMR structure. Horizontal 
grey bars indicate values within 15° of the dihedral angle observed in the fourth NMR structure 
(62°). Vertical grey bars indicate distances greater than the largest distance observed in the 24 
NMR structures. Dark and light colors indicate high and low populations, respectively. 
Corresponding plots for the simulations starting from the second and third NMR structure are 
shown in Figure 2.14. 
 
To validate this transitory model, we ran MD simulations to show that when MDM2 adopts 
the bound state in complex with its binding partner (small molecule or protein) that the His96 will 
flip back into the closed state. We conducted MD simulations of the full MDM2-p53 PPI complex 
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(PDB ID: 1YCR) in its native closed state and after manually rotating the His96 side chain into 
the open state. Figure 2.6A shows that, in the simulations starting in the open and closed states, 
His96 is in the closed state for 46% and 71% of the time, respectively, indicating that His96 can 
go from the open to the closed state when bound to a ligand (e.g. p53). To further confirm that 
His96 will sample the bound (closed) state we ran MD simulations of three randomly chosen 
inhibitor bound crystal structures of MDM2 (PDB IDs: 1T4E, 3VZV, 3LBK). Before starting the 
simulation, the rotamer of His96 was set to the open position. These simulations also demonstrate 
that His96 samples the closed state in the presence of a small molecule inhibitor (Figure 2.6B).  
 
Figure 2.6 Following final complexation, His96 rotomer returns to the closed state. A) Dihedral 
angle of His96 in simulations of the PPI structure of MDM2-p53 (PDB ID: 1YCR) starting from 
the (top) native closed or (bottom) open rotamer of His96. Shown are the percentage of frames 
that His96 is in the closed state. B) Dihedral angle of His 96 in simulations of inhibitor bound 
(His96 closed) crystal structures of MDM2.  
  24 
2.3.9 Examination of co-crystal structures of MDM2 inhibitors 
To validate the importance of the CB and CA atoms in opening the Phe19 and Leu26 pockets with 
experimental data, we examined how many of the co-crystallized structures of known MDM2 
inhibitors (N=28) contained a heavy atom in the same position (within 1.25 Å) as the CA and CB 
atoms of Trp23 (see Methods and Table 2.4). Figure 2.7 shows that 100% and 90% of the analyzed 
ligands have a heavy atom (typically carbon or nitrogen) in the same position as the CB and CA 
atoms, respectively. This agrees with our findings of the importance of the CB and CA atoms 
because only compounds with heavy atoms in those positions are able to open the binding site, as 
the Trp23 anchor does, successfully bind to the protein and be crystallized. This provides support 
for our simulation results and indicates that the coordination of the position and orientation of 
Val93 and His96 are critical for successful binding of small molecule inhibitors. 
 
 
Figure 2.7 Co-crystallized inhibitors have CB and CA analogs. Percent of co-crystallized MDM2 
inhibitors with heavy atoms within 1.25 Å of the CB (green sphere) and CA (orange sphere) atoms 
of Trp23. The radius of the spheres indicate the 1.25 Å region of overlap. 
 
  25 
2.4 DISCUSSION AND CONCLUSION 
The interaction between tumor-suppressor p53 and its inhibitor MDM2 have been shown to play 
a critical role in many human cancers[41]. Understanding, with atomic level detail, how these two 
proteins interact will provide useful insight into rational drug design efforts. When unbound, the 
MDM2 binding interface is closed, and the hydrophobic binding site is largely occluded (Figure 
2.1B) and the p53 peptide is disordered. The binding site of the Trp23 anchor of p53 is transitively 
open allowing for initial recognition of the binding partners[30]. In this work, we have used 
molecular dynamics simulations to explore the exact factors of the Trp23 anchor of p53 that are 
important to fully opening the binding site and allowing for binding to occur.  
Our MD simulations suggest that the binding of the Trp23 anchor residue is necessary to 
open the binding pocket by coordinating the position and orientation of Val93 and His96 through 
hydrophobic contacts of the Trp23 CB and CA carbons. These atoms regulate both the position 
and orientation of Val93 by pushing it into its bound-state position and orientation. We also have 
identified a putative transition state mechanism by which helix α-4 shifts towards the bound-like 
state and the side chain of His96 rotates outwards, thus opening the pocket for binding. These 
interactions open the binding cavity enough such that the Phe19 and Leu26 residues can bind and 
further induce the structural transition to the high-affinity complex, the full extent of which is 
beyond the scope of this paper. We have computationally verified that coordinating the position 
and orientation of Val93 to its bound state and His96 to its open, transition state is critical for 
opening the MDM2 binding cleft and allowing for full binding of p53 and small molecule 
inhibitors. 
We also examined the available crystallographic data of MDM2 inhibitors and have found 
that nearly all of them have a heavy atom in the same position as the CB and CA atoms.  
  26 
While the sample size of the crystallized inhibitors is relatively small, this provides 
evidence for the importance of Val93 and His96 positioning. Thus, when designing small molecule 
inhibitors of MDM2 one must incorporate this critical interaction. 
The impact of this work is two-fold. First, it provides a deeper understanding of the dynamic 
binding interaction of this important pair of proteins. Second, it provides insight into the rational 
design of small molecule inhibitors, of which the potential benefit to human health cannot be 
understated.  
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2.5 SUPPLEMENTARY FIGURES AND TABLES 
Table 2.4 List of PDB IDs of inhibitor bound structures of MDM2. Dots indicate whether the 
aligned ligand has a heavy atom within 1.25 Å of the CB or CA atoms of Trp23 of p53 from PDB 
1YCR. Three structures have been excluded from the analysis (indicated by an * ) as they bind to 
MDM2 in a non-canonical (non “three-fingered”) fashion; we have listed them here for 
completeness. 
PDB ID CB CA 
1RV1[42] • • 
1T4E[43] •  
2LZG[44] • • 
3JZK[45] • • 
3LBJ[26] • • 
3LBK[26] • • 
3LBL[26] • • 
3TJ2[46] • • 
3TU1[47] • • 
3VZV[25] • • 
3W69[25] • • 
4DIJ[48] • • 
4ERE[27] •  
4ERF[27] • • 
4HBM[49] • • 
4HG7[50] • • 
4JV7*,[51]   
4JV9*,[51]   
4JVE*,[51]   
4JVR[51] • • 
4JWR[51] • • 
4MDN[24] • • 
4MDQ[24] • • 
4OAS[52] • • 
4OBA[53] • • 
4OCC[54] • • 
4ODE[54] • • 
4ODF[54] • • 
4OGN[54] • • 
4OGT[54] • • 
4OGV[54] •  
4OQ3[55] • • 
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Figure 2.8 Distance restraints used in Val93 coordination simulation. Yellow dashed lines indicate 
the harmonic distance restraints used between the α-carbons of the labeled residues. 
 
Figure 2.9 RMSD of backbone atoms of binding pocket residues to the bound state for the NMR2 
and NMR3. RMSD results of simulations starting from the A) second and B) third NMR structure 
and distribution of the NMR structures. The lines are colored (here and throughout) as follows: 
apo: blue, Ind: red, IndCB: green, IndCA: yellow, NMR: grey. The horizontal dashed lines indicate 
the minimum and maximum RMSDs of the 24 NMR structures. The right side of the plot shows 
Gaussians fit to the data. 
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Figure 2.10 The distances measured for the Leu, Trp and Phe pockets NMR2 and NMR3 
simulations. Measurements of the simulations of the A) second and B) third NMR structures. The 
horizontal dashed lines indicate the distances in the bound structure and the minimum and 
maximum distances observed in the 24 unbound NMR structures. 
 
Figure 2.11 Distribution of dihedral angles of side chains of critical interaction residues. 
Distribution of dihedral angles observed for A) Val93 and B) His96 in the PPI structure, inhibitor 
bound and apo NMR structures. Vertical dashed lines indicate rotamer states referenced in the 
main text. In A) the “NMR rot1” and “NMR rot2” lines indicate the average values of the apo 
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structures whose dihedral angles are above or below 0, respectively. In B) the “Bound” line 
indicates the dihedral angle of the PPI structure and the “open” link indicates the dihedral angle of 
the fourth NMR  
 
Figure 2.12 Dihedral angle of Val93 side chain in the NMR2 and NMR3 simulations. Val93 
dihedral angle in simulations starting from the A) second and B) third NMR structure. The average 
dihedral angle of the two dominant unbound rotamer states and the rotamer angle of the bound 
state are shown as dashed grey lines. The shaded area indicates ±15˚ of the bound state rotamer. 
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Figure 2.13 Dihedral angle of His96 side chain in the NMR2 and NMR3 simulations. His96 side 
chain dihedral angle in the simulations starting from the A) second and B) third NMR structure. 
The dihedral angles of the bound “closed” state and the “open” state are shown as dashed grey 
lines. The shaded area indicates ±15˚ of the open state rotamer. 
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Figure 2.14 Heat map of the distance from the helix α2 to the α-carbon of His96 and the His96 
dihedral angle.Data shown form the four simulation types of the (A) second and (B) third NMR 
structure (NMR2 and NMR3). Horizontal grey bars indicate values within 15° of the dihedral angle 
observed in the fourth NMR structure (62°). Vertical grey bars indicate distances greater than the 
largest distance observed in the 24 NMR structures. Dark and light colors indicate high and low 
frequencies, respectively. 
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3.0 KNOWLEDGE BASED INSIGHT OF LEVERAGING CRYSTAL WATER 
MOLECULES IN RATIONAL DRUG DESIGN 
3.1 BACKGROUND 
Drug discovery efforts have traditionally relied on high throughput screening (HTS) experiments 
but HTS has several major drawbacks that are increasingly motivating other approaches[2]. 
Although HTS has been successfully used in a number of drug discovery efforts, it can be an 
extremely expensive approach with a fairly low accuracy for new drug targets[56]. In recent years, 
in silico virtual screening methods have become popular complements to HTS due to their many 
advantages including speed and relatively low cost[29, 56-61]. Virtual screening methods can 
provide great benefits as a prescreening approach to drastically reduce the size of a compound 
library to a small fraction that is highly enriched for compounds that are likely to be effective, thus 
resulting in savings in time, resources and money.  
There are many different virtual screening approaches that have been developed but they 
can be generally categorized into ligand-based methods or structure-based methods[62]. Ligand-
based methods characterize given ligands based on similarity to known active and inactive 
compounds[61] and typically do not require knowledge of the protein structure. Examples of 
ligand-based virtual screening methods include ligand-based pharmacophore modeling, 
quantitative structure-activity relationships (QSAR) approaches and molecular fingerprinting 
methods[56]. In contrast, structure-based methods incorporate information about the 3D protein 
structure. Examples of structure-based methods include molecular docking, structure-based 
pharmacophore models and scoring and energy minimization[62]. Ligand-based methods are 
  34 
particularly powerful when there are a large number of active and inactive compounds for the 
target that are already known. However, if there are few or no known actives or inactives, as is the 
case for novel targets, structure-based methods are more applicable. 
X-ray crystallography is often used to determine the three dimensional (3D) structure of 
macromolecules such as protein and DNA. Briefly, X-ray crystallography is conducted by 
exposing a purified crystal of the protein of interest to a beam of X-rays that diffract off the atoms 
of the protein and hit a detector. The position of the atoms of the protein can be calculated based 
on the pattern of the diffracted X-rays. In addition to determining the position of the atoms of the 
protein, often times X-ray crystallography is able to resolve the position of individual water 
molecules which are interacting with the protein through one or more hydrogen bonds. These water 
molecules are often referred to as “crystal waters.” 
We will describe our efforts to leverage information of these water molecules in the context 
of virtual screening efforts. Briefly, we examine pairs of crystal structures of proteins that are 
bound to a small molecule inhibitor and in their unbound, or apo, state. In the first phase, we 
classify clusters of crystal waters based on their geometry and interactions with the protein. In the 
second phase, we show that certain types of water clusters often overlap specific ligand functional 
groups observed in the inhibitor-bound crystal structures. From this we can create a mapping 
between water cluster types and ligand chemistries. This has useful applications in structure- based 
virtual screening efforts particularly in fragment-based methods. While conducting a virtual 
screen, if a given water cluster is observed in a crystal structure of the protein of interest, the 
compound database that is being screened can be limited to just those that have the corresponding 
functional group. 
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3.2 DATASET ASSEMBLY 
A database of over 23,000 pairs of unbound (apo) and ligand-bound (holo) protein structures was 
assembled from the AH-DB (Apo and Holo structures DataBase; http://ahdb.ee.ncku.edu.tw/)[63]. 
The following options were used for searching the AH-DB: Target proteins: all proteins in all 
organisms, Added molecules: without protein and without nucleic acid and with ligand, 
Miscellaneous: apo single protein and exclude NMR and technology consistency and 
completeness ≥ 95% and ML-superimposition. A permanent link to the search results is available 
here: http://ahdb.ee.ncku.edu.tw/53099. These filters ensure that the resulting pairs of structures 
only contain a single (and the same) protein without any other biomolecules such as DNA or other 
proteins.  
The initial search resulted in 47,202 pairs of structures. This initial set was subjected to a 
series of filters which eliminated pairs of structures for a variety of reasons, such as when the 
bound structure contained multiple copies of the ligand or protein or where the ligand name was 
the same as a standard amino acid. Pairs of structures were also eliminated if the apo structure 
failed to align to the holo structure or if there were no water molecules resolved in the binding site 
of the apo structure. After filtering, we are left with 23,654 pairs of structures which consisted 
1,729 holo and 1,424 apo structures. 
3.3 WATER CLUSTER CHARACTERIZATION 
For each apo structure, we examined all of the crystallographic water molecules observed in the 
entire protein structure. For each water molecule, we identified and counted the number of polar 
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contacts with the protein or other water molecules. Polar contacts were defined as polar atoms on 
the protein (e.g. oxygen and nitrogen) that are within specified distance and angle constraints 
(Figure 3.1). In this case, the distance cutoff was set at 4.0 Å and the angle cutoff (donor – donor 
hydrogen – acceptor) was set to 100°. Due to limitations in X-ray crystallography, the position of 
the hydrogen atoms of the protein or water are unable to be determined. There are a number of 
methods for adding hydrogen to protein structures that are quite reliable[64], however, because of 
the inherent number of degrees of freedom, most methods perform rather poorly at adding 
hydrogens to water molecules. Due to this limitation, we chose to not add hydrogens to the water 
molecules and assume that if a bond is otherwise reasonable, we accepted it. Because we can only 
calculate bonding angles when the donor is on the protein, we call this definition “semi-
directional” as opposes to “directional” or “non-directional” bonds. Later we will use the number 
of polar contacts with the protein as a primary characteristic of the clusters. Figure 3.2 shows the 
distribution of the number of polar contacts in all of the waters in the dataset.  
 
Figure 3.1 Polar contacts between crystal waters and the protein surface. Each crystal water (red 
spheres) has zero or more polar contacts (blue dashed lines) with the protein surface (purple lines). 
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Figure 3.2 Distribution of the number of polar contacts with the protein by binding site waters.Note 
that these do not include polar contacts with other water molecules. 
 
Clusters of waters were assembled by grouping all sets of water molecules which are within 
a specified cutoff distance of each other (4.0 Å). If there are no other water molecules within the 
specified cutoff, the water is put into it’s own cluster (Figure 3.3). The “size” of the water cluster 
is defined as the number of water molecules in it, typically 1-3. Figure 3.4 shows the distribution 
of water cluster sizes.  
In the future analysis, we will use these to general descriptors to classify the water clusters. 
In particular, the water clusters will be classified based on their size and average number of 
hydrogen bonds with the protein. To simplify the discussion, we will use a parenthetical notation 
to describe a water cluster such as (2, 3), meaning the cluster contains two water molecules which 
have an average of three polar contacts with the protein. Note that because this is an average, the 
number of bonds may not be evenly distributed between the water molecules, i.e. one water might 
  38 
have four bonds and the other might have two bonds. Also worth emphasizing is the fact that the 
average number of hydrogen bonds is with the protein only. Water clusters of size two or more 
have bonds between the waters in the cluster, but those bonds are excluded in this analysis. 
 
 
Figure 3.3 Defining water clusters on the protein surface. Each cluster is defined as water 
molecules within hydrogen bonding range of each other, if any. Yellow dashed lines indicate intra-
water hydrogen bonds, blue dashed lines indicate hydrogen bonds to the protein (shown in purple 
lines). 
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Figure 3.4 Distribution of the sizes of binding site water clusters 
3.4 CHARACTERIZING LIGAND FUNCTIONAL GROUPS 
For each ligand in the bound structures of the dataset, we determined what functional groups that 
it consisted of and which atoms contributed to each functional group. We compiled a list of 
functional group definitions starting from a list of SMARTS patterns[65] obtained from the 
‘maccs.txt’ file provided in OpenBabel v2.3.90[66]. SMARTS patterns can be thought of regular 
expressions for small molecules. For example, the SMARTS pattern '[N,n]=*' looks for a nitrogen 
‘[N,n]’ that is double bonded ‘=’ to anything ‘*’. Ligands that contains a nitrogen double-bonded 
to a carbon (N=C) would match this SMARTS pattern as would a ligand that contains a nitrogen 
double-bonded to another nitrogen (N=N). The full list of 50 functional groups that we used for 
the initial set this work are listed in Table 3.1. We excluded a number of the 166 functional groups 
originally defined in the ‘maccs.txt’ file that were noted in the original file as being incorrect or 
those that did not match any of the ligands in our dataset. 
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Table 3.1 List of functional groups considered for ligand characterization.In the comment section 
are human readable descriptions of the SMARTS pattern. Parentheses indicate branches, ‘Q’ 
indicates non-carbon or hydrogen atoms, ‘A’ indicates any atom, ‘X’ indicates a halogen, ‘-‘ 
indicates a single bond, ‘=’ indicates a double bond and ‘T’ indicates a triple bond. Bolded 
functional groups indicate those that had at least 100 representatives in the dataset. 
ID SMARTS Pattern Comment ID SMARTS Pattern Comment 
1 '[O,o]~[N,n](~[C,c])~[C,c]' ON(C)C 26 '[NH2]' NH2 
2 '[O,o]~[C,c](~[O,o])~[O,o]' OC(O)O 27 '[C,c]~[N,n](~[C,c])~[C,c]' CN(C)C 
3 '[N,n]~[C,c](~[O,o])~[O,o]' NC(O)O 28 '[S,s]' S 
4 '[N,n]-[O,o]' N-O 29 '[C,c]=[C,c]' C=C 
5 '[N,n]~[C,c](~[N,n])~[N,n]' NC(N)N 30 '[F,Cl,Br,I]~*(~*)~*' XA(A)A 
6 '[!C;!c;!#1]~[CH2]~[!C;!c;!#1]' QCH2Q 31 '[N,n]~[C,c]~[O,o]' NCO 
7 '[C,c]~[S,s]~[N,n]' CSN 32 '[CH3]~[CH2]~*' CH3CH2A 
8 '[N,n]~[S,s]' NS 33 '[N,n]~*~[O,o]' NAO 
9 '[N,n]~[C,c](~[O,o])~[N,n]' NC(O)N 34 '[N,n]=*' N=A 
10 '[N,n]~[C,c](~[C,c])~[N,n]' NC(C)N 35 '[O,o]~[C,c]~[O,o]' OCO 
11 '[O,o]~[S,s](~[O,o])~[O,o]' OS(O)O 36 '[F,Cl,Br,I]' X (HALOGEN) 
12 '[S,s]-[O,o]' S-O 37 '[!C;!c;R]' Heterocycle 
13 '[C,c]#[N,n]' CTN 38 '[OH,OH2,OH3]' OH 
14 '[S,s]~*~[N,n]' SAN 39 '[N!H0]' NH 
15 '[C,c]~[S,s]~[O,o]' CSO 40 '[O,o]~[C,c](~[C,c])~[C,c]' OC(C)C 
16 '[O,o]~[S,s]~[O,o]' OSO 41 '[C,c]=[O,o]' C=O 
17 '[O,o]~[N,n](~[O,o])~[C,c]' ON(O)C 42 '[C,c]-[O,o]' C-O 
18 '[$(O@*),$(o@*)]' O Heterocycle 43 '[C,c]-[N,n]' C-N 
19 '[S,s]=[O,o]' S=O 44 '[CH3]' CH3 
20 '*~[S,s](~*)~*' AS(A)A 45 '[N,n]' N 
21 '[C,c]~[C,c](~[C,c])(~[C,c])~*' CC(C)(C)A 46 'a' Aromatic 
22 '[N,n]~[O,o]' NO 47 '[O,o]' O 
23 '[CH3]~*~[CH3]' CH3ACH3 48 '[C,c]' any carbon 
24 '[C,c]=[C,c](~*)~*' C=C(A)A 49 '[C,c]~[C,c](~[O,o])~[N,n]' CC(O)N 
25 '[C,c]=[N,n]' C=N 50 '[O,o]~[P,p](~[O,o])(~[O,o])~[O,o]' OP(O)(O)O 
 
For each atom in the ligand, we are able to determine which of the functional groups listed 
in Table 3.1 it is a part of. From this information, we are able to create correlations between the 
water clusters and the ligand functional groups that displace them.  
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3.5 WATER CLUSTER DISPLACEMENT BY LIGAND FUNCTIONAL GROUPS  
For each functional group in a ligand, we can determine what water clusters in the corresponding 
apo structures overlap with it. In doing so, we can characterize water clusters found in the apo 
structure as being in the binding site or not. Figure 3.5A shows the distribution of all of the water 
clusters in the dataset based on the size of the cluster (number of waters) and the average number 
of polar contacts with the protein. Comparatively, Figure 3.5B shows the distribution of only 
binding site water clusters and Figure 3.5C shows the proportional difference between the water 
clusters in the binding site compared to the water clusters in the entire protein structure. We 
observe that there is a striking difference in the distribution of water clusters inside and outside the 
binding site. Highly coordinated pairs of waters i.e. (2, 2.5) and (2, 3) are much more prevalent in 
the binding site relative to throughout the entire protein. Additionally, pairs and trio of water with 
no (or few) polar contacts are more common in the binding site. These “unstable” waters are 
typically in hydrophobic pockets and are generally considered prime targets for displacement by 
an inhibitor[67]. Conversely, single waters, of all coordination states are more common outside 
the binding site.  
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Figure 3.5 Distribution of water cluster sizes and average polar contacts. Distribution of A) all or 
B) binding site water clusters based on cluster size and the average number of polar contacts with 
the protein. Lighter colors indicate higher proportion of water clusters. Clusters that represent less 
than 2.5% of all clusters in each set are hidden for clarity. C) The proportional difference between 
binding site water clusters and all water clusters. Deeper red colors indicate clusters that are more 
prevalent in the binding site and deeper blue colors indicate clusters that are more prevalent outside 
the binding site.  
 
For each of the functional groups listed in Table 3.1, we analyzed the distribution of water 
clusters that displace it in the dataset. From this list of 50 functional groups, 30 were represented 
at least 100 times (shown in bold in the table) and were further analyzed. The water clusters that 
most commonly displaced each functional group is shown in Table 3.2. Interestingly, all of the 
most commonly displaced water clusters are of size 1 or 2, despite the relative abundance of 
clusters of size 3 (Figure 3.4).  
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Table 3.2 Most common water clusters that are displaced by functional groups with at least 100 
examples 
Functional Group Size Avg. Contacts % represented  Total 
 AS(A)A    2 3.0 21.89% 3851 
 Aromatic  1 0.0 24.10% 1311 
 C-O       2 0.0 31.68% 2386 
 C=N       2 1.5 27.70% 473 
 C=O       1 1.0 25.83% 751 
 CC(C)(C)A  2 1.5 21.78% 101 
 CH3       1 2.0 21.55% 297 
 CSN       2 3.0 24.27% 2678 
 CSO       2 2.5 22.07% 2633 
 CTN       1 1.0 54.47% 123 
 N         1 3.0 20.83% 1805 
 N=A       2 1.5 26.36% 497 
 NAO       2 3.0 20.46% 3529 
 NC(C)N    2 1.5 28.45% 116 
 NC(N)N    1 1.0 24.77% 109 
 NH        1 3.0 27.83% 1247 
 NH2       1 3.0 33.54% 957 
 NS        2 3.0 26.05% 2668 
 O         1 2.0 21.17% 3434 
 O Heterocycle 2 1.5 25.00% 100 
 OP(O)(O)O  1 2.0 26.72% 524 
 OS(O)O    2 2.5 21.12% 805 
 OSO       2 2.5 22.85% 3335 
 S         2 0.0 27.13% 4427 
 S-O       2 2.5 22.15% 727 
 S=O       2 2.5 22.86% 3150 
 X (HALOGEN) 1 0.0 32.69% 104 
 XA(A)A    1 0.0 30.95% 294 
 any carbon 2 0.0 31.35% 5972 
 
An inspection of the ligands that contribute to each functional group revealed that several 
functional groups were identifying the same chemistry. For example, the functional groups 
AS(A)A, CSO, CSN, NAO, OSO, S=O, and S-O can all match a common sulfonamide chemistry: 
CS(O)(O)N (as in Figure 3.6B). Due to these overlapping descriptors, we manually selected a 
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handful of representative functional groups for further analysis: AS(A)A, NC(C)N, Aromatic, and 
X (Halogen). 
An analysis of the water clusters that overlap the functional group AS(A)A revealed a large 
propensity for displacement by (2, 2.5) and (2, 3) water clusters (Figure 3.6A). Figure 3.6B and C 
show two examples of ligand chemistries that are displaced by (2, 3) water clusters. The geometry 
of the water clusters is well matched to the chemistry of the ligands that displace them in the bound 
structure. These highly coordinated waters form many well defined hydrogen bonds that are well 
suited to replacement by the AS(A)A functional group. 
 
Figure 3.6 Distribution and examples of water clusters that overlap the AS(A)A functional group 
A) Heat map of the water clusters that overlap the AS(A)A functional group where “A” is any 
atom; (inset) chemical sketch of the functional group. Warmer colors indicate higher percentages. 
B) Inhibitor from a holo structure (light blue sticks; PDB ID: 1A42[68]) overlaid on the apo crystal 
structure of carbonic anhydrase II and a (2, 3) water cluster (PDB ID: 1FQL[69]). C) Small 
molecule from a holo structure (PDB ID: 1VXA[70]) overlaid on the apo crystal structure of 
myoglobin and a (2, 3) water cluster (PDB ID: 3H57[71]). 
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The NC(C)N functional revealed a high propensity for displacing (2, 1.5) water clusters 
(Figure 3.7A). An analysis the pairs of crystal structures revealed a variety of ligand chemistries 
that displaced the (2, 1.5) water clusters. Figure 3.7B shows one prime example of the NC(C)N 
functional group displacing the water cluster. In this case, the nitrogen atoms overlap the positions 
of the waters and the carbons form the connecting bond between the two fused aromatic rings. 
This overlap and replacement of the loosely coordinated (2, 1.5) water clusters is similarly 
observed in other protein families such as protein kinase CK2 shown in Figure 3.7C. 
 
Figure 3.7 Distribution and examples of water clusters that overlap the NC(C)N functional group. 
A) Heat map of the water clusters that overlap the NC(C)N functional group; (inset) chemical 
sketch of the functional group. Warmer colors indicate higher percentages. B) Inhibitor from a 
holo structure (light blue sticks; PDB ID: 1GZ8[72]) overlaid on the apo crystal structure of cyclin 
dependent kinase 2 (CDK2) and a (2, 1.5) water cluster (PDB ID: 1HCL[73]). C) Small molecule 
from a holo structure (light blue sticks; PDB ID: 1LPU[74]) overlaid on the apo crystal structure 
of protein kinase CK2 and a (2, 1.5) water cluster (PDB ID: 1JAM[75]). 
 
In addition to the polar functional groups mentioned above, (AS(A)A and NC(C)N) we 
also observed displacement of water molecules by hydrophobic functional groups (e.g. aromatics 
and halogens). Perhaps non-surprisingly, these hydrophobic functional groups most often displace 
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single waters molecules that have very few or no hydrogen bonds with the protein (Table 3.2). 
These water molecules are often found in hydrophobic cavities where they are entropically 
unfavorable. Thus their displacement from the non-polar cavity by a hydrophobic functional group 
can be easily rationalized. Figure 3.8A shows that aromatic functional groups most often displace 
(1, 0) water clusters. This is closely followed by (1, 1) and (2, 1.5) both of which are poorly 
coordinated and ripe for displacement by an aromatic group. Figure 3.8B and Figure 3.8C show 
two prime examples of unstable water molecules in hydrophobic pockets being displaced by 
aromatic groups on the ligand.  
 
Figure 3.8 Distribution and examples of water clusters that overlap the aromatic functional group. 
A) Heat map of the water clusters that overlap the aromatic functional group; (inset) chemical 
sketch of the functional group. Warmer colors indicate higher percentages. B) Inhibitor from a 
holo structure (light blue sticks; PDB ID: 1JNQ[76]) overlaid on the apo crystal structure of 
lipoxygenase-3 and a (1, 0) water cluster (PDB ID: 1LNH[77]). C) Small molecule from a holo 
structure (light blue sticks; PDB ID: 3IW2[78]) overlaid on the apo crystal structure of cytochrome 
P450 and a (1, 0) water cluster (PDB ID: 3IVY[78]). 
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Finally, we examined the water clusters that displace halogens (F, Cl, Br and I). Much like 
aromatic groups, halogens preferentially displace single water molecules (cluster size = 1), 
however the water clusters exhibit higher variability in their number of polar contacts (Figure 
3.9A). Unmatched water molecules are the most common followed by waters that have 1, 2 and 3 
contacts with the protein. Examples of the ligands that displace the most common (1, 0) water 
clusters is shown in Figure 3.9B and Figure 3.9C. The hydrophobic halogens are able to displace 
the unstable water molecules and fill the non-polar cavities.  
 
Figure 3.9 Distribution and examples of water clusters that overlap the X (Halogen) functional 
group. A) Heat map of the water clusters that overlap the X (Halogen) functional group; (inset) 
chemical sketch of the functional group. Warmer colors indicate higher percentages. B) Inhibitor 
from a holo structure (ligh blue sticks; PDB ID: 1BCD[79]) overlaid on the apo crystal structure 
of carbonic anhydrase II and a (1, 0) water cluster (PDB ID: 1DCA[80]). C) Small molecule from 
a holo structure (light blue sticks; PDB ID: 1LGX[81]) overlaid on the apo crystal structure of T4 
lysozyme and a (1, 0) water cluster (PDB ID: 157L[82]). 
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3.6 SUMMARY 
We have combined data mining and protein structural analysis to discover clusters of water 
molecules in X-ray crystal structures that are commonly displaced upon binding of a small 
molecule inhibitor. We compiled a dataset of 23,654 pairs of crystal structures in their unbound 
(apo) and bound (holo) states. We grouped water molecules in the apo structure into clusters and 
characterized them according to their size (the number of waters) and the number of semi-
directional hydrogen bonds observed with the protein. Clusters of water in inhibitor binding sites 
are generally larger and more coordinated compared to clusters of water found outside the binding 
site. 
 We used generalized descriptors of ligand chemistry (SMARTS patterns) to categorize the 
functional groups present in the ligands. By comparing the functional groups of the ligand in the 
holo structure with the directly overlapping water clusters from the apo structure, we were able to 
draw correlations between the two. Here we discussed four general functional groups: two polar 
(AS(A)A and NC(C)N) and two non-polar (Aromatic and X (Halogen)). All four functional groups 
have large numbers of representative examples in the dataset (>100 each). This allows us to draw 
strong associations between the geometry of the water clusters in the apo structure with the ligand 
functional groups that are likely to displace them.  
These findings have a number of applications in the realm of structure-based and fragment-
based drug design. For example, if a certain type of water cluster, which is associated with a 
functional group as described above, is observed in an existing crystal structure of the target, you 
can limit the search results of the virtual screen to only include ligands with the functional group 
of interest in that site.  Additionally, these finding might lead to the indentification of previously 
unknown allosteric binding sites, however more investigation is needed. 
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There are a number of improvements of this method planned or under way. Expansion of 
the initial set of queried functional groups beyond those found in the MACCS keys (see Table 3.1) 
might allow us to discover more nuanced functional groups. The four functional groups that we 
have analyzed in detail do not constitute an exhaustive list of functional groups which are amenable 
to this analysis methods.  
Currently, the water clusters are being characterized by two simple descriptors: the number 
of waters in the cluster and the average number of hydrogen bonds that they make with the protein. 
The creation of more complex descriptors, such as description of the distances and angles between 
the protein contacts, would allow us to perform a finer grain dissection of the types of water 
clusters that can be displaced by certain functional groups. This is also likely to be necessary to 
support the ongoing efforts provide the predictive model described above in a virtual screening 
setting.  
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4.0 DEVELOPMENT OF TOOLS TO INCORPORATE EXPERT KNOWLEDGE IN 
VIRTUAL SCREENING 
4.1 BACKGROUND 
4.1.1 High-Throughput Screening 
Structure-based drug design is an efficient and effective method for computationally predicting 
compounds that are likely to bind to and modulate the activity of a target protein[5, 29, 57, 58, 62, 
83]. In contrast to ligand-based drug design methods, structure-based methods use information 
from the target protein structure to predict compounds that are likely inhibitors[3, 59, 61]. 
Structure-based methods do not require prior knowledge of active compounds, which makes 
structure-based drug design the preferred method for predicting modulators of targets with no 
previously known inhibitors/activators. 
Historically, pharmaceutical companies have relied on high-throughput screening (HTS) 
to discover novel inhibitors (or activators) of a protein of interest. In general, HTS works as 
follows: a proprietary library of compounds (~1 million) are assayed against a protein in vitro by 
adding the drug to a vial containing the protein (typically using liquid handling robots) and 
measuring the effect either biochemically or in cellular assays[84]. Compounds that produce the 
desired effect are called “hits”. While HTS has worked successfully in the past[84], the cost often 
reaches into the millions of dollars[85].  
The cost of performing a high-throughput screen comes from a number of sources. The 
first is producing and maintaining the libraries of compounds, which often number in the hundreds 
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of thousands or millions[84]. Each compound requires a significant investment in time, effort and 
money to create (or recreate if you run out). Because of this cost, the compound libraries created 
by companies are considered proprietary information.  
The second major cost of HTS is acquiring sufficient quantities of the substrate, typically 
purified protein. Obtaining purified protein in the quantities required for HTS is non-trivial for 
most proteins and in some cases, such as membrane proteins or proteins that are hard to separate 
from similar proteins, purification is currently impossible[86]. These challenges limit the types of 
proteins that can be targeted with in vitro HTS methods and lend a great deal of cost to the process, 
especially early in the discovery process. 
Another major cost driver is in the equipment required to perform the HTS. Typically, HTS 
is performed by one or more robotic platforms that include functions for sample preparation, 
mixing and result detection. Some of these integrated platforms are able to test up to 100,000 
compounds per day. However, these robotic platforms are extremely expensive to purchase up 
front which typically limits smaller academic researchers from harnessing them.  
One of the main advantages of high-throughput screening is the speed by which they can 
screen compounds. However, being able to screen hundreds of thousands of compounds per day 
often comes at the cost of the fidelity of the assay. Simpler assays that provide less information (or 
less accurate information) but can be greatly scaled up are often favored. This tradeoff of speed 
versus accuracy is required in order to efficiently screen the millions of compounds in a company’s 
chemical library. Unfortunately, this may come at the cost of both false positives and false 
negatives, meaning that time might be wasted on compounds that are not actually hits or that an 
actual hit may have been accidently discarded.  
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In all, high-throughput screening has historically been useful in identifying “hits,” but at a 
great financial cost due to the need to test the entirety (or a sizable fraction) of the company’s 
chemical library. Creating and maintaining the chemical library, purifying sufficient protein and 
buying and maintaining robotics systems all lead to the often multi-million dollar cost of 
performing a high-throughput screen. This cost strains pharmaceutical and biotech companies that 
are already facing the increasing cost of drug discovery[84]. Fortunately, there are well-established 
and developing computational methods such as virtual screening, that allow for computationally 
testing the compounds before actually performing the expensive experiments, thus providing a 
much smaller set of compounds enriched for potential inhibitors that can be experimentally tested 
with higher fidelity assays at a greatly reduced overall cost. 
4.1.2 Virtual Screening 
Over the last five to ten years, the Camacho Lab at the University of Pittsburgh has developed a 
comprehensive computational pipeline for structure-based drug discovery. These open-access 
tools represent a start-to-finish method of identifying potential inhibitors for novel protein-protein 
interactions (PPIs)[29, 57, 58].  
Figure 4.1 illustrates the structure-based virtual screening pipeline that we employ in our 
drug discovery efforts. Given the structure of a PPI of therapeutic interest, key interaction 
residues are identified using the PocketQuery web service[58]. PocketQuery analyzes the 
interacting residues of the PPI and predicts a set of residues that are likely to be good starting 
points for a structure-based drug discovery effort. The identified residues can be exported with 
one click to ZincPharmer[57] or AnchorQuery[29]. ZincPharmer allows for extremely efficient 
searching of large databases of commercially available compounds (i.e. the ZINC database[87], 
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~35 million compounds) using a set of pharmacophores. Pharmacophores are general descriptors 
of a molecule such as hydrogen bond donors/acceptors, hydrophobic groups and 
positive/negative charges. In ZincPharmer, a database of compounds is searched using a set of 
pharmacophore features and compounds matching those features are returned. AnchorQuery is 
similar to ZincPharmer in that it also uses pharmacophores, but it searches a database of 
compounds (~31 million) that are biased to targeting protein-protein interactions. This is 
accomplished by incorporating the chemistry of an “anchor” residue in the compound. Anchor 
residues (typically, tryptophan, phenylalanine or leucine) play an important role in protein-
protein binding by binding deeply in the binding interface. Additionally, all of the compounds in 
the AnchorQuery database are synthetically available as a one-step, multi-component chemical 
reaction[29]. Both AnchorQuery and ZincPharmer allow for extremely fast searches of billions 
of conformers of 30+ million compounds through the use of specialized data structures[29, 57]. 
In most cases, the searches complete in under a minute, and are often much faster.  
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Figure 4.1 Overview of our structure-based virtual screening pipeline. 
Key interaction residues are identified using PocketQuery. These residues are transferred with one 
click to either ZincPharmer or AnchorQuery depending on whether commercially available 
compounds or new chemistry is desired, respectively. The results of the pharmacophore screen are 
energy minimized with respect to the protein surface using smina followed by simple filters based 
on the predicted score. Finally, the work presented here, ClusterMols, is used to allow for efficient 
visualization and selection of a small set of compounds that are purchased (or synthesized) for 
experimental validation.  
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Following the initial pharmacophore screen we are generally left with approximately 
1,000-20,000 compounds out of the initial set of 30+ million compounds. The first part of the 
secondary screening procedure is energy minimization with respect to the protein structure. 
There are numerous methods for accomplishing this[88-91], however we have found that smina, 
a tool developed in our lab which is based on AutoDock Vina[88], performs very well in terms 
of both efficiency and accuracy. After minimizing the compounds, smina predicts the energy of 
the final pose; we will refer to this as the “score” of the compound or pose. Following 
minimization, we filter out those that have very poor scores or that moved a significant amount 
during the minimization indicating that they no longer match the initial pharmacophore query. 
This results in 500-2,500 compounds that are presumably enriched for actual inhibitors. 
However, in many cases such as in pilot screens or in academic settings, this many compounds 
cannot be tested. Therefore, these 500-2,500 compounds must be further filtered down to a short 
list of likely inhibitors. Here we will discuss three ways that one could obtain this final set of 
compounds: sorting by predicted energy, a “linear manual selection” method and the method 
presented here, a software package that allows for efficient navigation and selection of 
compounds by substructure clustering. 
The first possible method for limiting the ~1,000 compounds which passed all of the 
previous filters is to simply rank them based on their predicted score and take the compounds 
with the highest score. For a number of reasons, this is likely the least effective method in 
finding likely inhibitors. First, the scoring functions used in smina, as well as in all other 
currently available methods, are not accurate enough to finely discriminate binders from non-
binders[92-111]. Even the best available methods are unable to accurately rank-order sets of 
congeneric compounds. In blinded competitions[93, 106, 107], the top methods are only able to 
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achieve correlation coefficients of around R2 = 0.65. This means that when choosing the top ten 
compounds for testing, we cannot be very confident that the top scoring compounds will actually 
be inhibitors. A second problem with this method is that when sorting by predicted affinity and 
taking the top N compounds, it is entirely possible that very similar or even identical compounds 
will be in the top N. Testing very similar compounds can be wasteful in initial screens where 
chemical diversity is preferred. 
The second method for selecting small sets of compounds for experimental testing is the 
“linear manual selection” method. Prior to the work presented here, this was the preferred 
method of selecting compounds at the end of a virtual screening effort. In this method, the 
minimized compounds are manually examined one at a time by a scientist and compounds of 
interest are noted (often on pencil and paper) for later analysis or selection. This method has a 
number of advantages and drawbacks. The main advantage of this method is that a scientist is 
able to evaluate the compounds based on both their prior knowledge and the compound’s 
predicted contacts with the protein. This allows for well-informed, high-quality predictions by 
leveraging the biochemical insight of the person performing the virtual screen, who just might be 
the world’s foremost expert on this particular target. However, there are several drawbacks to 
this method, the largest being the amount of time required to manually examine 100s or 1000s of 
compounds, which is often on the order of several full days. Additionally, the compounds are 
often sorted by their predicted affinity (if they are sorted at all), which makes it difficult to 
compare two similar compounds and choose the best if they are separated in the ranking. A third 
drawback of this method is that the user must manually visualize the contacts between each 
compound and the protein. Examining the contacts (hydrogen bonds, hydrophobic interactions, 
etc.) between the ligand and protein allows the user to understand the complementarity (or lack 
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thereof) between the two binding partners. This is often accomplished by using the measurement 
tool in PyMOL to visualize hydrogen bonds between the ligand and protein. While ultimately 
effective in identifying likely inhibitors, this method is also very time consuming. 
The method presented here is software called “ClusterMols,” which attempts to improve 
on the benefits of the linear manual selection method while addressing all of the drawbacks. This 
software product allows for extremely efficient examination of the set of compounds generated 
by previous virtual screening by grouping similar compounds together such that the most 
desirable compound in a scaffold can be chosen easily or, alternatively, the entire scaffold can be 
discarded. In addition, this software provides a number of tools for automatic visualization of 
polar contacts and allows for easy selection and extraction of compounds of interest. Overall, this 
tool allows users to apply their expert knowledge to select a small set of compounds much more 
rapidly than before. This reduces the required time for selecting a small set of compounds from 
the initial set of ~1000 from over a week to under a day in most cases. The software is 
implemented as a plugin in PyMOL with a full graphical interface (explained in Section 4.2) and 
extended with a set of keyboard controls. 
4.2 GENERAL METHOD 
ClusterMols has two major phases of calculation: pairwise similarity calculation and compound 
clustering. After loading the clustering results, ClusterMols provides a number of controls for 
efficiently navigating the search results, including advanced visualization of the protein-ligand 
contacts and keyboard shortcuts for selecting and extracting compounds of interest. As an 
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illustrative example, we will use a virtual screen of the XRCC1/DNA Polβ PPI interaction shown 
in Figure 4.2.  
 
 
Figure 4.2 Structure of a protein-protein interaction. Example PPI structure shown in green surface 
and purple sticks in the PyMOL user interface. Water molecules are shown as small red spheres. 
 
4.2.1 Similarity Calculations 
In the first phase of the calculation, the user selects the compounds to be analyzed: either a file 
(e.g. .sdf or .mol2) or an object that is already loaded into PyMOL (Figure 4.3). These compounds 
represent the ~1000 resulting from the pharmacophore search and the initial structural filtering. 
After choosing the compounds, the calculations and visualization proceed automatically with 
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default parameters. The user is then presented with the options pages shown in Figure 4.4 which 
allow for modifying the parameters of the similarity calculations and clustering. To perform the 
substructure clustering, a pairwise similarity matrix is computed using the chemfp[112] package 
from OpenBabel[66] using the FP3 fingerprint. Depending on the number of compounds in the 
input dataset, this calculation can take several minutes. Therefore, after computing the pairwise 
similarity matrix, the results are saved so future recalculation is not necessary. 
 
Figure 4.3 Load file dialog of ClusterMols. This pop-up window of ClusterMols allows the user 
to open a multi-compound file (e.g. .sdf or .mol2) or select previously loaded compounds from 
within PyMOL. Pressing “Ok” automatically starts the calculations. 
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Figure 4.4 Graphical User Interface (GUI) of ClusterMols. After loading the input file, the user is 
presented with a GUI that contains two pages of options that are used to control the respective 
phases of the program (left: similarity calculation, right: clustering). Each option is accompanied 
by a short description and some suggested values. There is also an “About” tab that contains 
information about how the program works and a description of the keyboard controls. 
 
4.2.2 Clustering 
In the second phase of calculations, hierarchical clustering is performed on the similarity matrix 
grouping similar compounds together. Hierarchical clustering is a machine learning method by 
which items start in their own cluster and pairs of clusters are merged based on the similarity until 
all items have been linked into one cluster. The advantage of using hierarchical clustering for this 
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problem is that clusters are created by “cutting” the tree at a specified height; which has been made 
a user tunable parameter such that the user can create clusters of compounds that are as similar or 
diverse as they desire. Figure 4.5 shows an example of hierarchical clustering. Increasing the cutoff 
parameter (dashed line in Figure 4.5) leads to fewer clusters with less internal similarity, 
decreasing the cutoff parameter leads to more clusters which are more internally similar. 
 
 
Figure 4.5 Hierarchical clustering of compounds based on their similarity. The dashed line 
indicates the user-tunable cut-off height. Colored clades beneath the cutoff height are loaded into 
PyMOL as clusters. The y-axis is in arbitrary units [AU]. 
4.3 USER INTERFACE 
The clusters are then loaded into PyMOL and the software automatically displays both favorable 
and unfavorable polar interactions with a specified protein structure (Figure 4.6). The clusters are 
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loaded into PyMOL as groups that make it easy for the user to show or hide clusters and their 
corresponding contacts (left side of Figure 4.6). In addition to these features, the user is also able 
to easily navigate the list of clusters using a set of keyboard commands listed in Table 4.1. One of 
the most useful keyboard shortcuts in ClusterMols is the ability to automatically extract 
compounds of interest from the list of clusters. For various reasons, this seemingly simple task is 
actually non-trivial in PyMOL without using ClusterMols. Selected compounds are added to a new 
object with the suffix “_selected,” which itself is a first-class PyMOL object that can be enabled 
or disabled, or more importantly, saved to a file for further analysis. 
 
Figure 4.6 Clustered virtual screening results showing polar contacts. The user interface of PyMOL 
and ClusterMols showing the clusters (15 in this example) loaded into PyMOL on the right side. 
In the structure viewer, the receptor structure is shown as green cartoon and surface and one of the 
virtual screening results is shown as sticks. The software automatically highlights both favorable 
(shown in yellow) polar contacts and unfavorable polar contacts (red). These colored dashed lines 
allow for the user to quickly evaluate the quality of the pose and either accept or reject it.  
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Table 4.1. ClusterMols keyboard commands. ClusterMols has a number of keyboard controls for 
navigating inside and between clusters, selecting compounds for later analysis and for getting 
vendor information. *Vendor information is only available if the compound names are ZINC[87] 
or MolPort IDs. In the latter case, price information is also reported. 
Cluster Movement 
Key Action 
Ctrl+W Move up one cluster 
Ctrl+S Move down one cluster 
Ctrl+D Go to next compound in cluster 
Ctrl+A Go to previous compound in cluster 
  
Compound Selection 
Key Action 
F1 Print currently selected molecule 
F2 Remove most recently added compound 
F3 Add current compound to list 
F4 Print list 
  
Vendor Information 
Key Action 
Ctrl+F Get purchasability information* 
 
As listed in Table 4.1, the user is also able to check for up-to-date information on the 
commercial availability of a compound of interest using the keyboard shortcut Ctrl+F. If the 
compound of interest originates from the ZINC database (i.e. results from ZincPharmer), the ZINC 
compound webpage is checked for available vendors. Example output is shown in Figure 4.7. 
Additionally, if the compound of interest originates from MolPort [www.molport.com], the prices 
and availability are extracted from the MolPort compound webpage.  
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Figure 4.7. Vendor information and prices of compounds of interest in ClusterMols. 
 
4.4 SUMMARY 
Structure-based virtual screening is a credible alternative to conventional high-throughput 
screening. It provides savings in time, resources and money by computationally predicting a small 
subset of compounds to experimentally test. The structure-based virtual screening pipeline that has 
been developed in the Camacho Laboratory at the University of Pittsburgh provides a proven 
pathway for discovering novel modulators of protein-protein interactions[113, 114].  
Presented here is a software solution allowing for extremely efficient selection of a highly 
enriched set of compounds which are most likely to bind to a protein target by leveraging a user’s 
expert knowledge. This software, called ClusterMols, is a plugin for the PyMOL molecular 
graphics viewer which automatically clusters compounds based on chemical similarity and 
displays them in PyMOL in a user-friendly manner. Additionally, ClusterMols provides a number 
of additional useful features such as automatic visualization of polar contacts/clashes, one-button 
extraction of compounds of interest and easy-to-use keyboard controls.  
ClusterMols vastly speeds up the time required for manually selecting compounds for 
purchase/synthesis by allowing the user to examine compounds on the scaffold level which allows 
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for easy exploring or discarding of the cluster. The software is designed to provide tools to the user 
that allow them to easily examine the compound-protein interactions and use their knowledge of 
the specific protein target to select the best set of compounds for experimental validation. This 
software has been successfully used as a part of a number of ongoing virtual screening efforts on 
a number of therapeutically relevant targets. 
This software is in active development and a number of features are planned or underway. 
This includes support for offloading the computationally expensive portions of the program to a 
remote server. This has a number of advantages including allowing the end user to avoid installing 
a number of dependencies as well as enabling analysis of large datasets on commodity hardware. 
Additionally, advancements are planned for improving the visualization of protein-ligand 
interactions, in particular, highlighting unmatched polar atoms on the protein and ligand. 
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5.0 CONCLUSIONS AND FUTURE RESEARCH 
The research presented in this dissertation has focused on applying biophysical insight to 
improving rational drug design. We have focused on three major challenges in computational drug 
discovery: protein flexibility, the role of water in ligand binding and using and understanding large 
virtual screening datasets. Using computational approaches, we have presented novel insights into 
these important areas. Below, we will briefly recap the main contributions of this research which 
were described in the previous chapters. 
In Chapter 2.0, we described our work in understanding the induced-fit binding mechanism 
of the tumor suppressor p53 and its inhibitor, MDM2. Using molecular dynamics simulations, we 
have determined the precise chemistry of the indole side chain of the Trp23 anchor residue of p53 
which is responsible for opening the binding cleft on MDM2. The indole group plus the beta-
carbon of the side chain proved to be the critical elements required for opening the binding pocket. 
This opening occurs through coordination of the position and orientation of MDM2 residues Val93 
and His96, which must first adopt a previously undescribed “open and out” transition state wherein 
helix α4 must be pushed partially outward and the side chain of His96 must adopt a rotated outward 
conformation. We have verified the importance of the indole chemistry by demonstrating its 
presence in all available inhibitor-bound co-crystal structures of MDM2. 
In Chapter 3.0, we examined the issue of water in ligand binding sites. We analyzed over 
23,000 pairs of protein structures in their apo and holo states. By comparing the clusters of water 
molecules in the binding site of apo structure to the overlapping ligand chemistries in the holo 
structure, we were able to draw associations between ligand functional groups and types of water 
clusters that they can displace. We identified four generalized functional groups which commonly 
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displace characteristic water clusters upon binding: two polar (AS(A)A and NC(C)N) and two 
non-polar (aromatic rings and halogens). In general, the polar functional groups displace larger 
water clusters with higher levels of polar coordination with the protein and the non-polar functional 
groups displace smaller water clusters (mostly lone waters) with few or no polar interactions with 
the protein. We have presented structural examples of each functional group demonstrating that 
the polar atoms of AS(A)A and NC(C)N align quite well with the water molecules in the apo 
structure, which validates our hypothesis of replacement of the polar interactions of the water 
molecules with those of the ligand. Additionally, we found that the non-polar functional groups 
often displaced poorly-coordinated, lone waters which are often found in hydrophobic cavities. 
These findings have applications in a structure-based virtual screening effort wherein compounds 
can be filtered out based on whether they have a functional group which can displace an observed 
water cluster. Future work will focus on enhancing the descriptors of water clusters beyond the 
simple descriptors of their size and the count of their polar contacts. These descriptors might 
include description of the angles and distances of their hydrogen bonding network. Increasing the 
diversity and specificity of the functional groups analyzed is an important next step as well. 
Additionally, virtual waters will be explored wherein, short molecular dynamics simulations can 
be run to solvate the system to better understand water clusters which might not be resolved in the 
crystal structure.  
In Chapter 4.0, we describe our approach for intelligently handling large amounts of virtual 
screening data. Our software, called “ClusterMols,” is a PyMOL plugin which clusters input 
compounds based on a user-tunable level of chemical similarity and presents the clusters to the 
user in the familar PyMOL interface in an easy to understand manner. This allows the user to 
navigate the results on the level of the chemical scaffold. This has many improvements over 
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previous methods as the user can quickly skip undesirable scaffolds or choose the best 
representative from a scaffold of interest. Included in the plugin are a number of advanced methods 
for visualizing the predicted polar interactions with the protein, both hydrogen bonds and polar 
clashes (i.e. acceptor-acceptor). These tools allow for rapid evaluation of a compound by drawing 
the attention of the user to problem areas as well as positive interactions. Finally, ClusterMols 
provides a number of keyboard controls for quickly navigating the clusters and selecting 
compounds of interest for further analysis as well as the ability to check online for commercial 
availability and prices of compounds of interest with the press of a button. This software provides 
a significant savings in time and effort in the virtual screening process and has been utilized in a 
number of ongoing virtual screening efforts. Future work will focus on expanding the visualization 
of the protein-ligand interactions, particularly in highlighting unpaired polar atoms on the protein 
and ligand. 
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APPENDIX A APPLICATIONS OF MODELING PROTEIN-LIPID INTERACTIONS 
In this appendix, we will present two published applications of modeling small molecule inhibitors 
to proteins. In Appendix A.1, we describe how we predicted the binding mode of a selective 
inhibitor of the c-Src kinase[115]. Then in Appendix A.2, we present how we predicted the binding 
site and pose of an allosteric activator of the ABL kinase[116]. Both are reproduced with 
permission. 
A.1 MODELING SELECTIVE INHIBITORS OF C-SRC 
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The c-Src tyrosine kinase co-operates with the focal
adhesion kinase to regulate cell adhesion and motility.
Focal adhesion kinase engages the regulatory SH3 and
SH2 domains of c-Src, resulting in localized kinase
activation that contributes to tumor cell metastasis.
Using assay conditions where c-Src kinase activity
required binding to a tyrosine phosphopeptide based
on the focal adhesion kinase SH3-SH2 docking
sequence, we screened a kinase-biased library for
selective inhibitors of the Src/focal adhesion kinase
peptide complex versus c-Src alone. This approach
identified an aminopyrimidinyl carbamate compound,
WH-4-124-2, with nanomolar inhibitory potency and
fivefold selectivity for c-Src when bound to the phos-
pho-focal adhesion kinase peptide. Molecular docking
studies indicate that WH-4-124-2 may preferentially
inhibit the ‘DFG-out’ conformation of the kinase active
site. These findings suggest that interaction of c-Src
with focal adhesion kinase induces a unique kinase
domain conformation amenable to selective inhibition.
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The c-Src protein-tyrosine kinase is the prototype of the
Src kinase family and is broadly expressed in virtually every
mammalian cell type (1). All eight mammalian Src-family
kinases (SFKs) share a common regulatory and kinase
domain organization (Figure 1A). At the N-terminus is a
signal sequence for myristoylation, which localizes c-Src to
the cell membrane. Membrane association facilitates inter-
actions of c-Src with binding partners and is essential for
function (2). The myristoylation signal is followed by a
unique domain, modular SH3 and SH2 domains, an SH2-
kinase linker, the kinase domain, and a C-terminal tail with
a conserved tyrosine residue essential for negative regula-
tion of kinase activity. The SH3 and SH2 domains, which
recognize proline-rich and phosphotyrosine-containing
sequences, respectively, are important for kinase regula-
tion as well as interactions with other cellular proteins.
SFKs maintain their inactive state through two intramolecu-
lar interactions involving the SH2 and SH3 domains. The
SH3 domain interacts with a polyproline type II helix
formed by the SH2-kinase linker while the SH2 domain
binds to the tyrosine-phosphorylated tail (3). Tail phosphor-
ylation is mediated by the independent regulatory kinase
Csk as well as the related kinase, Chk (4,5). These intra-
molecular regulatory interactions are present in the X-ray
crystal structure of c-Src in the downregulated conforma-
tion (modeled in Figure 1A) (6).
Multiple mechanisms of SFK activation have been
reported, including dephosphorylation of the C-terminal tail
tyrosine and subsequent release from the SH2 domain (7)
as well as displacement of one or both of the intramolecu-
lar interactions in trans (8,9). Based on their amino acid
sequences, the SH2-kinase linker and phosphorylated
C-terminal tail represent low affinity ligands for their
respective target domains. Displacement of these interac-
tions by proteins with higher affinities for the SH3 and/or
SH2 domains provides a mechanism for SFK activation by
both physiological substrates as well as exogenous pro-
teins expressed as a result of microbial infection. For
example, the Nef protein encoded by HIV-1 binds to the
SH3 domain of the Src-family member Hck, resulting in
linker displacement and constitutive kinase activation
(10,11). Alternatively, juxtamembrane autophosphorylation
sites on active receptor tyrosine kinases may recruit c-Src
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through its SH2 domain, resulting in kinase activation
through tail displacement. Other cellular protein partners
for c-Src contain both SH3- and SH2-binding sequences
believed to displace both intramolecular interactions, such
as p130Cas (12) and the focal adhesion kinase (FAK) (13).
Focal adhesion kinase is a non-receptor protein-tyrosine
kinase that localizes to focal adhesions, the intracellular
structures formed at sites of cell adhesion to the extracel-
lular matrix (ECM). The domain organization of FAK con-
sists of a protein 4.1/ezrin/radixin/moesin (FERM) domain,
followed by binding sites for the c-Src SH3 and SH2
domains (Figure 1B). The kinase domain of FAK is located
in the center of the protein, followed by a proline-rich
region with binding sites for the SH3 domains of p130Cas
and other components of the focal adhesion complex. The
C-terminal end of FAK encompasses the focal adhesion
targeting (FAT) domain which localizes FAK to focal adhe-
sions in response to integrin stimulation (14–16). Upon
recruitment to focal adhesions, FAK undergoes autophos-
phorylation on Y397, creating a high-affinity binding site for
the c-Src SH2 domain. Additionally, the c-Src SH3 domain
binds to the proline-rich sequence adjacent to the SH2
binding site. These tandem binding events displace both
intramolecular regulatory interactions, leading to c-Src
kinase activation. This mechanism integrates relocalization
of c-Src to focal contacts with kinase activation, providing
an elegant mechanism for spatial and temporal regulation
of c-Src function.
Active c-Src phosphorylates FAK at multiple tyrosine resi-
dues, including kinase domain activation loop tyrosines
important for full FAK kinase activity (17). Coordinated acti-
vation of c-Src and FAK stimulates multiple signaling path-
ways linked to focal adhesion turnover and cell migration,
an essential process in embryonic development, wound
healing, and the immune response (17). Cells lacking
c-Src and FAK show a dramatically reduced rate of migra-
tion (18,19) while hyperactivation of these kinases leads to
an increased rate of migration that has been implicated in
tumorigenesis. Indeed, overexpression and increased
activity of both c-Src and FAK have been reported in
multiple tumor sites (17,20).
The relationship of the c-Src:FAK complex to cancer pro-
gression highlights the potential for c-Src and FAK as tar-
gets for cancer therapy (21–24). Multiple inhibitors of both
c-Src and FAK have been discovered, and some have
progressed into clinical trials. However, the success of
these inhibitors, especially as monotherapy, has been lim-
ited (20,25). In this study, we hypothesized that binding of
FAK to c-Src induces a unique disease-associated confor-
mation of the Src active site that may be amenable to
selective inhibitor targeting. In an effort to find a selective
inhibitor of c-Src in the FAK-bound state, we first devel-
oped screening assay conditions where c-Src activity was
entirely dependent on the presence of a phosphopeptide
based on the FAK sequences for c-Src SH3/SH2 binding.
We then screened a small, kinase-biased inhibitor library
and identified several compounds selective for the c-Src:
pFAK peptide complex versus c-Src alone. The most
promising compound showed a fivefold preference for the
active complex in both end-point and kinetic kinase assays
and inhibited the complex with nanomolar potency. Com-
putational docking studies suggest that this compound
prefers the ‘DFG-out’ conformation of the kinase active
A
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Figure 1: Structure and domain organization of c-Src and focal
adhesion kinase (FAK). (A) Crystal structure of c-Src in the
downregulated conformation (PDB ID: 2SRC) showing the SH3
domain, SH3-SH2 connector, the SH2 domain, the SH2-kinase
linker, the kinase domain, and the C-terminal tail. Key kinase
domain features include the N-lobe, activation loop, aC-helix, and
C-lobe. The side chains of the conserved tyrosine residues in the
activation loop (Y416) and the tail (pY527) are also shown.
Intramolecular interactions between the SH3 domain and the
SH2-kinase linker as well as the SH2 domain and the tyrosine-
phosphorylated tail are required to maintain the inactive state. The
modular domain organization of c-Src is shown below the
structure, which includes a myristoylated N-terminal domain not
present in the crystal structure. The organization of the
recombinant Src-YEEI protein used for this study is also shown, in
which the N-terminal unique domain is replaced with a His-tag
and the C-terminal tail sequence is modified to encode YEEI. (B)
FAK consists of an N-terminal FERM domain, central kinase
domain, and a C-terminal FAT domain. The linker connecting the
FERM and kinase domains encompasses the binding site for c-
Src, consisting of a PxxP motif (SH3 binding) and an
autophosphorylation site in the sequence context pYAEI (SH2
binding). The sequence of the pFAK peptide based on this region
and used in the inhibitor screen is also shown, with the Src SH3
and SH2 binding sites underlined.
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site, suggesting that binding of the pFAK peptide induces
this c-Src kinase domain conformation. Our results provide
an important proof-of-concept result that state-selective
ATP-site inhibitors for c-Src can be identified under appro-
priate screening assay conditions. This approach may
provide a new path to the discovery of state and context-
selective inhibitors for large kinase families with highly
homologous active sites.
Materials and Methods
Expression and purification of recombinant Src-
YEEI
A human c-Src cDNA clone was modified on its C-termi-
nal tail to encode the sequence Tyr-Glu-Glu-Ile-Pro (‘YEEI’)
as described elsewhere (26). In addition, the N-terminal
unique domain was replaced with a hexa-histidine tag.
The resulting sequence was used to produce a recombi-
nant baculovirus in Sf9 insect cells using BaculoGold DNA
and the manufacturer’s protocol (BD Pharmingen) as pre-
viously described (27). Src-YEEI was co-expressed with
the Yersinia pestis YopH phosphatase to promote dephos-
phorylation of the activation loop tyrosine and maintain the
downregulated state (28,29). Sf9 cells were grown in
monolayer cultures and co-infected with the Src-YEEI and
YopH baculoviruses. Cells were harvested 72 h after infec-
tion, and Src-YEEI was purified as previously described
(27). Purified Src-YEEI protein was stored in 20 mM Tris–
HCl, pH 8.3, containing 100 mM NaCl. Kinase protein
used in the Z’Lyte in vitro kinase assays also contained
3 mM DTT. The molecular weight of purified Src-YEEI was
confirmed by mass spectrometry and determined to be
phosphorylated on the YEEI tail but not the activation loop
(26), consistent with the structure of the downregulated
conformation (6).
Chemical library screen
A library of 586 kinase-biased inhibitors (30,31) was
screened using the FRET-based Z’Lyte in vitro kinase
assay and Tyr2 peptide substrate (Life Technologies) (32).
Assays were performed in quadruplicate in 384-well low-
volume, non-binding, black polystyrene microplates (Corn-
ing) according to the manufacturer’s instructions and as
described previously (27,33,34). Briefly, the assay mea-
sures phosphorylation of the Tyr2 FRET-peptide substrate
which is labeled with coumarin and fluorescein on its N-
and C-terminii, respectively, which form a FRET pair. After
the kinase reaction, a development step involves site-spe-
cific proteolytic cleavage of the unphosphorylated but not
the phosphorylated peptide. Peptide cleavage results in
loss of the FRET signal. Src-YEEI was first titrated into the
assay over a concentration range of 0.5–500 ng/well
(0.908–908 nM). Kinase activity was measured in the
absence and presence of a 10-fold molar excess of a
pFAK peptide with the sequence AAAARALPSIPKLAN
NEKQGVRSHTVSVSETDDYPAEIID (13), as well as the
control peptides pYEEI (EPQYPEEIPIYL) (35), and VSL12
(VSLARRPLPPLP) (36). All peptides were synthesized by
the University of Pittsburgh Genomics and Proteomics
Core Laboratories, and the mass and purity of each com-
pound was confirmed by LC-MS. The kinase was preincu-
bated with or without the peptides for 15 min, and the
reaction was initiated by the addition of ATP (100 lM) and
Tyr2 peptide substrate (1 lM). The kinase reaction was
incubated 1 h, followed by addition of the development
protease to cleave the unphosphorylated substrate. Cou-
marin and fluorescein fluorescence were measured 1 h
later on a Molecular Devices SpectraMax M5 plate reader.
Results are expressed as percent of maximum kinase
activity relative to a stoichiometrically phosphorylated posi-
tive control peptide and negative control wells where no
ATP is present.
Screening assays were performed with Src-YEEI (30 ng) in
the presence of a 10-fold molar excess of the pFAK pep-
tide (545 nM pFAK versus 54.5 nM Src-YEEI) or with Src-
YEEI alone (125 ng; 227 nM). Each compound was
assayed at a final concentration of 10 lM with carrier sol-
vent (DMSO) at 2.5%. Src-YEEI was preincubated with the
pFAK peptide for 15 min. Compounds were then added
and the mixtures incubated for an additional 30 min before
initiating the kinase reaction by the addition of substrate
and ATP. The IC50 values for the hit compounds were
determined over a concentration range of 3 nM to 30 lM,
and the resulting concentration–response curves were
best-fit by nonlinear regression analysis to obtain the IC50
values (GraphPad Prism). Results are expressed as per-
cent inhibition, calculated relative to negative control wells
without ATP and positive control wells without inhibitor
(DMSO only).
Kinetic kinase assays
These studies used the fluorescence-based ADP Quest
Assay (DiscoveRx), which monitors the production of ADP
in kinase reactions over time (37). All kinase assays were
performed in quadruplicate in black 384-well microplates
(Corning # 3571), in a final assay volume of 50 lL/well at
25 °C. ATP stocks were prepared in 10 mM Tris–HCl, pH
7.0, and the ATP concentration in each assay was held
constant at 100 lM. The SFK substrate peptide, YIYGSFK
(Anaspec) (38) was prepared in ADP Quest assay buffer
(15 mM HEPES, pH 7.4, 20 mM NaCl, 1 mM EGTA, 0.02%
Tween-20, 10 mM MgCl2, 0.1 mg/mL bovine c-globulin).
The substrate concentration in the assay was set to the
Km value (162 lM). In kinase inhibition assays, the Src-
YEEI concentration in the absence of the pFAK peptide
was 40 ng/well (14.5 nM) and in the presence of the pep-
tide was 15.6 ng/well (5.7 nM). Kinase reactions were initi-
ated by the addition of ATP. Assay plates were read every
5 min for 3 h on a Molecular Devices SpectraMax M5 mi-
croplate reader. Results are expressed as percent of maxi-
mum kinase activity relative to the activity of the kinase in
the absence of inhibitor. The mass and purity of inhibitors
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WH-4-124-2 and WH-4-023 were confirmed by LC-MS
(>95%). WH-4-023 has been previously described as a
potent inhibitor for c-Src and Lck (39).
Computational docking
The binding mode of the inhibitor WH-4-124-2 was mod-
eled to the X-ray crystal structure of the Tyr416-dephos-
phorylated, imatinib-bound Lck kinase domain (PDB ID:
2PL0) by generating conformers of the compound using
OMEGA2 (40) (OpenEye) with default settings. A pharma-
cophore alignment of each WH-4-124-2 conformer was
then performed with the piperazine and aliphatic rings of
imatinib in this Lck structure using Pharmer (41). The
aligned conformers were energy-minimized using smina
(42) with the default minimization parameters and fixed
receptor protein. Poses of WH-4-124-2 that showed a
low-energy score and a good structural alignment to the
carbamate core of a related inhibitor (compound 43)
bound in a crystal complex with phosphorylated Lck (PDB
ID: 2OFU) (39) in a region with high structural similarity with
dephosphorylated Lck were selected for refinement/mini-
mization. Finally, the low-energy-minimized structure,
which recovers most of the interactions present in both
Lck co-crystal structures, was selected as the best model.
The binding mode of WH-4-023 was modeled to the X-ray
crystal structures of the Lck kinase domain in the DFG-in
(PDB: 2OFU) (39) and DFG-out (PDB: 2PL0) (43) states
through pharmacophore alignment and energy minimiza-
tion.
Results and Discussion
Development of a screening assay for Src:FAK
selective inhibitors
To screen for selective inhibitors of the c-Src:pFAK com-
plex, we used a synthetic peptide based on the c-Src
SH3/SH2 docking region from FAK (pFAK phosphopep-
tide; Figure 2) to activate recombinant, downregulated
c-Src. Our goal was to model the conformation of active
c-Src that results from interaction with FAK in focal adhe-
sions. Previous studies have shown that this pFAK peptide
binds to a tandem c-Src SH3-SH2 protein with low
nanomolar affinity and is sufficient to activate c-Src via
regulatory domain displacement in vitro (13).
Before initiating the chemical library screen, we first estab-
lished kinase assay conditions under which c-Src activity
was wholly dependent upon binding to the pFAK peptide.
The form of recombinant, downregulated c-Src used in
these studies has a modified C-terminal tail in which the
wild-type sequence, Y527QPGENL, is replaced with YEEI
to create a high-affinity SH2-binding sequence. This modi-
fication allows the kinase, termed Src-YEEI, to undergo tail
autophosphorylation, enabling expression and purification
in the downregulated state (26).
We first measured purified Src-YEEI activity over a range
of kinase concentrations in the absence or presence of
the pFAK peptide, using the Z’Lyte kinase assay (44).
As shown in Figure 2A, the extent of substrate phos-
phorylation increased in sigmoidal fashion as a function
of input kinase concentration, with an EC50 value of
151 ng/well (275 nM) in the absence of peptide. When
this experiment was repeated in the presence of the
pFAK peptide, the activation curve was shifted markedly
to the left, yielding an EC50 value of 34 ng/well (61 nM).
This result is consistent with the interaction of the pFAK
peptide with the Src-YEEI SH3 and SH2 domains,
resulting in displacement of the regulatory apparatus
from the back of the kinase domain and subsequent
activation.
To provide additional evidence that dual engagement of
the SH3 and SH2 domains is necessary for maximal acti-
vation of Src-YEEI in our assay, we examined the effect of
peptides that bind individually to the SH3 domain (VSL12)
or the SH2 domain (pYEEI) on kinase activity. The
sequences of these peptides are presented in Figure 2B.
Both of these peptides also activated Src-YEEI, but to a
lesser extent than the pFAK peptide (Figure 2A). The pY-
EEI peptide, which binds only to the SH2 domain, resulted
in an EC50 value for Src-YEEI activation of 101 ng/well
(184 nM), while the VSL12 peptide, which exclusively
engages the SH3 domain, yielded an EC50 value of 68 ng/
well (124 nM). Both values are higher than that obtained
A
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Figure 2: Activation of Src-YEEI by SH3- and SH2-binding
peptides. The activity of Src-YEEI was measured in the Z’Lyte in
vitro kinase assay in the absence or presence of peptides that
bind to the SH3 domain alone (VSL12), the SH2 domain alone
(pYEEI), or to both (pFAK). Recombinant Src-YEEI was titrated
into the assay over the range of 2-500 ng as shown, and
peptides were added at a 10-fold molar excess at each kinase
concentration. The concentration of Src-YEEI required to reach
50% maximal activation (EC50) for each condition is shown on the
right. The arrow indicates the Src-YEEI concentration used for the
library screen, where Src-YEEI activity is dependent on the pFAK
peptide (30 ng kinase input; 54.5 nM). The sequences of the
peptides are shown below the graph with the docking sites for
the Src SH3 and SH2 domains indicated.
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with the pFAK peptide, supporting the idea that dual regu-
latory domain displacement results in maximal kinase
activity.
Identification of inhibitors selective for Src-YEEI in
complex with the pFAK peptide
For inhibitor screening, we chose a concentration of Src-
YEEI that was dependent on the pFAK peptide for activ-
ity so as to model the kinase conformation induced by
FAK binding. As indicated by the arrow in Figure 2A,
Src-YEEI alone was inactive in the assay at 30 ng/well,
while addition of the pFAK peptide resulted in 40% of
maximal activation at this Src-YEEI concentration. This
condition was therefore used for the library screen. We
also identified a higher concentration of Src-YEEI alone
(125 ng/well) with activity comparable to that of the Src-
YEEI:pFAK peptide complex, as a basis of comparison.
The ATP concentration was set to 100 lM, which is in
excess of published Km values for c-Src (26,45–47) while
the peptide substrate concentration was set to 1 lM.
Using these assay conditions, we screened a kinase-
biased small molecule library of 586 compounds for pref-
erential inhibitors of Src-YEEI in the presence of the
pFAK peptide compared with Src-YEEI alone. Most of
the compounds in this library were designed to bind
kinase domains in the so-called Type II mode and exploit
specific ATP-site conformations to impart binding speci-
ficity (30,31). Compounds were screened at a final con-
centration of 10 lM, and the rank order of inhibitory
potency for each compound against the Src-YEEI:pFAK
peptide complex is presented in Figure 3A.
The 97 compounds that showed at least 50% inhibition
of the Src-YEEI:pFAK complex at 10 lM were then
assessed for inhibition of Src-YEEI alone. Results for
each of these compounds were then ranked according
to their selectivity ratios, defined as the percent inhibition
of the Src-YEEI:pFAK peptide complex divided by the
percent inhibition of Src-YEEI alone. Twenty-four com-
pounds with a selectivity ratio >3 (Figure 3B) were
selected for further evaluation in concentration–response
experiments. Of these, four compounds reproducibly
inhibited Src-YEEI in the presence of the pFAK peptide
to a greater extent than Src-YEEI alone with selectivity
ratios ranging from 5 to almost 20 (data not shown).
However, the overall potency for three of these com-
pounds was rather low, with only about 50% inhibition of
the kinase:peptide complex at a concentration of 10 lM.
For this reason, we did not follow up on these com-
pounds. Instead, we focused on the aminopyrimidinyl
carbamate designated WH-4-124-2 (see Figure 4A for
structure) because it was the most potent inhibitor of
Src-YEEI in the presence of the pFAK peptide. As shown
in Figure 4A and Table 1, WH-4-124-2 inhibited the Src-
YEEI:pFAK peptide complex with an IC50 value of
0.89 lM in the Z’Lyte assay, as compared to 4.95 lM for
Src-YEEI alone.
WH-4-124-2 is a selective inhibitor of the
Src-YEEI:pFAK complex
We next investigated the specific structural features of
WH-4-124-2 responsible for its selectivity toward the
Src-YEEI:pFAK complex. The compound WH-4-023,
which is a substructure of WH-4-124-2 (Figure 4B),
inhibited both the Src-YEEI:pFAK peptide complex and
Src-YEEI alone by more than 70% in the screening
assay (blue data point in Figure 3A). We therefore per-
formed a concentration–response experiment with this
compound and found that it inhibited Src-YEEI alone
and in complex with the pFAK peptide with an IC50
value of about 1.3 lM (Figure 4B). This result strongly
suggests that the methylpiperazinyl trifluoromethylbenza-
mide substituent present in WH-4-124-2 contributes to
inhibitor selectivity.
A
B
Figure 3: Chemical library screen for selective inhibitors of pFAK-
dependent Src-YEEI activity. A kinase-biased library of 586
compounds was screened for inhibitors of Src-YEEI activity in the
presence of the pFAK peptide using the FRET-based Z’Lyte
assay as described in the text. (A) Inhibitory activities of all 586
compounds are ranked by percent inhibition relative to the
unphosphorylated substrate peptide control. Ninety-seven
compounds inhibited kinase activity by at least 50% (dotted line).
(B) A selectivity ratio was determined for compounds showing
>50% inhibition of the Src-YEEI:pFAK complex in part A. This
ratio was calculated as the percent inhibition of the Src-YEEI:
pFAK complex divided by the percent inhibition observed with
Src-YEEI alone. Twenty-four compounds exhibited a selectivity
ratio >3 (dotted line). The hit compound WH-4-124-2 is indicated
in each graph by a red dot, while the control compound WH-4-
023 is indicated with a blue dot.
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We next investigated whether displacement of either the
SH3 or SH2 domain alone was sufficient to cause the
conformational rearrangement responsible for inhibitor
selectivity. As shown in Figure 5, activation of Src-YEEI by
displacement of either the SH3 domain (with the VSL12
peptide; see Figure 2B) or the SH2 domain (with the
pYEEI peptide) both resulted in enhanced inhibition by
WH-4-124-2. Interestingly, inhibition of VSL12-activated
Src-YEEI (via SH3 domain displacement) was less
A B
Figure 4: Selective inhibition of Src-YEEI by WH-4-124-2 in the presence of the pFAK peptide but not its structural analog, WH-4-023.
WH-4-124-2 (A) and WH-4-023 (B) were assayed against Src-YEEI alone (gray circles) and the Src-YEEI:pFAK complex (black
circles) over the range of inhibitor concentrations shown using the Z’Lyte end-point assay. All data points were measured in
quadruplicate, and the values shown represent the mean ! SE. IC50 values were determined by nonlinear regression analysis and are
shown in Table 1.
A
B
Figure 5: Selective inhibition of Src-YEEI by WH-4-124-2 by the
pFAK peptide involves displacement of both SH2-tail and SH3-
linker interactions. (A) Src-YEEI alone or together with the SH2
peptide ligand pYEEI, the SH3 peptide ligand VSL12, or the pFAK
peptide was assayed over the range of inhibitor concentrations
shown using the Z’Lyte end-point assay. All data points were
measured in quadruplicate, and the values shown represent the
mean ! SE. (B) IC50 values were determined by nonlinear
regression analysis and are shown in Table 1.
Table 1: IC50 values for kinase inhibitors WH-4-124-2 and WH-
4-023 against Src-YEEI in the presence and absence of the pFAK
peptide
WH-4-124-2 WH-4-023
Z’Lyte ADP Quest Z’Lyte ADP Quest
Src-YEEI + pFAKa 0.89 0.114 1.36 0.025
Src-YEEI alonea 4.95 0.531 1.28 0.019
Selectivity ratiob 5.56 4.82 0.94 0.76
aIC50 values (lM) were generated in the Z’Lyte end-point assay
used for the library screen and in the ADP Quest kinetic kinase
assay for Src-YEEI in complex with the pFAK peptide versus Src-
YEEI alone.
bIC50 for inhibition of the Src-YEEI:pFAK peptide complex divided
by the IC50 for inhibition of Src-YEEI alone.
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pronounced than inhibition following activation by either
the pFAK or pYEEI peptides. These findings suggest that
SH3 displacement alone does not allow the kinase domain
to adopt the conformation preferred by this inhibitor.
Selective inhibitor discovery and characterization described
so far were performed using the Z’Lyte end-point kinase
assay, which does not provide direct information about the
effect of either the activator peptide or the inhibitors on the
kinase reaction rate. We therefore turned to the ADP
Quest assay, which measures the progress of the kinase
reaction as the accumulation of ADP. We first measured
Src-YEEI activity in the absence or presence of the pFAK
peptide to establish conditions for testing the compounds
(Figure 6A). As with the Z’Lyte assay, these initial experi-
ments identified a Src-YEEI concentration dependent on
the presence of the pFAK peptide for activity (15.6 ng/
well). ADP production was barely detectable in the
absence of the pFAK peptide at this Src-YEEI concentra-
tion, but increased to 1.0 pmol ADP produced/min in the
presence of the pFAK peptide. Src-YEEI alone at 40 ng/
well resulted in the same rate of 1.0 pmol ADP produced/
min and was used for comparative purposes.
Both WH-4-124-2 and WH-4-023 inhibited Src-YEEI activ-
ity in the ADP Quest assay in a concentration–dependent
manner (Figure 6B, C and Table 1). WH-4-124-2 is more
potent against Src-YEEI in complex with the pFAK peptide
than Src-YEEI alone, with IC50 values of 114 versus
531 nM, respectively. By contrast, WH-4-023 inhibited Src-
YEEI alone and in complex with the pFAK peptide with
very similar potencies, yielding IC50 values of 19 and
25 nM, respectively (Figure 6C and Table 1). While the IC50
values generated for both inhibitors in the ADP Quest
assay are lower than those generated in the Z’Lyte assay,
the selectivity for the Src-YEEI:pFAK complex is the same
in both. This difference in apparent potency is likely due to
the different peptide substrates used as well as the assay
types involved (end-point versus kinetic).
Docking studies are consistent with pFAK peptide
binding inducing a DFG flip in the c-Src kinase
domain that favors WH-4-124-2 binding
Data presented in the previous sections suggest that bind-
ing of pFAK to c-Src may induce a conformation of the
kinase active site that is stabilized by WH-4-124-2 binding.
One well-known determinant of kinase inhibitor specificity
relates to the conformation of the highly conserved aspar-
tate–phenylalanine–glycine (‘DFG’) motif at the N-terminal
end of the activation loop in the kinase active site (48,49). In
the active state, the aspartate in the DFG motif moves into
the active site where it contributes to the co-ordination of
ATP-Mg++. In the inactive state, however, this aspartate
residue moves away from the active site while the phenylala-
nine side chain moves inward, resulting in the so-called
DFG-out conformation. Previous structural studies have
shown that inhibitors such as imatinib prefer the DFG-out
conformation, which accounts in part for its selectivity
toward the Abl kinase domain (48,50). Interestingly, imatinib
has also been co-crystallized with both c-Src and Lck,
where it binds to a similar DFG-out conformation (43,51).
These observations led us to consider whether WH-4-124-2
may exhibit some of its selectivity by inhibiting the DFG-out
state of Src-family kinase domains.
Comparison of the chemical structures of WH-4-124-2
and imatinib reveals significant overlap (Figure 7A), allow-
ing us to align WH-4-124-2 with imatinib in the X-ray crys-
tal structure of the Lck kinase domain. This Src-family
kinase structure was chosen because all of its kinase
A
B
C
Figure 6: WH-4-124-2 exhibits increased potency while
maintaining selectivity in a kinetic kinase assay. (A) The activity of
Src-YEEI was measured in the ADP Quest kinetic kinase assay in
the absence (gray circles) or presence (black circles) of 30 lM
pFAK peptide over the range of input kinase concentrations
shown. Compounds WH-4-124-2 (B) and WH-4-023 (C) were
assayed against Src-YEEI alone (gray circles) and the Src-YEEI:
pFAK complex (black circles) in this assay over the range of
inhibitor concentrations shown. Reaction rates at each compound
concentration were measured in quadruplicate and are presented
as the mean ! SE. IC50 values were determined by nonlinear
regression analysis and are shown in Table 1.
150 Chem Biol Drug Des 2015; 86: 144–155
Moroco et al.
domain features are resolved, including the activation loop
and autophosphorylation site, which are missing from the
c-Src structure with imatinib (51). Binding of imatinib to
the kinase domains of both Lck and c-Src stabilizes the
DFG-out conformation, similar to what is observed with
the Abl kinase domain when bound to this drug (52). In
Lck, however, the activation loop and tyrosine autophos-
phorylation site are extended outward (Figure 7B),
whereas in Abl, the equivalent tyrosine residue is hydro-
gen-bonded to the catalytic aspartate (52). This compari-
son suggests that in Lck (and by analogy, c-Src), imatinib
traps a ‘primed’ or intermediate state between the down-
regulated and fully active forms of the kinase domain.
WH-4-124-2 was aligned with imatinib in the Lck kinase
domain crystal structure using the docking routine smina
(42) a modified version of AutoDock Vina (53) optimized for
user-specified custom scoring functions (see Methods for
details of the docking approach). WH-4-124-2 was readily
accommodated by the crystal conformation of the imati-
nib-bound Lck active site. Remarkably, no structural rear-
rangement of the imatinib-bound Lck structure was
necessary to obtain the final model presented in Fig-
ure 7B, supporting the idea that this inhibitor prefers the
DFG-out conformation. A similar docking routine was also
performed using the X-ray crystal structure of the c-Src
kinase domain bound to imatinib (PDB: 2OIQ) (51). This
analysis yielded an almost identical result, although the
activation loop is not resolved in this structure (not shown).
These docking models suggest that binding of the pFAK
peptide and displacement of the SH3-SH2 regulatory su-
bunits allow the kinase to adopt the DFG-out conforma-
tion, which in turn is trapped by WH-4-124-2. In contrast,
attempts to dock WH-4-124-2 to the kinase domain of
Lck in the active conformation (PDB ID: 3LCK) (54) were
unsuccessful, resulting in steric clash (not shown). In the
active structure, the Lck DFG motif is rotated inward,
which is incompatible with compound binding.
Unlike WH-4-124-2, which selectively inhibits the Src-
YEEI:pFAK peptide complex, compound WH-4-023
potently inhibited c-Src activity regardless of pFAK peptide
binding. This observation suggests that WH-4-023 may
inhibit both the DFG-out and DFG-in conformations of the
kinase domain. Molecular docking studies support this
idea. The 2-aminopyrimidine carbamate backbone in WH-
4-023 closely resembles a similar ligand in an X-ray crystal
structure of the Lck kinase domain in the DFG-in confor-
mation (compound 43; PDB: 2OFU) (39). Docking of WH-
4-023 to this structure recovered the same binding mode
found for compound 43 in the co-crystal (Figure 8A). We
then docked WH-4-023 in the same pocket of the DFG-
out structure of the Lck kinase domain described above
(PDB: 2PL0) (43). The binding orientations of WH-4-023
are very similar in the two models (Figure 8B) and match
that of the closely related ligand (compound 43) in struc-
ture 2OFU. One minor difference between the two docking
models involves the orientation of the WH-4-023 dimeth-
oxyphenyl ring, which is rotated 180° in the DFG-out bind-
ing mode to accommodate the side chain of the DFG
phenylalanine (Figure 8B, arrow). However, the very similar
binding modes for WH-4-023 to both states of the Lck
kinase domain may help to explain the almost identical
potencies of this compound for c-Src in the presence and
absence of the pFAK peptide.
Docking studies presented above suggest that binding of
the pFAK peptide to the SH3-SH2 region of Src allows the
kinase domain to adopt the DFG-out conformation pre-
ferred by WH-4-124-2. However, kinase activation is asso-
ciated with movement of the DFG motif into the active
site, suggesting that preactivation of c-Src by incubation
A
B
Figure 7: Computational docking of WH-4-124-2 to the X-ray
crystal structure of the Lck kinase domain bound to imatinib. (A)
Comparison of the structures of WH-4-124-2 and imatinib reveals
a shared methylpiperazinylmethyl-N-phenylbenzamide backbone
(red). (B) Close-up view of the Lck active site with WH-4-124-2
(carbon atoms in cyan) aligned to imatinib (carbon atoms in
yellow). WH-4-124-2 was readily accommodated by this imatinib-
binding conformation of the Lck kinase domain. In this structure,
the N-terminal portion of the activation loop (blue) adopts the
DFG-out conformation, with the autophosphorylation site (Y416)
extending outward. The side chains of the catalytic aspartate and
the gatekeeper residue (T338) are shown for reference. Docking
model was produced using the X-ray crystal structure of the Src-
family kinase Lck bound to imatinib (PDB: 2PL0). Residue
numbering is based on the crystal structure of c-Src (PDB:
2SRC).
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with ATP before inhibitor addition may interfere with WH-
4-124-2 action. To test this idea experimentally, we per-
formed a concentration–response experiment with WH-4-
124-2 using Src-YEEI that was preincubated with ATP
under conditions previously shown to result in stoichiome-
tric autophosphorylation of the activation loop (26). As
shown in Figure 9, autophosphorylation of Src-YEEI did
not appreciably influence inhibition by this compound
compared to a matched control preincubated under identi-
cal conditions in the absence of ATP. Addition of the pFAK
peptide to the assay enhanced inhibitor sensitivity as
observed previously, regardless of ATP preincubation, pro-
viding further evidence that peptide engagement of the
regulatory domains is largely responsible for the observed
enhancement in inhibitor action.
Previous studies have established that the Abl kinase
inhibitor imatinib derives its specificity, in part, from its
preference for the DFG-out conformation of the Abl kinase
domain (48). Docking studies presented in Figure 7 sug-
gest that pFAK peptide binding may induce the DFG-out
state of Src, because the preferred docking pose for WH-
4-124-2 requires this kinase domain conformation. Taken
together, these observations suggest that pFAK peptide
binding may also enhance the sensitivity of Src to inhibition
by imatinib. To test this idea, we performed concentra-
tion–response experiments with imatinib and Src-YEEI in
the presence and absence of pFAK as before. As shown
in Figure 10, imatinib exhibited very little activity against
Src-YEEI alone, consistent with literature reports that imati-
nib is a very poor Src inhibitor (51). Interestingly, when the
experiment was repeated with the Src:pFAK peptide com-
plex, partial inhibition was observed, although only at very
A
B
Figure 8: Computational docking of WH-4-023 to the X-ray
crystal structures of the DFG-in and DFG-out conformations of
the Lck kinase domain. (A) View of the Lck active site with WH-4-
023 (carbons in green) aligned to the related 2-aminopyrimidine
carbamate (compound 43; carbons in yellow) in the crystal
structure of the Lck kinase domain in the DFG-in conformation
(PDB: 2OFU). In the DFG-in state, the activation loop tyrosine is
phosphorylated (pY416). (B) Crystal structure of the Lck kinase
domain in the DFG-out conformation (PDB: 2PL0) accommodates
WH-4-023 in the same binding pocket as in panel A, with the
ligand dimethoxyphenyl moiety rotated to accommodate the
phenylalanine side chain of the DFG motif (arrow). In both models,
the activation loop is colored in blue with the side chains of the
DFG motif, the catalytic aspartate and the gatekeeper residue
(T338) shown. Residue numbering is based on the crystal
structure of c-Src (PDB: 2SRC).
Figure 9: Preincubation with ATP does not affect WH-4-124-2
potency for Src-YEEI. Src-YEEI was preincubated in the presence
(top panel) or absence (bottom panel) of ATP (at the Km) for 3 h
at 25 °C to induce autophosphorylation of Tyr416 in the activation
loop as described previously (26). Each kinase preparation was
then assayed for sensitivity to WH-4-124-2 in the presence or
absence of the pFAK peptide using the Z’Lyte end-point assay.
All data points were measured in quadruplicate, and the values
shown represent the mean ! SE.
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high imatinib concentrations (~25% inhibition at 100 lM).
This result suggests that the additional methylphenylpiper-
azine and/or dimethoxybenzyl moieties present in WH-4-
124-2 account for its much greater potency against the
pFAK:Src complex relative to imatinib (see Figure 7). Nev-
ertheless, these findings support the idea that pFAK pep-
tide binding induces the DFG-out conformation.
Interestingly, the presence of the pFAK peptide also
resulted in a modest increase in the sensitivity of Src to
inhibition by dasatinib (~4 fold; Figure 10), despite its clas-
sification as a ‘Type I’ kinase inhibitor (i.e., one that does
not sense differences in the position of the DFG motif)
(30,55). This observation suggests that SH3-SH2 engage-
ment by the pFAK peptide may induce unique conforma-
tional changes in the active site in addition to influencing
the status of the DFG motif.
Summary and Conclusions
In this study, we describe a screening strategy that
enables discovery of c-Src inhibitors that appear to prefer
a specific active site conformation. SFKs are involved in a
wide variety of cellular signaling pathways and most cells
express multiple members of the Src kinase family, making
the search for isoform- and pathway-selective inhibitors
difficult. Rather than focusing on the Src kinase domain in
isolation, we developed an assay method that models a
disease-specific conformation of near-full-length c-Src that
is induced by interaction with FAK. Using a synthetic tyro-
sine phosphopeptide containing the natural FAK sequence
known to bind to the tandem SH3/SH2 unit of c-Src, we
first identified screening assay conditions where Src-YEEI
activity was dependent on the presence of the pFAK pep-
tide. Using pFAK-activated Src-YEEI, we then screened a
small library of kinase-biased inhibitors and identified WH-
4-124-2, an aminopyrimidinyl carbamate with enhanced
potency for Src-YEEI in the presence of the pFAK peptide.
This compound exhibited fivefold greater potency for the
Src-pFAK peptide complex relative to Src-YEEI alone in
both end-point and kinetic kinase assays. Interestingly, a
smaller structural analog of WH-4-124-2 showed no pref-
erence, supporting the idea that WH-4-124-2 stabilizes a
specific conformation of the kinase active site that is
induced by interaction with the pFAK peptide.
Docking studies with WH-4-124-2 and the imatinib-bound
crystal structures of two Src-family kinase domains (c-Src
and Lck) suggest that binding to the pFAK peptide may
allow a unique DFG-out conformation that is preferentially
inhibited by this compound. In this conformation, the aC-
helices of both kinase domains are rotated inward, allow-
ing the formation of the conserved lysine to glutamate salt
bridges. The DFG motif at the distal end of the activation
loop in each kinase is rotated outward, in the same man-
ner originally observed for imatinib binding to the Abl
kinase domain (48). However, in the Lck structure, the
autophosphorylation site is extended outward, although
the tyrosine is not phosphorylated (this region is not
resolved in the c-Src kinase domain structure with imati-
nib). Using the structural overlap with imatinib as a starting
point, WH-4-124-2 was readily docked into this unique
Lck kinase domain conformation. This observation with
Lck suggests that pFAK peptide binding may induce a
similar kinase domain conformation in c-Src, thereby
accounting for preferential inhibition by WH-4-124-2 in the
presence of the pFAK peptide. Whether or not binding to
full-length FAK results in similar changes to the c-Src
active site in a cellular context will require further investiga-
tion. Nevertheless, these studies support the more general
concept that unique disease-state-specific conformations
of Src-family kinases exist in cells that may be amenable
to selective inhibition with active site inhibitors.
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Abstract
The ABL protein-tyrosine kinase regulates intracellular signaling pathways controlling
diverse cellular processes and contributes to several forms of cancer. The kinase activity of
ABL is repressed by intramolecular interactions involving its regulatory Ncap, SH3 and SH2
domains. Small molecules that allosterically regulate ABL kinase activity through its non-
catalytic domains may represent selective probes of ABL function. Here we report a screen-
ing assay for chemical modulators of ABL kinase activity that target the regulatory interac-
tion of the SH3 domain with the SH2-kinase linker. This fluorescence polarization (FP)
assay is based on a purified recombinant ABL protein consisting of the N-cap, SH3 and
SH2 domains plus the SH2-kinase linker (N32L protein) and a short fluorescein-labeled
probe peptide that binds to the SH3 domain. In assay development experiments, we found
that the probe peptide binds to the recombinant ABL N32L protein in vitro, producing a
robust FP signal that can be competed with an excess of unlabeled peptide. The FP signal
is not observed with control N32L proteins bearing either an inactivating mutation in the
SH3 domain or enhanced SH3:linker interaction. A pilot screen of 1200 FDA-approved
drugs identified four compounds that specifically reduced the FP signal by at least three
standard deviations from the untreated controls. Secondary assays showed that one of
these hit compounds, the antithrombotic drug dipyridamole, enhances ABL kinase activity
in vitro to a greater extent than the previously described ABL agonist, DPH. Docking studies
predicted that this compound binds to a pocket formed at the interface of the SH3 domain
and the linker, suggesting that it activates ABL by disrupting this regulatory interaction.
These results show that screening assays based on the non-catalytic domains of ABL can
identify allosteric small molecule regulators of kinase function, providing a new approach to
selective drug discovery for this important kinase system.
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Introduction
The ABL protein-tyrosine kinase plays diverse roles in the regulation of cell proliferation, sur-
vival, adhesion, migration and the genotoxic stress response [1–3]. ABL kinase activity is per-
haps best known in the context of BCR-ABL, the translocation gene product responsible for
chronic myelogenous leukemia (CML) and some forms of acute lymphocytic leukemia [4,5].
The clinical management of CML has been revolutionized by selective ATP-competitive inhibi-
tors of BCR-ABL, of which imatinib is the prototype [6]. However, chronic use of kinase inhib-
itors often leads to drug resistance due to selection for mutations that disrupt drug binding or
allosterically influence the conformation of the drug binding pocket [7].
The growing problem of imatininb resistance in BCR-ABL has fueled efforts to identify
compounds that work outside of the kinase active site. Such compounds offer advantages in
terms of enhanced specificity, because they have the potential to exploit non-conserved regula-
tory features unique to ABL that persist to some extent in BCR-ABL as well [8]. The kinase
activity of ABL is tightly regulated in vivo by an auto-inhibitory mechanism. The ABL ‘core’
region, which includes a myristoylated N-terminal ‘cap’ (N-cap), SH3 and SH2 domains, an
SH2-kinase linker and the kinase domain, is both necessary and sufficient for ABL auto-inhibi-
tion [9]. Subsequent X-ray crystal structures of the ABL core revealed three critical intramolec-
ular interactions that regulate kinase activity [10–12] (Fig 1A and 1B). First, the SH2-kinase
linker forms a polyproline type II helix that binds to the SH3 domain, forming an interface
between the SH3 domain and the N-lobe of the kinase domain. Second, the SH2 domain inter-
acts with the back of the kinase domain C-lobe through an extensive network of hydrogen
bonds. Aromatic interactions between the side chains of SH2 Tyr158 and kinase domain
Tyr361 also help to stabilize this interaction (see Panjarian et al. for an explanation of the ABL
amino acid numbering scheme [13]). Finally, the myristoylated N-cap binds a deep hydropho-
bic pocket in the C-lobe of the kinase domain, clamping the SH3 and SH2 domains against the
back of the kinase domain. Small molecules that occupy the myristic acid binding site in the C-
lobe of the kinase domain have proven to be effective allosteric inhibitors of BCR-ABL function
[14,15].
Mutational analysis demonstrates that intramolecular SH3:linker interaction plays a central
role in ABL auto-inhibition. Substitution of linker proline residues at positions 242 and 249
with glutamate disrupts SH3:linker interaction, resulting in ABL kinase activation [16]. In con-
trast, increasing the proline content of the linker enhances internal SH3 binding and over-
comes the activating effects of mutations in the myristic acid binding pocket as well as the
kinase domain gatekeeper residue (Thr315) [8]. Remarkably, enhanced SH3:linker interaction
also dramatically sensitizes BCR-ABL-transformed cells to inhibition by both imatinib and the
allosteric inhibitor, GNF-2, which binds to the myristic acid binding pocket [8]. These findings
suggest that small molecules enhancing or disrupting this natural regulatory mechanism may
represent selective allosteric modulators of ABL kinase activity.
In contrast to the tremendous research efforts invested in discovering inhibitors for ABL
kinase activity, few studies have explored the discovery of small molecules that activate ABL.
Selective agonists may represent useful probes to examine the role of ABL kinase activity in
normal cellular functions, such as DNA-damage repair pathways. ABL is activated in response
to multiple forms of genotoxic stress and interacts with modulators of both DNA damage-
induced apoptosis (e.g. p73) and DNA repair (e.g. Rad51), resulting in cell death or survival
depending on the cellular environment [2]. Moreover, recent studies have shown that ABL
inhibits the growth of breast cancer xenografts and promotes the phenotypic reversion of inva-
sive breast cancer cells [17,18]. Selective and potent agonists would provide a new approach to
explore these and other biological roles of ABL in vivo.
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Fig 1. FP assay for small moleculemodulators of ABL kinase function. A) Crystal structure of the auto-inhibited ABL core (PDB: 2FO0) [11]. Key
features include the N-cap, SH3 and SH2 domains, the SH2-kinase linker, and the kinase domain. The disordered portion of the N-cap is indicated by the
dotted line. The N-terminal portion of the N-cap is myristoylated and engages a deep pocket in the kinase domain C-lobe. B) Cartoon depiction of the
intramolecular interactions regulating assembly of the downregulated ABL core. Note that the linker forms a polyproline helix that binds in cis to the SH3
domain. C) Fluorescence polarization (FP) assay. The FP assay combines a recombinant ABL Ncap-SH3-SH2-linker (N32L) protein and a SH3-binding
peptide probe labeled with a fluorescent moiety (F). The probe peptide binds the SH3 domain in the ABL N32L protein, resulting in an FP signal. Small
molecules (S) may bind to the SH3 domain and block probe peptide binding directly; such molecules would be expected to disrupt SH3:linker interaction
(case 1). Alternatively, small molecules may stabilize SH3:linker interaction, making the SH3 domain inaccessible to the probe peptide (case 2). In either
case, small molecule binding is predicted to result in a loss of the FP signal.
doi:10.1371/journal.pone.0133590.g001
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In this study, we report the development and validation of a high-throughput screening
assay for the identification of small molecules that interact directly with the non-catalytic
region of the ABL core. Our assay is based on the interaction of a fluorescent probe peptide
with the SH3 domain in the context of a recombinant protein encompassing the regulatory
region of the ABL core (Ncap-SH3-SH2-linker; referred to hereafter as the ABL ‘N32L’ pro-
tein). Interaction of the probe peptide with the ABL N32L protein results in fluorescence polar-
ization (FP), providing a convenient assay for SH3 occupancy in a format compatible with
high-throughput chemical library screening. In theory, small molecules that bind to SH3 and
disrupt probe binding may also disrupt SH3:linker interaction in the context of ABL, resulting
in kinase activation. On the other hand, compounds that enhance internal SH3 binding to the
natural linker may represent allosteric inhibitors. Using this FP approach, we screened a small
library of FDA-approved drugs and identified a compound that specifically inhibited the FP
signal from the complex of the ABL N32L protein with the probe peptide, suggesting that it
may interfere with SH3:linker interaction. This compound, a substituted pyrimido-pyrimidine
known as dipyridamole, was confirmed to bind directly to the ABL N32L protein using both
differential scanning fluorimetry and surface plasmon resonance. Dipyridamole was found to
enhance the activity of a recombinant downregulated ABL core protein, but had no effect on
an ABL core with engineered high-affinity SH3:linker interaction or on the SRC-family kinase,
HCK. These observations suggest that dipyridamole binds selectively to the ABL SH3 domain,
resulting in linker displacement and kinase activation. This binding model is supported by
molecular dynamics (MD) simulations and molecular docking. Our findings provide an
important proof-of-concept that small molecules acting on the ABL SH3:linker interface can
allosterically modulate ABL kinase activity, and provide a simple yet powerful assay method
for their discovery.
Materials and Methods
Expression and purification of recombinant kinase proteins
The coding sequence for the ABL Ncap-SH3-SH2-linker region (N32L; corresponding to resi-
dues 2–255 with an internal deletion of residues 15–56; numbering based on the crystal struc-
ture of the human ABL core; PDB: 2FO0 [11]) was amplified by PCR and subcloned into the
bacterial expression vector, pET21a (EMDMillipore). A similar construct was prepared using
the sequence of ABL with a high-affinity linker (‘HAL9’) substitution as described previously
[8]. One glycine and six histidine residues (GHHHHHH) were introduced at the N-terminus
of the coding sequence of these proteins during sub-cloning. An inactivating mutation of the
SH3 domain (W118A) was introduced by site-directed mutagenesis using the QuikChange II
method (Stratagene) and the pET21a-ABL N32LWT plasmid as a template. The ABL N32L
proteins were expressed in E.coli strain Rosetta2(DE3)pLysS (EMDMillipore) and purified
using immobilized metal affinity chromatography. The purified proteins were then dialyzed
against 20 mM Tris-HCl (pH 8.3) containing 200 mMNaCl and 1 mMDTT.
The wild type and high-affinity linker (‘HAL9’) ABL core proteins (residues 1–531 with an
internal deletion of residues 15–56) were expressed in Sf9 insect cells as previously described
[8]. The ABL core proteins were purified using a combination of ion-exchange and affinity
chromatography and dialyzed against 20 mM Tris-HCl (pH 8.3) containing 100 mMNaCl and
3 mM DTT. The molecular weight and purity of all recombinant ABL proteins were confirmed
by SDS-PAGE and mass spectrometry.
The SRC-family kinase HCK-YEEI was expressed in Sf9 insect cells and purified as previ-
ously described [19].
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Peptide synthesis
ABL SH3 domain-binding peptides p41, p40, p8, and 3BP-1 [20,21] were synthesized by the
University of Pittsburgh Genomics and Proteomics Core Laboratories. For the FP assay, the
peptides were labeled with 6-carboxyfluorescein at their N-termini. Molecular weight and purity
of all peptides were verified by mass spectrometry. Stock solutions (10 mM) were prepared in a
1:1 mixture of DMSO and FP assay buffer (20 mM Tris-HCl, pH 8.3) for labeled peptides and
neat FP assay buffer for unlabeled peptides. Peptide stock solutions were stored at -20°C.
Fluorescence polarization assay
Fluorescence Polarization (FP) experiments were performed in quadruplicate in low volume
black 384 well plates with a non-binding surface (Corning; catalog # 3676). Peptides and proteins
were added to each well in FP assay buffer (20 mMTris-HCl, pH 8.3) for a final assay volume of
20 μL and mixed by shaking for 5 min at room temperature. The FP signal in millipolarization
(mP) units was measured at an excitation wavelength of 485 nM and emission wavelength of
515 nM in a SpectraMax M5microplate reader (Molecular Devices) using the Softmax Pro soft-
ware (version 5.4.1). Each plate was read three times and the values were averaged prior to analy-
sis. Raw fluorescence intensity was also read at the same wavelengths for each assay.
Chemical library screening
A collection of 1200 FDA-approved small molecules (Prestwick Chemical, Inc.) was used in a
pilot screen with the FP assay. Each library compound was screened at 10 μM and a final
DMSO concentration of 1%. Compounds were added to 384-well assay plates first, followed by
a pre-mixed complex of the ABL N32L protein (25 μg) and the p41 probe peptide (50 nM).
Each plate also contained twenty-eight wells of the wild type N32L protein plus p41 probe and
DMSO as positive controls as well as twenty-eight wells of mutant ABL N32L-W118A protein
plus p41 probe peptide and DMSO as negative controls. Each plate was mixed on the shaker
for 5 min, read three consecutive times, and the average FP signal for each well was calculated.
To identify potential hit compounds, three measures were used: (i) average FP signal; (ii) con-
trol normalized percent inhibition, in which the FP signal with each compound was normal-
ized to the mean FP signal of the positive and negative plate controls according to the formula:
[(sample FP–mean FPWT) / (mean FPW118A –mean FPWT) x 100] [22,23]; (iii) Z score, a statis-
tical measure of variation of the mean sample FP signal that is independent of plate controls,
calculated according to the formula: [(sample FP–mean FPsamples) / standard deviationsamples]
[22,23]. The compounds were then ranked in order of increasing FP signal, decreasing control
normalized percent inhibition, and increasing Z score. Potential hit compounds were then
retested in quadruplicate using the FP assay under screening assay conditions.
Differential Scanning Fluorimetry
Hit compounds (100 μM) were pre-incubated with the ABL N32L WT protein (1 μM) for 30
minutes in bicine assay buffer (10 mM bicine, 150 mMNaCl, pH 8.0). SYPRO Orange (Sigma)
was added at 5X final concentration and fluorimetry profiles were acquired with a StepOnePlus
real-time quantitative PCR instrument (Applied Biosystems) and software (version 2.3). Assays
were performed in duplicate in sealed MicroAmp Fast 96-well qPCR plates (Applied Biosys-
tems), and control reactions without proteins were included to correct for background fluores-
cence. Assays were equilibrated at 25°C for 2 minutes, followed by an increase in temperature
at the rate of 1% (1.6°C/min) to 99°C, with continuous data collection. Mean fluorescence
intensities, after subtracting background fluorescence, were plotted against temperature. Non-
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linear regression analysis using the Boltzmann sigmoid function in GraphPad Prism 6 was
used to determine the Tm values, the midpoint of the melt curve between the minimum and
maximum fluorescence intensities.
Surface Plasmon Resonance (SPR)
SPR analysis was performed on a BIAcore T100 instrument (GE Healthcare) using four-chan-
nel CM5 biosensor chips at 25°C. Recombinant purified ABL proteins were covalently attached
to the CM5 chip via standard amine coupling chemistry [24,25]. Compound 142 (dipyrida-
mole; Prestwick Chemical) was prepared in 20 mM Tris-HCl, pH 8.3, 150 mMNaCl and 0.1%
DMSO and flowed past the immobilized ABL protein channel and a reference channel on the
biosensor at a flow rate of 50 μL/min for 3 min over a range of concentrations. The initial bind-
ing reaction was followed by dissociation for 5 min, and the chip surface was regenerated using
20 mM Tris-HCl, pH 8.3, 150 mMNaCl, 0.1% DMSO, 0.05% Tween 20 and 1 mMDTT at a
flow rate of 50 μL/min for 10 min. Sensorgrams were recorded in triplicate, corrected for buffer
effects, and fitted with the 1:1 Langmuir binding model using the BIAevaluation software suite
version 2.0.4 (GE Healthcare).
Protein kinase assays
The ADP Quest assay (DiscoverRx) [26], which fluorimetrically measures kinase activity as the
production of ADP, was used to determine ABL kinase reaction velocities. Assays were per-
formed in quadruplicate in black 384 well plates (Corning #3571) in reaction volumes of
10 μL/well. Recombinant kinase protein concentrations were fixed at 40 ng/well for the wild
type ABL core, 9 ng/well for the high affinity linker ABL core, and 250 ng/well for the SRC fam-
ily kinase HCK. The Tyr2 substrate peptide for ABL (EAIYAAPFAKKK) as well as the SFK
substrate peptide (YIYGSFK) were dissolved in the ADP Quest assay buffer (15 mMHEPES,
pH 7.4, 20 mMNaCl, 1 mM EGTA, 0.02% Tween-20, 10 mMMgCl2, 0.1 mg/ml bovine γ-glob-
ulins), while ATP stocks were prepared in 10 mM Tris-HCl (pH 7.0). Each kinase reaction was
initiated by the addition of ATP and read at 5 min intervals for 3 h in a SpectraMax M5 Micro-
plate reader (Molecular Devices). To determine the substrate Km for ABL kinases, the ATP
concentration was fixed at 50 μM and the substrate peptide was serially diluted from 0.2–
200 μM. For ABL kinase ATP Km determination, the substrate concentration was fixed at the
respective substrate Km for each of the kinases, and the ATP concentration was titrated over
the range of 0.2–200 μM. The resulting progress curves were analyzed according to the method
of Moroco et al. [19]. Briefly, raw fluorescence data were corrected for non-enzymatic ADP
production (no kinase or substrate control) and kinase auto-phosphorylation (rate observed in
the absence of substrate), and converted to pmol ADP produced using an ADP standard curve
generated under the same reaction conditions. The resulting values were normalized to the
amount of kinase present in each reaction, and plotted against time. The linear portion of each
progress curve was fit by regression analysis to determine the reaction velocity. Substrate and
ATP Km values were determined by non-linear regression analysis using the Michaelis-Menten
equation (GraphPad Prism 6).
Half-maximal effective concentrations (EC50) and activation constants (Kact) were deter-
mined for the ABL kinase core by both dipyridamole and the known ABL activator, DPH (5-
(1,3-diaryl-1H-pyrazol-4-yl)hydantoin; Sigma-Aldrich) [27]. The kinase was pre-incubated with
each compound (10 nM to 100 μM) for 30 min at room temperature, followed by kinase assay
with the substrate and ATP concentrations fixed at their respective Km values. The rate of each
reaction was plotted against compound concentration, and analyzed by non-linear regression
analysis (GraphPad Prism 6) to determine the EC50 value. To determine the activation constant
HTS Assays for Chemical Probes of ABL Kinase
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Kact, the basal rate of kinase activity was subtracted from the rates of reaction in the presence of
each compound concentration, and plotted as a function of compound concentration. The
resulting curves obeyed saturation kinetics and were best-fit by the following equation [19]:
Va ¼ Vact½L=ðKact þ ½LÞ
where Va is the reaction velocity in the presence of each activator concentration, Vact is the maxi-
mal reaction velocity, L is the activator concentration, and Kact is the activator concentration that
yields half-maximal reaction velocity.
Molecular dynamics
To understand the dynamics of the recombinant N32L protein, for which there is no X-ray
crystal structure, we ran unconstrained molecular dynamics (MD) simulations of residues 65–
254 of the assembled, downregulated ABL core structure (PDB 2FO0). We disrupted the inter-
action between linker Pro249 and the SH3 domain by rotating the backbone bonds of linker
Gly246. This glycine residue was chosen as a pivot point as it is more flexible and is located
between Pro249 and the next strongly interacting residue (Val244) based on the predicted
interaction energy with the SH3 domain [28]. We also ran MD simulations of the (unmodified)
isolated SH3 domain (residues 80–145) using the same parameters described below.
MD simulations were conducted with the pmemd.cuda [29] module of AMBER14 [30],
using the force fields AMBER ff14SB and gaff (general amber force fields) [31]. An octahedral
TIP3P water box was constructed with 12 Å from the edge of the box to the solute and the total
system charge was neutralized by adding chloride ions. The non-bonded cutoff was specified at
10 Å. In the first energy minimization run, the solute was held fixed and the solvent was relaxed
through 500 cycles of steepest descent followed by 500 cycles of conjugate gradient minimiza-
tion. Subsequently, the system was minimized again with no constraints through 2,000 cycles
of steepest descent followed by 3,000 cycles of conjugate gradient minimization. Following the
energy minimization, a 50,000 step MD simulation was used to raise the system temperature to
300 K while holding the solute fixed with weak (10.0 kcal/mol) restraints on the solute atoms.
The bonds involving hydrogens were held at a fixed length and an integration step of 2 fs was
used. This simulation was followed by a second equilibration simulation at constant pressure
for 50,000 steps. The final MD simulation of this equilibrated structure was run with no con-
straints for 100 ns.
Computational docking
The binding mode of hit compound 142 (dipyrimadole) was modeled to snapshots of the N32L
and SH3 simulations by molecular docking using the program smina [32] with default docking
parameters. The box was defined by the coordinates of linker residues 247–251 plus an outer
shell of 8 Å after alignment to the SH3 domain of the crystal structure (PDB 2FO0).
Transient expression of ABL core proteins in 293T cells
ABL core proteins were expressed in human 293T cells and analyzed for kinase activity as
described elsewhere [8]. Briefly, cells were grown overnight in 60 mm plates, transfected with
an expression vector for the wild type ABL core, and treated with compounds 2 h post- trans-
fection. Cells were lysed by sonication 24 h later, and cell lysates clarified by centrifugation.
ABL was immunoprecipitated via the C-terminal His-tag, resolved by SDS-PAGE, and trans-
ferred to nitrocellulose membranes for immunoblot analysis with antibodies to the ABL pro-
tein and the three autophosphorylation sites: pTyr412 (activation loop), pTyr245 (SH2-kinase
linker), and pTyr89 (SH3 domain).
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Results and Discussion
ABL fluorescence polarization (FP) assay design
In this study, we developed a screening assay for small molecule allosteric modulators of ABL
kinase function. Our goal was to enable discovery of chemical scaffolds that interact with the
regulatory region of the ABL kinase core, as opposed to the kinase domain, thereby providing a
path to enhanced selectivity and allosteric control of kinase function. In addition, we wanted a
flexible assay with the potential to identify both inhibitors and activators of ABL function. To
accomplish these goals, we developed a fluorescence polarization (FP) assay based on the N-
terminal region of ABL consisting of the Ncap, SH3 and SH2 domains, and the SH2-kinase
linker (ABL N32L protein). Binding of a fluorescently labeled probe peptide to the SH3 domain
(displacing the linker) should result in an increased FP signal due to the slowed rotation of the
N32L target protein-peptide complex (Fig 1C). A small molecule that binds to the ABL N32L
protein and enhances SH3 interaction with the linker in cis is predicted to prevent probe pep-
tide binding, resulting in a decrease in the FP signal. Molecules in this class are predicted to act
as allosteric inhibitors of ABL kinase activity, because they may enhance the natural negative
regulatory interaction between the SH3 domain and the linker. Alternatively, compounds that
interact with the SH3 domain and block probe peptide binding are also predicted to cause a
decrease in the FP signal. By displacing SH3:linker interaction in the context of downregulated
ABL, compounds of this type may act as allosteric activators of kinase activity. This assay
design therefore has the potential to identify both types of ABL-binding compounds in a single
chemical library screen. Their impact on ABL function can be easily distinguished in secondary
assays for direct binding to the ABL domains, as well as functional assays.
Recombinant ABL regulatory proteins for FP assay development
The target protein for the ABL FP assay consists of the first 255 residues of ABL (isoform 1b),
and encompasses the Ncap, the SH3 and SH2 domains, as well as the SH2-kinase linker as
described above. This ABL N32L protein was expressed in bacteria in soluble form, purified to
homogeneity, and its purity and identity were confirmed by SDS-polyacrylamide gel electro-
phoresis and mass spectrometry, respectively (Fig 2). Previous studies have established that
regulatory SH3:linker interaction is maintained in this construct, despite the absence of the
kinase domain [8,33]. In addition to the wild type protein, two mutant forms of N32L were
produced for use as controls. The first of these has an alanine substitution for a conserved tryp-
tophan on the SH3 domain binding surface (W118A mutant; see Fig 3 for SH3 domain struc-
ture), which renders it unable to bind to the probe peptide and thus serves as a negative
control. In the second mutant, five linker residues were replaced with prolines to enhance
interaction with the SH3 domain [8]. This high-affinity linker (HAL) substitution suppresses
the activating effects of kinase domain mutations and influences the conformation of the kinase
domain, enhancing both imatinib and allosteric inhibitor action (see Introduction). The HAL
protein therefore represents a second negative control for probe peptide binding to the SH3
domain. Both the W118A and HAL forms of the ABL N32L protein were also expressed and
purified from bacteria, and yielded soluble purified proteins of the expected mass (Fig 2).
Structural basis for high affinity probe peptide binding to the ABL SH3
domain
A suitable probe for the ABL N32L FP assay required a short, proline-rich peptide with
sequence specificity for the ABL SH3 domain. In addition, the probe peptide needed to bind to
the SH3 domain with sufficient affinity to compete for cis-interaction of the SH3 domain with
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the natural linker (Fig 1). A survey of the literature identified four ABL SH3-binding peptides
with the potential to serve as probes [20,21]. These peptides, designated p41, p40, p8, and 3BP-
1, have KD values for the ABL SH3 domain in the 0.4 to 34 μM range. The ABL SH3-binding
peptide sequences are presented in Fig 3A, and are aligned with those of the wild type and
high-affinity SH2-kinase linkers of ABL.
To explore the potential of known ABL SH3 peptide ligands to compete for natural SH3:
linker interaction, we first compared the structure of the ABL SH3:linker interface from the
downregulated ABL core (PDB: 2FO0) [11] with the crystal structure of the p41 peptide in
complex with the ABL SH3 domain (PDB: 1BBZ) [21]. The C-terminal half of the p41 peptide
is comprised exclusively of proline, which facilitates both PPII helix formation as well as tight
interaction with the hydrophobic SH3 binding surface (Fig 3B). In contrast, this region of the
SH2-kinase linker is comprised of the less favorable SH3-binding sequence, KPTVY (Fig 3C).
Specifically, p41 proline residues 9 and 10 fill the hydrophobic groove formed by the aromatic
side chains of SH3 tyrosines 89 and 134; the linker is substituted with lysine in this position
(Lys241). The main chain carbonyl of p41 Pro8 forms a stabilizing hydrogen bond with
Tyr134. This position is substituted with threonine (Thr243) in the linker, which swings away
from the SH3 surface. The N-terminal sequence of the p41 peptide forms a network of polar
contacts involving SH3 residues Ser94, Asp96, and Trp118. None of these contacts are present
in the SH3:linker interface, and the side chain of SH3 Asp96 is rotated away from the linker.
Fig 2. Recombinant ABL Ncap-SH3-SH2-linker (N32L) proteins.Wild type ABL N32L protein and the corresponding high-affinity linker (HAL) andW118A
mutants were expressed in E. coli using the pET system [40] and purified by immobilized metal affinity chromatography. Protein purity and mass were verified
by SDS polyacrylamide gel electrophoresis (A) and mass spectrometry (B).
doi:10.1371/journal.pone.0133590.g002
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Taken together, these structural features strongly suggested that p41, or one of the closely
related peptides (p40, p8, and 3BP-1), may interact with the ABL N32L target protein with suf-
ficient affinity to displace the wild type linker and provide a stable FP signal.
Selection of a probe peptide for the ABL N32L FP assay
To evaluate the suitability of the four ABL SH3 peptide ligands (p41, p40, p8, 3BP-1; Fig 3A) as
FP probes, each peptide was synthesized and labeled with 6-carboxyfluorescein on its N-termi-
nus. We first examined the baseline FP signal as well as the fluorescence intensity exhibited by
each labeled peptide over a broad concentration range (1–1,000 nM) in the absence of the ABL
Fig 3. Peptide and linker interactions with the ABL SH3 domain. A) Sequences of the ABL SH3 binding peptides, p41, p40, p8, and 3BP-1, and their
published binding affinities for the ABL SH3 domain [20,21]. Sequences of the wild type (WT) and high-affinity (HAL) SH2-kinase linker sequences are also
shown at the bottom. The peptide sequences are presented in the C- to N-terminal orientation to align with those of the linkers. B) Crystal structure of the p41
peptide (cyan) bound to the ABL SH3 domain (PDB: 1BBZ) [21]. The SH3 surface is shown as a space filling model (red) and side chains of residues that
interact with the p41 peptide are shown as sticks. C) Crystal structure of the SH2-kinase linker (orange) bound to the ABL SH3 domain (red) from the ABL
core (PDB: 2FO0) [11]. Side chains of SH3 domain residues that interact with the p41 peptide as per panel B are shown as sticks. Note the lack of
hydrophobic interactions and hydrogen bonds between the SH3 domain and the linker in comparison to the p41 peptide.
doi:10.1371/journal.pone.0133590.g003
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N32L target protein. As shown in Fig 4A, probe peptide concentrations greater than 50 nM
exhibited stable baseline FP readings with minimal well-to-well variation.
To test for ABL N32L protein interaction with each peptide in the FP assay, we held each
probe peptide concentration at 50 nM and added the wild type N32L protein over a range of
concentrations. As shown in Fig 4B, both the p40 and p41 probe peptides produced a strong,
saturable FP signal as a function of the N32L protein concentration. The p8 peptide also pro-
duced an FP response, albeit somewhat lower than that observed with p40 and p41, while the
3BP-1 peptide was inactive. These FP results correspond to the rank order of binding affinities
previously reported for these peptides with the isolated SH3 domain [20,21]. Since the struc-
ture of the ABL SH3 domain in complex with p41 is known (Fig 3B), we chose the p41 peptide
for FP assay optimization.
ABL N32L FP assay development and optimization
We next investigated whether the FP signal obtained with the p41 probe peptide was due to
interaction with SH3 domain of the recombinant ABL N32L target protein. For these experi-
ments, we compared the FP signal produced from the wild type ABL N32L protein with the
SH3 domain mutant (W118A) as well as the high-affinity linker (HAL) protein. As shown in
Fig 5A, the wild type ABL N32L protein produced a concentration-dependent increase in the
FP signal as observed previously. In contrast, the N32LW118A mutant failed to produce an FP
signal with the p41 peptide over the same concentration range, indicating that the peptide
requires this conserved SH3 domain tryptophan residue for binding as predicted from the crys-
tal structure (see Fig 3). On the other hand, the ABL N32L HAL protein showed a greatly
reduced FP signal in comparison to the wild type protein with the p41 probe. This result is con-
sistent with enhanced cis-interaction of the linker with SH3 domain in this protein as a result
of the higher linker proline content (see Fig 3A for HAL sequence). Results with these control
proteins demonstrate that the p41 probe peptide interacts with the ABL N32L target protein
through its SH3 domain. FP experiments with the recombinant purified ABL SH3 domain
alone also produced a very similar FP response, supporting this conclusion (data not shown).
Findings with these ABL N32L mutants support the idea that small molecules that disrupt or
stabilize intramolecular interaction between the SH3 domain and linker will also reduce probe
peptide binding and loss of the FP signal.
We next tested the stability of the FP signal as a function of time (Fig 5B). For this experi-
ment, the p41 probe peptide (50 nM) and ABL N32L protein (12.8 μg/well) concentrations
were held constant. Under these conditions, no significant variation in the FP signal was
observed up to 10 hours. We also found that DMSO, the carrier solvent for the screening
library compounds, did not influence the FP signal or the negative controls even at the highest
concentration tested (1%; Fig 5C).
In a final validation experiment, we tested the effect of unlabeled p41 peptide on the FP sig-
nal (Fig 5D). For this study, we fixed the p41 probe peptide concentration at 50 nM and the
wild type ABL N32L protein concentration at 20 μg/well. Unlabeled p41 peptide was added to
the assay over the concentration range of 2.5 to 100 μM. The FP signal decreased as a function
of unlabeled p41 peptide concentration, demonstrating competition for the labeled probe pep-
tide binding to the N32L protein. As a negative control, the peptide competition experiment
was repeated with a non-specific peptide of similar length. This peptide had no effect on the FP
signal, even at a concentration of 100 μM, demonstrating the specificity of p41 peptide recogni-
tion by the SH3 domain in the N32L target protein.
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Identification of inhibitors of p41 interaction with ABL N32L
To test the performance of the ABL N32L FP assay under screening conditions, we performed
a pilot screen of 1200 FDA-approved compounds. The wild type ABL N32L protein (25 μg)
was added to each well together with the p41 probe peptide (50 nM). The compounds were
then added to a final concentration of 10 μM in 1% DMSO. Each plate contained twenty-eight
wells with the wild type N32L target protein plus DMSO as positive controls, and twenty-eight
Fig 4. Identification of p41 as optimal probe peptide for the ABL N32L FP assay. A) To characterize the
baseline FP signal, the 6-carboxy-fluorescein labeled probe peptides p41 (red), p40 (green), p8 (blue), and
3BP-1 (black) were serially diluted in the concentration range of 1–1000 nM. The FP signals (solid lines, left Y
axis) and corresponding fluorescence intensities (dashed lines, right Y axis) were measured and plotted as a
function of peptide concentration. Average values are shown ± SE from four measurements per condition. B)
To test for probe peptide interaction with ABL N32L by FP, each peptide (50 nM) was incubated with the ABL
N32L protein over the range of 0.08–25 μg/well. The resulting FP signals were corrected for baseline FP
signal recorded in the absence of the N32L protein and plotted against the N32L protein concentration.
Average FP values are shown ± SE from four measurements per condition; error bars are smaller than the
diameter of some data points.
doi:10.1371/journal.pone.0133590.g004
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wells with the non-binding W118A mutant protein plus DMSO as negative controls. The over-
all Z factor for the pilot screen was 0.57, indicative of a reliable screening assay [34]. The aver-
age FP signals observed with the controls as well as the readings observed with each of the test
compounds are presented in Fig 6A.
The FP signals for each compound were ranked by three different methods: increasing raw
FP signal, decreasing normalized percent inhibition, and increasing Z score (see Materials and
Methods). We then compared the top 1% of compounds present in each of these three rank-
ings. Five compounds were present in at least two of these rankings, and were selected for fol-
low-up assays (compound numbers 3, 42, 142, 787, and 1415; Fig 6A). Each of the raw hit
compounds was then retested in multiple wells under screening assay conditions (Fig 6B). Four
Fig 5. ABL N32L FP assay development and optimization. A) The p41 FP probe binds the ABL N32L protein through the SH3 domain. The p41 probe
peptide (50 nM) was combined with wild type, HAL, andW118A ABL N32L proteins over the range of concentrations shown. The resulting FP signals were
measured and plotted as a function of N32L protein concentration. B) FP assay stability. The p41 probe peptide (50 nM) was combined with the three ABL
N32L proteins (12.8 μg/well) and FP signals were recorded over the time course shown. C) DMSO tolerance. FP assays consisting of the p41 probe peptide
(50 nM) and each ABL N32L protein (25 μg/well) were incubated with the DMSO concentrations shown, and FP signals were recorded 1 h later. D)Unlabeled
peptide competition. For the competition assay, the p41 probe peptide (50 nM) was mixed with unlabeled p41 peptide or a negative control peptide of
unrelated sequence (QKEGERALPSIP) and similar length (Con) over the range of concentrations shown. The ABL N32L protein (20 μg/well) was then
added, and FP signals were recorded. FP signals were corrected for the background p41 peptide FP signal and plotted as a function of the unlabeled peptide
concentration. In all experiments (A through D), average FP values are shown ± SE from four measurements per condition.
doi:10.1371/journal.pone.0133590.g005
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Fig 6. Pilot screen identifies inhibitors of p41 interaction with the ABL N32L protein. A) A library of 1200 FDA-approved compounds was screened
using the ABL N32L protein (25 μg/well) and the p41 probe peptide (50 nM) in the FP assay. The solid lines correspond to the mean FP signals for the wild
type (WT) and SH3mutant (W118A) control N32L proteins across all assay plates, with the dotted lines indicating three standard deviations from the means
(± 3σ). Compounds were screened at 10 μM and each FP signal is represented as an individual circle. Five putative hit compounds were identified (green
circles). B) The five potential hit compounds were re-tested in quadruplicate at 10 μM vs. the DMSO control under FP screening assay conditions, and the
mean FP values are shown ± SE. Four of these compounds significantly inhibited the FP signal relative to the DMSO control as indicated by the asterisk
(p < 0.05; 2-tailed t-test). The dotted line shows the FP value three standard deviations below the DMSO control FP signal (-3σ).
doi:10.1371/journal.pone.0133590.g006
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out of the five compounds produced a significant inhibition of the FP signal relative to the
DMSO controls (compounds 42, 142, 787, and 1415). We then performed control FP experi-
ments with each of these compounds under the same conditions but in the absence of the
N32L target protein. This counter-screen showed that compound 787 also inhibited the base-
line FP signal produced by the p41 probe peptide, indicating non-specific quenching of the FP
signal (data not shown). None of the other compounds affected baseline p41 probe peptide
fluorescence, and were therefore moved forward into secondary assays.
Compounds identified in the ABL N32L FP screen interact directly with
the ABL N32L protein in orthogonal assays
As an independent measure of hit compound interaction with the ABL N32L target protein, we
performed differential scanning fluorimetry assays [35]. For these experiments, the ABL N32L
protein was heated with a molar excess of each compound in the presence of the reporter dye,
SYPRO orange. As the temperature rises and the N32L protein unfolds, the reporter dye
accesses the hydrophobic interior of the protein, resulting in an increase in dye fluorescence.
The resulting protein ‘melt curve’ is then fit by regression analysis to obtain a Tm value, the
temperature at which half-maximal thermal denaturation is observed. Small molecule binding
to a target protein can either increase or decrease the Tm value, depending upon the effect of
the compound on protein stability. Differential scanning fluorimetry was performed with the
wild type N32L protein in the presence of each of the hit compounds from the FP assay, and
the change in Tm value (ΔTm) was determined compared to DMSO as the reference control. As
shown in Fig 7A, all four compounds produced a significant decrease in the Tm value. Com-
pound 142 had the largest impact on N32L thermal stability, producing a decrease of more
than 2°C in the Tm, consistent with its effect in the FP assay (Fig 6B).
To confirm direct interaction of compound 142 with the ABL N32L protein and explore the
binding kinetics, we next performed surface plasmon resonance assays. For these experiments,
the ABL N32L protein was immobilized on the biosensor surface while compound 142 was flo-
wed past the immobilized protein over a range of concentrations. As shown in Fig 7B, concen-
tration-dependent interaction of compound 142 with ABL N32L was readily detected by this
approach, yielding an association rate constant of 3.87 ± 0.59 x 103 M-1s-1 and a dissociation
rate constant of 2.70 ± 0.72 x 10−2 s-1. The equilibrium dissociation constant (KD) for this inter-
action, calculated as the ratio of kd/ka, is 6.90 ± 0.78 x 10
−6 M.
Compounds that inhibit the FP signal in the ABL N32L assay may either interfere directly
with probe peptide binding to the SH3 domain or allosterically tighten the cis-interaction of
the SH3 with the linker, indirectly reducing probe peptide interaction. To distinguish between
these two possibilities with compound 142, we performed FP assays with the N32L protein as
well as the isolated ABL SH3 domain. As shown in Fig 7C, Compound 142 resulted in a con-
centration-dependent decrease in the FP signal with both the ABL N32L and SH3 proteins,
suggesting that this compound binds directly to the ABL SH3 domain.
Allosteric activation of ABL kinase by compound 142
Compound 142 reproducibly scored as a hit in the ABL N32L FP assay and demonstrated
direct interaction with ABL N32L protein by both differential scanning fluorimetry and SPR.
This compound, a symmetrically substituted pyrimido-pyrimidine known as dipyridamole
(Fig 7D), is a selective inhibitor of phosphodiesterase V and also an adenosine transport inhibi-
tor used clinically for its antithrombotic activity [36]. However its potential impact on protein
kinase function has not been reported. Because compound 142 interacts with the regulatory
region of ABL, we investigated its effects on ABL kinase activity using two purified
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recombinant forms of ABL in a kinetic kinase assay. These included the wild type ABL core
region, consisting of the Ncap, the SH3 and SH2 domains, the SH2-kinase linker, and the
kinase domain. This ABL protein was produced in Sf9 insect cells, which results in myristoyla-
tion of the N-cap and interaction with the C-lobe of the kinase domain, thereby assembling the
downregulated state (Fig 1A). In addition to the wild type core, we also tested a high-affinity
linker (HAL) mutant version of the ABL protein, which has a modified proline-rich linker that
packs more tightly against the SH3 domain [8].
Fig 7. Hit compound 142 interacts directly with the ABL N32L protein. A) Differential scanning fluorimetry assays were performed on the ABL N32L
protein in the presence of the four confirmed hit compounds as described under Materials and Methods. The average change in the mid-point of the thermal
melt profile (ΔTm) relative to the Tm obtained with the N32L protein in the presence of the DMSO carrier solvent is plotted on the Y-axis ± SE (n = 2). B)
Surface plasmon resonance was performed with the ABL N32L protein immobilized on the biosensor chip and compound 142 as analyte. Responses were
recorded for the four compound concentrations shown, and the flow path was switched back to buffer after 180 s to induce dissociation (arrow). The resulting
sensorgrams (black lines) were fit by a 1:1 Langmuir binding model (red lines) to generate kinetic constants. C) Compound 142 inhibits p41 peptide binding to
the ABL N32L and SH3 proteins in the FP assay. Compound 142 was added to N32L and SH3 FP assays over the range of concentrations shown, and the
resulting FP signals are presented as the mean ± SE. Significant inhibition for both N32L and SH3 was observed at 3 and 10 μM (*p < 0.05 by 2-tailed t-test).
D) Chemical structure of compound 142 (dipyridamole).
doi:10.1371/journal.pone.0133590.g007
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Baseline kinase activities and kinetic parameters of each recombinant ABL kinase core pro-
tein were determined first using a fluorimetric assay that measures the kinase reaction rate as
the generation of ADP [26]. For wild type ABL, we obtained Km values of 9.78 ± 0.14 μM and
144.65 ± 1.64 μM for ATP and peptide substrate, respectively. The ABL HAL core yielded a
similar Km value for substrate (150.25 ± 5.35 μM), with a higher value for ATP
(21.24 ± 1.6 μM). In subsequent experiments, the ATP and peptide substrate concentrations
were set to their respective Km values, and input kinase concentrations were adjusted to yield
the same basal reaction rates (7 pmol ADP produced per minute).
We first examined the effect of compound 142 on the activity of the wild type ABL kinase
core protein. As shown in Fig 8, compound 142 stimulated wild type ABL kinase activity by
about 40% at a concentration of 10 μM relative to the DMSO control in this assay. As a positive
control, we also assayed ABL core activity in the presence of the same concentration of a previ-
ously described ABL activator, DPH, and observed a similar degree of activation. DPH, unlike
compound 142, stimulates ABL through the kinase domain via the myristic acid binding
pocket in the C-lobe [27].
The mechanism of ABL activation by compound 142 may involve binding to the SH3
domain and subsequent displacement of its regulatory interaction with the SH2-kinase linker.
Indeed, mutations that disrupt SH3:linker interaction also have a stimulatory effect on ABL
kinase activity (see Introduction). To test this idea, we next examined the effect of this com-
pound on the ABL core mutant with enhanced SH3:linker interaction. Unlike wild type ABL,
compound 142 did not affect the kinase activity of the ABL core with the HAL substitution
(Fig 8), consistent with the idea that enhanced SH3:linker interaction prevents compound 142
access to the ABL SH3 domain. Interestingly, DPH did not activate the ABL HAL core protein
either, consistent with previous results showing that enhanced SH3:linker interaction over-
comes ABL core activation by mutations in the myristic-acid binding pocket [8].
To further characterize ABL activation by compound 142, we repeated kinetic kinase assays
with the wild type ABL core over a range of compound concentrations. As shown in Fig 9,
compound 142 activates the ABL core in a concentration-dependent manner, with an EC50
value of 0.63 ± 0.07 μM. This value compares favorably to that obtained with DPH, the myristic
acid binding pocket agonist (EC50 = 1.11 ± 0.5 μM). We also calculated the activation constant
(Kact) for each compound from these data, which is defined as the concentration at which the
reaction rate reaches half-maximum velocity (Vact). For compound 142, the Kact was calculated
as 0.4 ± 0.02 μM, while DPH yielded a value of 1.02 ± 0.07 μM. This analysis also showed that
the extent of ABL activation by compound 142 was higher than that observed for DPH, based
on the Vmax.
Molecular dynamics simulations and docking studies predict binding of
compound 142 to the SH3:linker interface in the ABL kinase core
Data presented in the previous sections demonstrate that compound 142 interacts with the reg-
ulatory N32L region of ABL, resulting in a decrease in thermal stability and a concomitant
increase in kinase activity. We used molecular dynamics (MD) simulations to explore the
dynamics of the N32L region used in the assays. To model the effect of the linker being dis-
placed from the SH3 domain, we manually pulled the linker a short distance away from the
SH3 domain prior to the simulation (see Materials and Methods). After approximately 20 ns,
the linker reconnected with the SH3 domain through the interaction of linker Pro249 and SH3
Trp118. To explore possible binding sites for this compound on the N32L region of the ABL
kinase core, we used the computational docking tool smina [32] to dock 142 to snapshots of
the simulation prior to the reconnection of the SH3:linker interface. As shown in Fig 10 (top
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panel), compound 142 fits into a surface pocket defined by the SH3:linker interface in the
N32L protein. This predicted binding site involves an aromatic interaction between the pyri-
mido-pyrimidine moiety of 142 and the indole side chain of SH3 Trp118, as well as polar con-
tacts involving all four hydroxyl groups on the ligand. This aromatic interaction is consistent
with probe peptide displacement as well as the observed decrease in the FP signal produced by
the W118A mutation (Fig 5C). Two of the hydroxyl groups of 142 make potential hydrogen
bonds with the side and main chains of SH3 Asn97 as well as the side chain of Thr98. The
other two hydroxyl groups of 142 form hydrogen bonds with the main chain carbonyls of
Fig 8. Compound 142 activates the ABL kinase core in vitro. Top: The recombinant ABL core protein, consisting of the Ncap, SH3, SH2 and kinase
domains, was assayed in the presence of compound 142 (10 μM), the known ABL activator DPH (10 μM), and imatinib (1 μM) or with DMSO as control (Con)
using a kinetic kinase assay (see Materials and Methods). Data are plotted as pmol ADP produced per ng kinase as a function of time. The cartoon (right)
depicts the domain organization of the wild type ABL core, and indicates the binding site for DPH (myristic acid binding pocket) as well as the predicted
binding site for compound 142 (SH3 domain). Bottom: Kinase assays were performed using an ABL core protein with a high-affinity linker (HAL) in the
presence of the same three compounds; the cartoon indicates the position of the modified linker (HAL). In both cases, the ATP and peptide substrate
concentrations were set to their respective Km values (wild type ABL: 9.78 ± 0.14 μM for ATP and 144.65 ± 1.64 μM for substrate; ABL HAL: 21.24 ± 1.6 μM
for ATP and 150.25 ± 5.35 μM for substrate).
doi:10.1371/journal.pone.0133590.g008
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linker Gly246 and Val247 as well as the side chain of SH3 Asn115. In addition, one of the
piperidine groups of compound 142 makes hydrophobic contacts with SH3 Trp129, while the
other approaches the side chains of linker residues Pro249 and Trp254. Note that in the crystal
structure of the fully assembled, downregulated conformation of the ABL core, linker Pro249
Fig 9. Concentration-dependent activation of the ABL kinase core protein by compound 142. The wild
type ABL kinase core was assayed in the presence of compound 142 and DPH at the indicated
concentrations using a kinetic kinase assay (see Materials and Methods). Reaction velocities are plotted as a
function of compound concentrations. The resulting data were curve-fit to determine the EC50, Kact and Vmax
for each activator as described under Materials and Methods. Each of these parameters was determined in
triplicate, and the mean values ± SE are presented in the table below the graph. The table also provides the
ratio Vmax/Kact as a measure of overall enhancement of catalytic efficiency in the presence of each of these
two ABL agonists.
doi:10.1371/journal.pone.0133590.g009
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Fig 10. Molecular dynamics (MD) andmolecular docking predict binding of compound 142 to the ABL
SH3:linker interface. Top: The lowest energy pose of the ligand (compound 142; carbon atoms rendered in
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inserts between SH3 Trp118 and Trp129 (Fig 10, middle panel); displacement of this regulatory
contact by compound 142 binding may contribute to kinase activation.
For comparison, we also ran unconstrained MD simulations of the SH3 domain in the
absence of the linker. Our docked model to a snapshot from this simulation is shown in Fig 10
(bottom panel). The overall position of the ligand in this model is quite similar to that observed
with the N32L snapshot (within 1.5 Å RMSD), and includes the potential stacking interaction
with SH3 Trp118 and hydrogen bonding to SH3 Asn97, Thr98 and Asn115. Polar contacts of
compound 142 with linker Gly246 and Val247 as well as hydrophobic interactions with linker
Trp254 and Pro249 are not possible. However, additional hydrogen bonds are observed with
SH3 Glu117. Loss of these hydrophobic interactions in the SH3-only model helps to explain
the lower binding affinity of compound 142 for the isolated SH3 domain (KD = 3.00 ± 0.40 x
10−5 M) relative to the N32L protein (KD = 6.90 ± 0.78 x 10
−6 M) as determined by SPR (data
not shown and Fig 7B).
Compound 142 does not activate the SRC-family kinase, HCK
Like ABL, SRC-family kinases exhibit a very similar arrangement of SH3, SH2, and kinase
domains in the downregulated conformation, and are also susceptible to activation by muta-
tions and binding partners that disrupt intramolecular SH3:linker interaction [37,38]. To
determine whether compound 142 also activates SRC-family kinases by a similar SH3:linker
displacement mechanism, we performed kinetic kinase assays on the SRC-family member
HCK in the presence and absence of this ABL activator. As shown in Fig 11, addition of com-
pound 142 to recombinant near-full-length HCK had no effect the reaction velocity, suggesting
that it is selective for ABL. Alignment of the SH3 domain and SH2-kinase linker sequences
supports this view (Fig 11, bottom). Five of the seven residues predicted by the docking model
to participate in compound 142 binding to the ABL SH3:linker surface are either substituted
with different amino acids or are missing from the HCK sequence. These observations suggest
that even subtle differences in the SH3 and linker sequences of ABL and SRC-family kinases
can be exploited for the development of selective agonists or antagonists.
Compound 142 cooperates with DPH to activate ABL in cells
In a final series of studies, we evaluated the effect of compound 142 on the activity of the ABL
core in cells. For these studies, we expressed the wild type ABL core in 293T cells, and then
treated the cells over a range of compound 142 concentrations (1–10 μM). We then immuno-
precipitated ABL and analyzed the level of phosphorylation at three important regulatory tyro-
sine sites by immunoblotting with phosphospecific antibodies [8,39]: pY412 (activation loop),
pY245 (SH2-kinase linker), and pY89 (SH3 domain). As shown in Fig 12, treatment with
green) is shown docked to a snapshot of an MD simulation of the ABL N32L structure. SH3 domain residues
predicted to contribute to ligand binding include Asn97, Thr98, Asn115, Trp118, and Trp129 (carbons in red).
The backbone of the linker is shown as an orange ribbon, with Gly246, Val247, Pro249 and Trp254 predicted
to contribute to the binding pocket. One of the piperidine groups of compound 142 makes hydrophobic
contacts with linker Pro249 and Trp254, while the pyrimido-pyrimidine scaffold of compound 142 is π-
stacking with Trp118.Middle panel: Model of the SH3:linker interface in the N32L region based on the crystal
structure of the downregulated ABL core (PDB:2FO0), highlighting the interaction of linker Pro249 with SH3
Trp118 and Trp129. Ligand binding (top panel) is predicted to displace this regulatory interaction, leading to
kinase activation. Lower panel: The lowest energy pose of compound 142 is shown docked to a snapshot of
an MD simulation of the SH3 domain in the absence of the linker. The position of the 142 ligand is similar
(within 1.5 Å RMSD) to that in the SH3 domain of N32L (top), except that the ligand contacts Glu117 rather
than linker residues Gly246 and Val247. Without the linker, the potential hydrophobic stabilization of the 142
piperidine group is also lost.
doi:10.1371/journal.pone.0133590.g010
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Fig 11. Compound 142 fails to activate downregulated HCK in vitro. Top panels: Recombinant,
downregulated wild type ABL core and near full-length HCK proteins were assayed in the presence of
compound 142 (1 μM) or with DMSO alone as control (Con) using a kinetic kinase assay (see Materials and
Methods). Data are plotted as pmol ADP produced per ng kinase as a function of time. Bottom: Amino acid
sequence alignment of the ABL and HCK SH3 domains and SH2-kinase linkers. SH3 and linker residues
predicted to contribute to compound 142 binding are highlighted in red (see Fig 10). The type of interaction is
indicated as side chain (s), main chain (m), or aromatic (a).
doi:10.1371/journal.pone.0133590.g011
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compound 142 alone did not affect phosphorylation of these sites. We then repeated this exper-
iment in the presence of DPH, the myristic acid binding pocket activator described above, at a
concentration of 10 μM. In the absence of compound 142, DPH had a very small effect on ABL
phosphorylation. However, the combination of compound 142 and DPH led to remarkable
enhancement of phosphorylation on all three regulatory tyrosines, providing strong evidence
for an activating effect of compound 142 on ABL in cells. These observations suggest that in
the cellular environment, unlike in vitro, compound 142 alone may be not sufficient to disturb
SH3:linker interaction and stimulate ABL activity. However, when the regulatory interaction of
the myristoylated Ncap with the kinase domain C-lobe is perturbed by DPH, then the activat-
ing effect of SH3:linker displacement becomes readily apparent.
Summary and Conclusions
In this study, we developed a screening strategy to identify allosteric small molecule modula-
tors of ABL kinase activity that work outside of the kinase domain. Our FP-based assay targets
the regulatory domains of ABL that control its kinase activity through intramolecular interac-
tions. Specifically, this assay is based on a recombinant ABL protein comprising the complete
regulatory apparatus (Ncap-SH3-SH2-linker) and a synthetic polyproline probe peptide (p41)
that selectively binds the ABL SH3 domain. Interaction of the probe peptide with the ABL
N32L protein results in a robust and reproducible FP signal. Mutation of the SH3 binding site
Fig 12. Compound 142 cooperates with DPH to stimulate ABL core autophosphorylation in cells.Human embryonic kidney 293T cells were
transfected with an expression vector for the wild type ABL core followed by treatment with compound 142 overnight over the range of concentrations shown.
The experiment was performed in the absence or presence of the myristic acid binding pocket agonist DPH at a final concentration of 10 μM. ABL proteins
were immunoprecipitated from clarified cell lysates, and analyzed by immunoblotting with phosphospecific antibodies to three regulatory sites: pTyr412 in the
activation loop, pTyr89 in the SH3 domain, and pTyr245 in the SH2-kinase linker, as well as an ABL antibody to control for protein recovery. This experiment
was repeated twice with comparable results.
doi:10.1371/journal.pone.0133590.g012
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(W118A) or introduction of a high-affinity linker both resulted in loss of the FP signal, demon-
strating that probe access requires an intact and accessible SH3 domain. A small-scale pilot
screen of 1200 FDA-approved compounds identified dipyridamole (compound 142) as an
inhibitor of the FP signal observed with the N32L:p41 complex, and direct interaction of this
compound with the ABL N32L protein was confirmed by SPR and DSF assays. Dipyridamole
was observed to stimulate the kinase activity of downregulated ABL kinase in vitro, and was
more potent than the previously described ABL agonist DPH which targets the myristic acid
binding pocket in the kinase domain. In contrast to wild type ABL, dipyridamole had no effect
on a modified ABL core protein with a high-affinity linker, suggesting that it works by binding
to the SH3 domain and disrupting the SH3:linker interface. Molecular dynamics simulations in
combination with molecular docking support this proposed mechanism of action: dipyrida-
mole was predicted to interact with the ABL core through a pocket defined by the SH3:linker
interface. This interaction involved Trp118 on the SH3 domain binding surface, potentially
disrupting a key regulatory interaction with Pro249 in the linker. Discovery of dipyridamole as
an ABL agonist provides an important proof of concept that small molecules altering SH3:
linker interaction represent allosteric modulators of ABL kinase activity. Selective agonists of
ABL function have potential as chemical probes to better understand the role of ABL kinase
activity in solid tumors and in response to genotoxic stress. Conversely, allosteric antagonists
may also be discovered by this approach and have the potential to complement current ATP-
competitive inhibitors of BCR-ABL in the context of CML and other cancers. The allosteric
inhibitor discovery concept may also be extended to the discovery of allosteric modulators of
other kinases systems with multi-domain regulatory interactions, including members of the
SRC and TEC kinase families.
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APPENDIX B APPLICATION OF MODELING PROTEIN-LIPID INTERACTIONS 
In this appendix, we will present an application of modeling the interactions of small molecules 
and lipids to the lipoxygenase h-5-LOX[117]. Reproduced with permission. 
B.1 MODELING LIPID INTERACTIONS WITH H-5-LOX 
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Allosteric bindingLipoxygenases (LOXs) and cyclooxygenases (COXs) metabolize poly-unsaturated fatty acids into inflam-
matory signaling molecules. Modulation of the activity of these enzymes may provide new approaches
for therapy of inflammatory diseases. In this study, we screened novel anacardic acid derivatives as mod-
ulators of human 5-LOX and COX-2 activity. Interestingly, a novel salicylate derivative 23a was identified
as a surprisingly potent activator of human 5-LOX. This compound showed both non-competitive activa-
tion towards the human 5-LOX activator adenosine triphosphate (ATP) and non-essential mixed type
activation against the substrate linoleic acid, while having no effect on the conversion of the substrate
arachidonic acid. The kinetic analysis demonstrated a non-essential activation of the linoleic acid conver-
sion with a KA of 8.65 lM, aKA of 0.38 lM and a b value of 1.76. It is also of interest that a comparable
derivative 23d showed a mixed type inhibition for linoleic acid conversion. These observations indicate
the presence of an allosteric binding site in human 5-LOX distinct from the ATP binding site. The activa-
tory and inhibitory behavior of 23a and 23d on the conversion of linoleic compared to arachidonic acid
are rationalized by docking studies, which suggest that the activator 23a stabilizes linoleic acid binding,
whereas the larger inhibitor 23d blocks the enzyme active site.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
The lipoxygenases (LOXs) and the cyclooxygenases (COXs) are
enzymes that play key roles in the major metabolic pathways of
poly-unsaturated fatty acids (PUFAs). These pathways convert PU-
FAs into inflammatory mediators such as lipoxins, leukotrienes,
and prostaglandins, which play a regulatory role in numerous
inflammatory and proliferative diseases including asthma, arthritis
and cancer.1 The biological roles of LOXs and COXs in metabolic
pathways towards inflammatory mediators and signaling mole-
cules demonstrate the utility of these enzymes as therapeutic
targets.
Lipoxygenases are non-heme iron containing enzymes. There
are four types of lipoxygenases with different positional specifici-
ties for arachidonic acid oxidation present in mammalian tissues;
5-LOX, 8-LOX, 12-LOX and 15-LOX. In general, lipoxygenases com-
prise of two domains in which the N-terminal domain is the regu-latory domain and the C-terminal domain is the catalytic domain.2
Although, human lipoxygenases show about 60% sequence similar-
ities,3 their regulatory mechanisms are variable. Unlike other LOXs,
5-LOX activity requires the presence of activators such as Ca2+ and
adenosine triphosphate (ATP). In addition, different types of LOXs
have been identified based on their distribution over different tis-
sues. For example, 12-LOX is subdivided in platelet 12-LOX (p12-
LOX) and 12R-LOX. As its name implies, platelet 12-LOX (p12-
LOX) is mostly found in platelets, whereas 12R-LOX is most fre-
quently found in skin cells.4,5 Similarly, 15-LOX is subdivided in
15-LOX-1 and 15-LOX-2. 15-LOX-1 is highly expressed in leuko-
cytes and airways endothelial cells,6,7 whereas 15-LOX-2 is ex-
pressed in multiple tissues such as prostate, lung, cornea, liver,
colon, kidney, and brain but not in leukocytes.8 Moreover, stimula-
tion of cells by interleukin (IL)-4 and IL-13 shows selective
enhancement of the 15-LOX-1 expression and not 15-LOX-2
expression.9 In addition, 15-LOX-1 and 15-LOX-2 lack similarity
at the primary sequence level, which also hints at distinct biologi-
cal roles and the possibility to develop selective inhibitors or
activators.10
The overexpression of certain lipoxygenases has been reported
in numerous inflammatory diseases. For example, increased 15-
LOX-1 expression in bronchial epithelium, which is accompanied
by elevated concentrations of 15-hydroxyeicosatetraenoic acid
7764 R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778(15-HETE), has been observed in patients with asthma and chronic
bronchitis.11,12 In addition, activity of other LOXs isoenzymes has
been reported to be significantly increased in disease conditions.
For example, upregulation of 12R-LOX activity has been observed
in the development of skin tumor and melanoma.13,14 In addition,
overexpression of 5-LOX has been reported to contribute to airway
inflammation in asthma and to the growth of some tumors in, for
example, lung, prostate, brain and colon.15–19 In contrast, lipoxins,
another type of arachidonic acid metabolites, have been reported
to have important roles as anti-inflammatory and pro-resolution
mediators,20 which play an important role in the termination of
immune responses. Production of lipoxins upon inflammatory
stimulation involves two main lipoxygenase-mediated pathways.
The first pathway involving 15-LOX and 5-LOX occurs in mucosal
tissues, such as the respiratory tract, gastrointestinal tract and
the oral cavity. The second pathway involves 5-LOX and p12-
LOX, in which 5-LOX produces the Leukotriene A4 (LTA4) and
p12-LOX converts the LTA4 to lipoxin A4 (LXA4).21 Lipoxin A4
has important roles in stopping neutrophil migration, stimulation
of monocyte and macrophage activation, and inhibition of leukotri-
ene B4 formation.20 Induction of 15-LOX-1 by IL-13 in synovial tis-
sues of patients with rheumatoid arthritis enhances the level of
LX4 in a negative feedback loop to limit inflammatory responses
induced by pro-inflammatory mediators such as Leukotriene
B4.22 Another study showed that prior to induction with peroxi-
some proliferator-activated receptors gamma (PPARc) agonists in
brain, the 5-LOX expression was enhanced in association with
the increase of cerebral LX4 production and inhibition of Leukotri-
ene B4 production.23 The association of 5-lipoxygenase activity in
the production of both pro- and anti-inflammatory mediators indi-
cates its crucial role in pathophysiological processes of inflamma-
tion. Based on these findings we speculate that activators of 5-
lipoxygenase might also have beneficial effects in inflammation
by triggering the termination of immune responses. In addition,
it might be speculated that the redirection of lipoxygenase metab-
olism by 5-LOX activators towards other substrates might also lead
to the formation of less harmful pro-inflammatory products. En-
zyme activation as a concept in drug discovery has been shown
to be successful for glucokinase activators.24 We stress, however,
that lipoxygenase activation by small molecules with the aim to
limit inflammation is a novel concept and lacks experimental
proof.
Prostaglandin endoperoxide H synthases (PGHSs), are also
known as cyclooxygenases (COXs), catalyze the formation of pros-
taglandins (PGs). COXs are comprised of two main sites, a heme
site with peroxidase activity and a bis-oxygenase site. COXs con-
vert arachidonic acid into prostaglandin endoperoxide H2 (PGH2)
in a two steps process. The first step is enzymatic catalysis of the
insertion of two molecules O2 into arachidonic acid to generate
prostaglandin G2 (PGG2). The second step is the peroxidase reac-
tion in which the PGG2 is oxidized to PGH2 by a two electron
abstraction. The peroxidase reaction occurs at a heme-containing
active site located near the protein surface, whereas the oxygena-
tion reaction occurs in a hydrophobic channel in the core of the
enzyme.25 The COX isoenzymes COX-1 and COX-2 are differentially
expressed in various tissues. Under normal conditions, COX-1 is
expressed in most mammalian cells, whereas COX-2 is not ex-
pressed. The COX-2 expression is increased under inflammatory
conditions. Animal models of inflammatory arthritis indicate that
overexpression of COX-2 is responsible for the increase of PGs in
joint tissue and cause acute and chronic inflammation.26 Elevated
levels of PGs were observed in inflammatory bowel diseases
(IBD).27,28 A similar behavior was observed in cancers. For example,
the expression of COX-2, but not COX-1, was observed in various
regions of the colon in human colorectal cancer.29,30 Therefore,COX-2 inhibition is considered to be a relevant therapeutic strat-
egy for treatment of cancer and inflammatory diseases.
Anacardic acid is a naturally occurring 6-alkyl substituted salic-
ylate that is identified from cashew nutshells. Previously, we found
that this salicylate and its derivatives are allosteric regulators of
lipoxygenase activity. We identified an allosteric inhibitor of soy-
bean lipoxygenase-1 (SLO-1) (19) and an allosteric activator of po-
tato 5-lipoxygenase (5-LOXs) (21).31 It should, however, be noted
that the lack of similarity between the human and plant enzymes
prohibits extrapolation or these data towards biological effects in
cell-based studies.32 Therefore, we continue our previous studies
by exploring the inhibitory potency of a salicylate-based com-
pound collection for inhibition of human 5-lipoxygenase and
cyclooxygenase-2. In this study, we describe the synthesis of a no-
vel focused collection of salicylate-based compounds and we
investigate their influence on the enzyme activity of human 5-
LOX and human COX-2. This enabled the identification of a novel
activator 23a and a mixed inhibitor 23d of the conversion of the
linoleic acid by h-5-LOX. Interestingly, no effect on the arachidonic
acid conversion was observed. Enzyme kinetic investigations dem-
onstrated that activator 23a binds to an allosteric binding site on
h-5-LOX that is different from the ATP regulatory site. Modeling
studies suggest that 23a binds close to the substrate linoleic acid,
thereby enhancing the Km and kcat for its conversion.
2. Results and discussion
2.1. Synthesis
Our salicylate-based compound collection that is inspired by
anacardic acid (14) comprises of the previously published salicy-
lates 14–19, and 21 and the newly synthesized salicylates 20, 22,
23a–d, 24b–c and benzoxazole 25. The synthesis of anacardic acid
(14) and its derivatives 15–19, and 21 were described previously
by Ghizzoni et al.33,34 This collection includes the previously de-
scribed compounds that were reported as inhibitors or activator
of soybean lipoxygenase-1 (SLO1) (19) and potato 5-LOX (21).31
The newly synthesized compounds were inspired by compound
19 and 21, which contain either a 6-phenylethyl substitution or a
6-alkoxy substitution. This was merged into a para-alkoxybenzyl-
oxy substitution, which can be synthesized using convenient
methods.
The starting materials, acetonide 1 (Scheme 1) and triflate 10
(Scheme 2), were synthesized as described by Uchiyama et al.35
2-Hydroxy-6-(nonyloxy)benzoic acid (22) was synthesized from
commercially available 1-bromononane and acetonide 1 following
synthetic procedure described by Ghizzoni et al.33 (Scheme 1). p-
Alkyloxybenzylbromides (3a–d) and m-alkyloxybenzylbromides
(5b–c) were prepared in three steps from p-hydroxybenzaldehyde
or m-hydroxybenzaldehyde. The first step involves the coupling of
alkylbromides with the hydroxybenzaldehydes to give the corre-
sponding ethers. Subsequently, the benzaldehydes were reduced
to the corresponding benzyl alcohols 2a–d and 4b–c36 in high
yields. Direct coupling of benzyl alcohols to phenol 1 by Mitsunobu
reaction did not provide the desired ethers. Therefore, the ben-
zylalcohols 2a–d and 4b–c were brominated using PBr3 to give
the corresponding benzylbromides 3a–d and 4b–c. The benzylbro-
mides were coupled to acetonide 1 to give the corresponding prod-
ucts 12a–d and 13b-c in high yields (>70%). Subsequently, the
acetonide protecting group was cleaved using potassium hydrox-
ide in THF to provide the final products 23a–d as potassium salts
(Scheme 1). Isolation of salicylates 23a–d as salicylate salts proved
to be necessary to avoid degradation of the p-alkoxybenzylethers
by the strongly acidic salicylic acids. Acidification results a slow
hydrolysis of the product to give 2,6-dihydroxybenzoate and the
Scheme 1. Reagents and conditions: (a) SOCl2, DMAP, DME, acetone, 0 C for 1 h, then rt overnight; (b) 1-bromo alkane, K2CO3, DMF, rt overnight; (c) NaBH4, MeOH, 0 C for
1 h, then rt for 30 min; (d) PBr3, CH2Cl2, 0 C for 1.5 h; (e) 1-bromononane, K2CO3, DMF, rt overnight; (f) compound 1, K2CO3, DMF, rt overnight; (g) 5 M KOH, THF, 60 C
overnight.
Scheme 2. Reagents and conditions: (a) decanoylchloride, AlCl3, CH2Cl2, 60 C for 1 h; (b) NH2NH2H2O, KOH, 1-octanol, reflux, 3 h; (c) trimethylsilyl-acetylene, CuI,
PdCl2(PPh3)2, Et2NH, PPh3, CH3CN, (MW, 120 C, 95 W, 35 min); (d) TBAF, THF, 0 C, 10 min; (e) CuI, PdCl2(PPh3)2, Et2NH, triflate 10, CH3CN (MW, 120 C, 70 W, 35 min); (f) H2,
Pd/C, MeOH, 45 C, 24 h; (g) 2-aminophenol, polyphosphatic acid, 180 C for 6.5 h.
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by the electrondonating alkyloxy substituent on the para- postion.
As expected, for the meta-substituted benzyl substituents 24b–c
this problem was not observed.
p-Decylphenyl bromide (8) (Scheme 2) was prepared from bro-
mobenzene 6 and decanoylchloride following two reaction steps.
The first step was the formation of 1-(4-bromophenyl)decan-1-
one 7 through Friedel–Craft acylation using AlCl3.37 The second
step was the Wolff–Kishner reduction of 1-(4-bromophenyl)dec-
an-1-one 7 using hydrazine monohydrate and potassium hydrox-
ide to give product 8.37 Subsequently, arylbromide 8 was
converted to alkyne 9 by coupling with trimethyl-silyl (TMS) acet-
ylene by a Sonogashira reaction and subsequent removal of the
TMS protection using tetra butyl ammonium fluoride (TBAF). The
resulting alkyne 9 was coupled to triflate 1038 to give the product
in high yield (80%), which was subsequently converted into prod-
uct 20 by catalytic hydrogenation.
2.2. Enzyme inhibition
LOXs are non-heme iron dependent enzymes. Benzoxazole 25
was designed based on the presumption that iron-binding is a
key property for the inhibition of lipoxygenases and cyclooxygen-ases. Benzoxazole 25 was synthesized from salicylic acid and 2-
amino phenol through direct cyclization using polyphosphoric acid
(Scheme 2).39 Compound 25 did not inhibit h-5-LOX, however it
gives 50% COX-2 inhibition at 50 lM inhibitor concentration. This
indicates that 25 is a potential starting point for development of
selective inhibitors of COX-2 (Fig. 1).
The influence of the salicylates (Table 1) on the enzyme activity
of human 5-lipoxygenase and/or cyclooxygenase-2 was investi-
gated. The h-5-LOX activity was monitored in real time by detec-
tion of the formation of the UV absorbance of the conjugated
diene 13-hydroperoxy-cis-9-trans-11-octa decanoic acid (13-
HPOD) from linoleic acid.40,41 The residual h-5-LOX activity was
monitored after 10 min pre-incubation with 50 lM of the com-
pound of interest. The COX-2 activity was determined by measur-
ing the conversion or arachidonic acid, which conversion is
monitored by the oxidation of N,N,N0,N0-tetramethyl-p-phenylene-
diamine (TMPD).42 The residual enzyme activity was measured
after 5 min pre-incubation in the presence of 50 lM of the com-
pound of interest. The enzyme activity without inhibitor present
was taken as control and set to 100% and the activity without en-
zyme present was set to 0%. The residual enzyme activities of h-5-
LOX and COX-2 in the presence of different salicylates are shown in
Figure 1.
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Figure 1. Residual enzyme activity that was observed for the screening of a salicylate-based compound collection for inhibition of h-5-LOX and COX-2 activity in the presence
of 50 lM of the respective compounds. The h-5-LOX activity was determined in presence of 100 lM linoleic acid as a substrate. The COX-2 activity was determined in
presence of 2 mM arachidonic acid as a substrate. The results presented were the average of three independent experiments and the standard deviations are shown.
Table 1
Focused compound collection
Compounds R1 R2 R3
O
R1
OOH
R2 R3
14 H H
15 H H
16 H H
17 H OH
18 H H
19 H OH
20 H OH
21 H H O
22 H H O
23a (PK131) K H
O
O
23b K H
O
O
23c K H
O
O
23d (PK147) K H
O
O
24b H H O
O
24c H H O
O
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O
HO
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of both h-5-LOX and COX-2 at 50 lM. In comparison to anacardic
acid 14, a slight improvement in the inhibitory potency of h-5-
LOX was observed for compound 17. Importantly, neither inhibi-
tion nor activation was observed from compound 21, which in
our previous report31 shows a strong activation on potato 5-LOX,
which demonstrates the difference between plant and human
enzymes.Compounds 23a–d with alkoxy substituents in the para-posi-
tions of the benzylethers, show an interesting structure activity
relationship for modulation of h-5-LOX activity. Compound 23a
shows strong activation of h-5-LOX at 50 lM, whereas compound
23b and 23cwith a longer side chain show no or little inhibition of
h-5-LOX. Furthermore, compound 23d with a branched side chain
provides almost 50% inhibitions of h-5-LOX at the same concentra-
tion. The compound is racemic at its asymmetric carbon.
Figure 2. Surface tensions of (A) anacardic acid 14 and (B) compound 23a (C) compound 23d against the logarithm of concentration. CMC values (A–C) were measured in
human 5-LOX assay conditions, Tris buffer (50 mM), 2 mM EDTA and 2 mM CaCl2, pH 7.5, rt (t = 19 C).
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Figure 3. Concentration dependent activation of the linoleic acid conversion by h-
5-LOX in the presence of various concentrations of compound 23a and in its
absence (control). The results were the average of three independent experiments
with error bars (±SD).
R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778 7767The data in Figure 1 demonstrate that the salicylate-based com-
pounds do not inhibit COX-2 activity more than 50% at 50 lM,
which indicates that this type of compounds has a tendency for
selective modulation of h-5-LOX compared to COX-2. Interestingly,
benzoxazole 25 inhibits the COX-2 activity by about 50%, whereas
no inhibition was observed on h-5-LOX, which indicates that fur-
ther optimization of this class of compound may be feasible.
In order to assure that the assays are performed in homogenous
solutions the critical micelle concentrations (CMCs) of the different
compounds were determined and the assays were performed at
concentration below the CMC. Homogenous solutions are required
for proper analysis of the enzyme kinetics. The CMCs for 23a and
23d at the assay conditions (50 mM Tris buffer, 2 mM EDTA and
2 mM CaCl2, pH 7.5, rt) are, respectively, 628 lM and 395 lM
(Fig. 2B and C) which indicate that micelle formation does not oc-
cur at concentrations employed for inhibition or activation of h-5-
LOX. In addition, we found a CMC value for linoleic acid of 185 lM
(Fig. 2A),43 which demonstrates that the substrate concentration in
the inhibition studies (100 lM) was below the CMC.
2.3. Enzyme kinetic studies for human 5-lipoxygenase
A steady-state enzyme kinetic analysis of h-5-LOX in the pres-
ence of the activator 23a was performed in order to unravel the
activation mechanism. The kinetic characterization of h-5-LOX
activity versus linoleic acid in the presence of activator 23a shows
a concentration dependent activation (Fig. 3). The activation wasdetermined in the presence of various concentrations of the natu-
ral substrate linoleic acid or the h-5-LOX activator ATP. The initial
velocities of h-5-LOX were determined at various concentration of
ATP, various concentrations 23a (0, 12.5 and 25 lM) and a fixed
concentration of linoleic acid (100 lM). The velocities were plotted
in the Michaelis–Menten and the Lineweaver–Burk plot as shown
in Figure 4.
The Michaelis-–Menten data show that activator 23a causes an
increase in Vmax, whereas the Km remains constant (Table 2).
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Figure 5. Steady-state kinetic characterization of the linoleic acid conversion by h-
5-LOX activation by activator 23a. (A) Michaelis–Menten plots and (B) Lineweaver–
Burk plots show the relation of h-5-LOX activity versus linoleic acid concentrations
at three selected concentrations of 23a (j) 0 lM, (d) 12.5 lM, and (N) 25 lM.
Table 3
Enzyme kinetic parameters for activation of h-5-LOX by activator 23a versus linoleic
acid
23a (lM) Kappm (mM) V
app
max (lM/s) R
2
0 0.590 ± 0.080 2.14 ± 0.21 0.999
12.5 0.438 ± 0.020 2.39 ± 0.07 0.999
25 0.383 ± 0.011 2.70 ± 0.05 0.999
Scheme 3. Kinetic model for non-essential activation.
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Figure 4. Steady-state kinetic characterization of the linoleic acid conversion
versus the ATP concentration of h-5-LOX activator 23a. (A) The Michaelis–Menten
plots and (B) the Lineweaver–Burk plots show the relation of h-5-LOX activity
versus the ATP concentration at three selected concentration of 23a (j) 0 lM, (d)
12.5 lM, and (N) 25 lM in the presence of 100 lM linoleic acid substrate.
Table 2
Enzyme kinetic parameter for activation of h-5-LOX by activator 23a versus ATP
23a (lM) Kappm (lM) V
app
max (nM/s) R
2
0 27.9 ± 1.7 230.9 ± 4.2 0.998
12.5 28.3 ± 1.7 386.1 ± 7.3 0.999
25 28.6 ± 2.3 523.6 ± 13.7 0.999
7768 R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778Lineweaver–Burk analysis provided similar values. The values
demonstrate non-competitive activation of linoleic acid conversion
by h-5-LOX by compound 23a compared to ATP. The fact that bind-
ing of 23a does not influence the binding constant of ATP to h-5-
LOX indicates that 23a does not compete for binding in the ATP
binding pocket that allosterically regulates h-5-LOX activity. This
indicates the presence of an allosteric binding pocket that is dis-
tinct from the ATP binding pocket and regulates the h-5-LOX en-
zyme activity.
The enzyme kinetics of 23a were further investigated through
the Michaelis–Menten and the Lineweaver–Burk plots (Fig. 5).
The initial velocities of h-5-LOX at different concentration of lino-
leic acid and a fixed concentration of ATP (100 lM), and at several
selected concentrations of 23a (0, 12.5 and 25 lM) were measured.
Activator 23a causes an increase in Vmax and a decrease in Km (Ta-
ble 3), which indicates non-essential mixed type activation. Thisindicates that the activator can bind to the free enzyme (E,
Scheme 3) and also to the substrate bound enzyme (ES, Scheme 3).
In this model binding of the substrate and 23a mutually influence
each other. According to this model the activation of h-5-LOX by
23a can be described by Eq. 1 (Fig. 7).
The enzyme kinetic parameters were derived as described in
the material and methods using methods from Leskovac.44 The
activator dissociation constant (KA), the change in the affinity of
Table 4
Enzyme kinetic parameter for inhibition of h-5-LOX by inhibitor 23d versus linoleic
acid
23a (lM) Kappm (mM) V
app
max (lM/s) R
2
0 0.624 ± 0.085 2.24 ± 0.23 0.999
25 0.666 ± 0.121 1.84 ± 0.25 0.998
50 0.690 ± 0.101 1.47 ± 0.16 0.999
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Figure 8. Steady-state kinetic characterization of linoleic acid conversion by h-5-
LOX by inhibitor 23d. (A) Michaelis–Menten plots and (B) Lineweaver–Burk plots
show the relation of h-5-LOX activity versus linoleic acid concentration at three
selected concentrations of 23d (j) 0 lM, (d) 25 lM, and (N) 50 lM.
Scheme 4. Kinetic model for mixed type enzyme inhibition.
Figure 6. Re-plot of 1/D slopes and 1/Dy intercept versus concentration of 23a.
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Figure 7. Equation 1 for the enzyme kinetics according to the model in Scheme 2.44
v is the reaction velocity, Vmax is the maximal reaction velocity, [S] is the substrate
concentration and Km is the Michaelis–Menten constant, [A] is the activator
concentration. a and b, respectively, are the parameters to describe the change in
the affinity of substrate binding and the change in the catalytic constant.
R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778 7769substrate binding (a) and the change in the catalytic constant (b)
were determined by re-plotting the slopes and the y-interceptions
derived from the Lineweaver–Burk plot as a function of activator
23a concentration (Fig. 6)44 The KA value was determined from
the intersection of 1/Dslopes plot and 1/Dy intercept plot. The
intersection of 1/Dy intercept plot with the ordinate is defined as
bVmax/(b  1) from which the b value was derived. Subsequently,
the resulting b value was substituted to the equation bVmax/Km(-
b  a), which is the intersection of 1/Dslopes plot with the ordi-
nate, to acquire the a value.
The analysis shows that a is 0.0438, b is 1.76 and KA is 8.65 lM.
The a value, which indicates the change in substrate binding, gives
about 50-fold affinity enhancement of the substrate binding to the
activator bound enzyme compared to the free enzyme. Compound
23a shows a high potency as an activator of h-5-LOX with the KA
value in the micromolar range. Furthermore, the affinity of 23a
to the substrate bound enzyme is about 50-fold enhanced, which
indicates that activation of h-5-LOX at high substrate concentra-
tions (>10 lM) takes place at low activator 23a concentrations
(<10 lM) (Fig. 3). The catalytic constant for substrate conversion
reaction was enhanced by 1.76-fold in the presence of the activator
23a compared to the normal reaction conditions. In conclusion,
compound 23a gives a non-essential mixed-type activation of h-
5-LOX and binds with high affinity (aKA = 390 nM) to the substrate
bound enzyme and enhances the conversion of the substrate lino-
leic acid.
The observed results from the enzyme kinetic studies that give
non-essential mixed-type activation versus linoleic acid and non-
essential non-competitive activation versus ATP demonstrate that
there is an allosteric regulatory site in h-5-LOX that is distinct from
the ATP binding site. In order to get a better understanding of this
allosteric site in the regulation of the enzyme activity, we also
studied the inhibition mechanism of h-5-LOX by compound 23d.
Interestingly, compound 23d has a structure that is closely re-
lated to 23a and this compound inhibits h-5-LOX at 50 lM. We
analyzed the underlying enzyme kinetic parameters. The Michae-
lis–Menten plots and the Lineweaver–Burk plots show an increaseof the Kappm and reduction of the K
app
max (Table 4), which is a mixed-
type inhibition of h-5-LOX (Fig. 8). This indicates that inhibitor
23d can bind to the free enzyme as well as to the substrate bound
enzyme following the inhibition model in Scheme 4 from which
the kinetic parameters Vmax and Km can be derived by non-linear
curve fitting of equation 2 (Fig. 9). Furthermore, the changes in
the Km and Vmax are a/a0. Km and Vmax/a0 are used to determine
the Ki and K
0
i values for inhibitor 23d using equations 3 and 4
(Fig. 9). Ki and K
0
i values for inhibitor 23d respectively are
Figure 10. Residual enzyme activity that was observed for compounds 23a and 23d
for inhibition of h-5-LOX in the presence of 50 lM of the respective compounds
with linoleic acid or arachidonic acid as a substrate both at final concentrations of
100 lM. The results presented were the average of three independent experiments
and the standard deviations are shown.
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Figure 9. Equations 2(a), 3(b) and 4(c) for the enzyme kinetics according to the
model in Scheme 2. v is the reaction velocity, Vmax is the maximal reaction velocity,
[S] is the substrate concentration and Km is the Michaelis–Menten constant. a and
a0 , respectively, are the parameters to describe the change of substrate binding
affinity to the enzyme and the change of the maximum velocities. Ki is the
dissociation constant of the inhibitor to the free enzyme and K 0i is the dissociation
constant of the inhibitor to the enzyme-substrate complex.
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type inhibition also indicates the presence of an allosteric site in
human 5-lipoxygenase. We presume that compound 23d binds
to the same allosteric binding pocket as 23a but that the difference
in the alkyl chain causes a difference in affinity as well as a change
from activation to inhibition.
Taking this together, the kinetic studies on activation or inhibi-
tion of human 5-lipoxygenase by either 23a or 23d indicate the
presence of an allosteric binding site that influences the enzyme
activity. In addition, both activation and inhibition obey a compa-
rable kinetic model, which suggests that both effects originate
from the same binding site in the enzyme. Presumably, depending
on the structure of the compounds that bind to this allosteric site
the enzyme would either be activated or inhibited. This is in line
with the literature where the presence of an allosteric binding site
in h-5-LOX that regulates its activity has been described fre-
quently.45–48 We conclude that anacardic acid derivatives can be
used as tools to modulate the h-5-LOX activity toward linoleic acid
and that these compounds modulate the activity of this enzyme by
binding to an allosteric binding site.
We continued our studies with investigation of the modulation
of 23a and 23d of the h-5-LOX activity for arachidonic acid
(Fig. 10). Interestingly, no modulation of the h-5-LOX activity to-
ward arachidonic acid was observed in presence of 23a or 23d.
These results demonstrate that 23a and 23d are selective modula-
tors of linoleic acid conversion and not arachidonic acid conversion
by h-5-LOX.
2.4. Molecular modeling
These results justify the hypothesis that the allosteric regulators
23a and 23d bind to an allosteric regulatory site in h-5-LOX that isclose to the active site. The hypothesis is supported by a previous
report, which stated that h-5-LOX has a wide active site compared
to the others LOXs, which could harbor two substrate molecules.49
The observation that 23a and 23d modulate the conversion of lin-
oleic acid, which has 18 carbon atoms, and not arachidonic acid,
which has 20 carbon atoms, is in line with this hypothesis, because
it is an indication for steric interactions between the substrate and
23a or 23d. Therefore, we hypothesize that the substrates together
with either 23a or 23d bind in the active site, thus resulting in a
different binding constant and a different turnover rate of the sub-
strate linoleic acid. We employed this presumption as a basis for
the modeling studies.
The binding models of the activator 23a and the inhibitor 23d in
the linoleic acid bound as well as the arachidonic acid bound h-5-
LOX active site were made based on the recently published crystal
structure of h-5-LOX (PDB code 3V99).50 The model of h-5-LOX
was further refined using the related PDB structures 3V98 and
3V92 to model Ile673 and its carboxylic acid of the C-terminal
(missing in 3V99), which coordinates the catalytic iron in the ac-
tive site. We note that the model is not meant to capture the role
of the phosphomimic S663D, but only as the structural basis for
substrate binding. Additionally, the active site is in an open config-
uration accessible to a second small molecule. The above notwith-
standing the structure is nearly indistinguishable from the wild
type structure.50
The arachidonic acid substrate molecule lacks visible specific
interactions with the protein except for the interaction of the cis
double bond at carbon 11 to the catalytic iron. This lack of visible
specific interactions renders the virtual re-docking of arachidonic
acid and de novo docking of linoleic acid in the h-5-LOX enzyme
active site futile. Therefore, we modeled a bound structure of lino-
leic acid by manually threading the lipid into the crystal structure
of arachidonic acid using PYMOL.51 The threaded linoleic acid was
then minimized using default settings in UCSF Chimera (version
1.6)52 to produce the final model of linoleic acid bound to the h-
5-LOX active site as shown in Figure 11A. This model is justified
by the high similarity of linoleic acid to arachidonic acid, which
is present in the crystal structure. This model demonstrates that
arachidonic acid protrudes further into the active site then linoleic
acid, which support the idea that steric interaction between 23a
and 23d with the lipid substrate plays a role in the observed en-
zyme kinetics.
Compound 23a and 23dwere docked in the free enzyme, which
can be justified by the observations that their affinity for the en-
zyme is higher (23a KA 8.6 lM, 23d Ki 70 lM) than the substrate
linoleic acid (Km 600 lM). Using the structure of h-5-LOX with
the arachidonic acid substrate removed, we modeled the binding
mode of 23a and 23d by molecular docking using smina55 and
the resulting poses were reranked using the vina scoring function.
Despite the large binding site (relative to the size of the com-
pound), we observe a common binding mode for compounds 23a
and 23d (as well as 23b and 23c, not shown). Subsequently, the
substrate linoleic acid or arachidonic acid were put into the en-
zyme as described above. This binding mode of 23a and 23d is
characterized by a strong pi–pi stacking interaction between the
central phenyl ring of the compound and Phe177 on one side and
the hydrophobic side chain of Ala410 on the other (Fig. 11B). The
buried polar functionalities of the planar salicylate head group
may be stabilized by a hydrogen bond between the carboxylic –
OH group of the head group and the side chain of His372. Also of
importance is the hydrogen bond between the backbone nitrogen
of Phe177 and the ether oxygen of the hydrophobic tail
(Fig. 11C). The dominant docking poses of compounds 23a–d share
a similar geometry. A few of the low score poses have the salicylate
head group rotated by 180 degrees. Compounds 23a–d are identi-
cal except for the length of their alkoxy tails (Table 1). The only
Figure 11. Docking models of Compounds 23 a,b,c,d in a model of linoleic acid bound to h-5-LOX. (A) Model of bound linoleic acid (yellow) based on a superposition to the
configuration of arachidonic acid in the crystal structure (blue). Front (B) and back (C) view of the highest ranking binding mode of compound 23a (green) and compound 23d
(orange) in the linoleic acid bound active site (A). Yellow dashed lines indicate the hydrogen bond between the ether oxygen and the backbone nitrogen of Phe177. Black
dashed lines indicate hydrophobic interactions. (D) Superposition of highest ranked docked configurations of compounds 23a (green), 23b (purple), 23c (dark blue), 23d
(orange) show that larger carbon tails block larger portions of the entrance to the catalytic site. Linoleic acid (yellow) and arachidonic acid (blue) are also shown as references.
R. Wisastra et al. / Bioorg. Med. Chem. 21 (2013) 7763–7778 7771differences in the full series of docked conformations is in the long
flexible alkoxy tails of 23c–d that can fit in a variety of conforma-
tions with almost identical energy scores (Fig. 11D).
The models of 23a–d (Fig. 11D) are consistent with our experi-
mental observations. Figure 1 and Table 1 demonstrate that the h-
5-LOX enzymatic activity decreases with an increase in the alkoxy
tail length. In addition, it was observed that 23a and 23d influence
the linoleic acid conversion and not the arachidonic acid conver-
sion by h-5-LOX (Fig. 10).
Our docking experiments suggest that 23a binds alongside the
substrate linoleic acid and stabilizes its binding and enhances the
enzyme activity. Compound 23d has a longer tail with multiple
binding modes that are likely to block the end of the binding site,
hindering the entry of linoleic acid and thus reducing enzymatic
activity (Fig. 11C). Thus, the shorter linoleic acid substrate leaves
space for the alkoxy tails of 23a and 23d (Fig. 11C). This model
would explain the high affinity of 23a for the linoleic acid bound
enzyme (aKA 0.38 lM) compared to the free enzyme (KA 8.7 lM)
and it is also in line with a higher conversion rate (b 1.76). Perhaps
more interestingly, the model of 23d indicates that an increase in
‘bulk’ for the alkoxy tail provides inhibition of the enzyme activity
for linoleic acid in contrast to the observed activation by 23a.
Namely, the increased ‘bulk’ in 23d must interfere with theenzymatic activity for linoleic acid by disrupting the necessary
binding pose or by blocking the entrance to the active site, which
limits the access of linoleic acid. Conversely, the larger arachidonic
acid might not permit binding of 23a or 23d and thus is its enzy-
matic activity is unaffected.
Taking all these data together we propose a model to explain
our observations. We conclude that compound 23a is an activator
for linoleic acid conversion by h-5-LOX, presumably because it sta-
bilizes the substrate–enzyme complex without blocking the en-
trance to the active site. On the other hand, compound 23d could
bind in a comparable configuration but its larger carbon tail, pre-
sumably, blocks one end of the active site which interferes with
the diffusion of the substrate and molecular oxygen thus overrid-
ing the stabilization effect. Although these models provide plausi-
ble explanations for the observed behavior of this compound class,
we realize crystallography studies would provide the ultimate
experimental proof for the mode of action of these molecules.
3. Conclusion
Anacardic acid derivatives show interesting structure–activity
relationships that demonstrate that these compounds can either
activate or inhibit the activity of human-5-LOX. Compound 23a
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ward linoleic acid as a substrate depending on the substitution in
para-position of the 2-(benzyloxy)-6-hydroxybenzoic acid core.
Compound 23a was identified as a non-essential activator of hu-
man 5-lipoxygenase with KA is 8.65 lM, a is 0.0438, and b is
1.76. The affinity of activator 23a to the substrate bound enzyme
(aKA) is 0.38 lM, which is 50 times higher than to the free enzyme.
Furthermore, activator 23a acts as non-competitive activator
against ATP, which indicates the presence of an allosteric site that
is different from the ATP binding site. Kinetic studies on inhibitor
23d show a mixed type inhibition, which indicates the presence
of an allosteric regulatory site for human 5-LOX activity. Both mod-
ulators 23a and 23d demonstrated no effect on the conversion of
the substrate arachidonic acid by h-5-LOX. Molecular modeling
studies indicate that 23a and 23d bind close to the substrate lino-
leic acid in the active site of h-5-LOX, but that these modulators do
not fit simultaneously in the active site with the arachidonic acid,
which is slightly larger than linoleic acid.
4. Experimental
4.1. Chemistry
4.1.1. General
All reagents and solvents were purchased from commercial
suppliers (Fluka, Sigma–Aldrich, Acros Organics) and were used
without further purification. Dichloromethane was distilled over
CaH2 before use. Merck silica gel 60 F254 plates were used for
analytical thin layer chromatography (TLC) and spots were de-
tected by UV light, or stained using KMnO4 solution. Column
chromatography was performed with MP Ecochrom silica gel
32–63, 60 Å using the flash chromatography technique. 1H
(200 MHz) and 13C (50 MHz) NMR spectra were recorded on a
Varian Gemini 200 spectrometer. 13C NMR spectra were recorded
using the attached proton test (APT). Chemical shifts are re-
ported in ppm (d) relative to the solvent. Atmospheric Pressure
Photoionization mass spectra (APPI-MS) and electrospray ioniza-
tion (ESI) were recorded on an Applied Biosystems/SCIEX
API3000-triple quadrupole mass spectrometer. High-resolution
mass spectra (HR-MS) were recorded using a flow injection
method on a LTQ-Orbitrap XL mass spectrometer (Thermo Elec-
tron, Bremen, Germany) with a resolution of 60,000 at m/z 400.
Protonated testosterone (lock mass m/z = 289.2162) was used for
internal recalibration in real time.
N,N,N0,N0-Tetramethyl-p-phenylenediamine (TMPD) hydrochlo-
ride, human 5-lipoxygenase enzyme, and COX-2 (human recombi-
nant) were obtained from Cayman Chemicals. Adenosine tri-
phosphate (ATP), arachidonic acid, and linoleic acid were obtained
from Sigma–Aldrich. Raw Blue cells assay was obtained from Inviv-
oGen. The MTS assay kit was obtained from Promega. Interferon c
(IFN-c) was obtained from PeproTech.
4.1.2. Synthetic procedure 1: synthesis of alkoxy benzyl alcohol
1-Bromo alkane (13 mmol) was added to a light yellow suspen-
sion of hydroxybenzaldehyde (1.1 g, 9.0 mmol) and K2CO3 (5.2 g,
37 mmol) in 45 mL DMF under nitrogen atmosphere. The suspen-
sion was stirred overnight at room temperature. The reaction mix-
ture was diluted with demiwater (100 mL) and extracted with
ethylacetate (3  80 mL). The combined organic layers were
washed with demiwater (4  80 mL), 0.1 M aqueous HCl
(100 mL), brine (2  30 mL), dried with MgSO4, filtered and con-
centrated in vacuo.
NaBH4 (0.17 g, 4.5 mmol) was added to a solution of benzalde-
hyde (8.0 mmol) in 30 mL methanol at 0 C under nitrogen atmo-
sphere. The reaction mixture was stirred for 1 h at 0 C and thenwarmed to room temperature. The reaction mixture was diluted
with demiwater (80 mL) and extracted with ethylacetate
(2  60 mL). The combined organic layers were washed with demi-
water (2  40 mL), brine (2  40 mL), dried with MgSO4, filtered
and concentrated in vacuo. The product was obtained after crystal-
lization or purification using column chromatography.
4.1.3. Synthetic procedure 2: bromination of alkyloxy benzyl
alcohol
Phosphorus tribromide (PBr3) (0.34 mL, 3.6 mmol) was added
slowly to a suspension of alkyloxy benzyl alcohol (2.5 mmol) in
10 mL CH2Cl2 under nitrogen atmosphere at 0 C to give an orange
suspension. The reaction mixture was stirred for 1.5 h at 0 C. The
reaction mixture was poured into 80 mL ice water, and extracted
with ethylacetate (3  50 mL). The combined organic layers were
washed with demiwater (50 mL), 0.1 M aqueous HCl (2  30 mL),
brine (50 mL), dried with MgSO4, filtered and concentrated in va-
cuo. The aryl bromide product was obtained after purification
using column chromatography.
4.1.4. Synthetic procedure 3: Williamson ether synthesis
coupling of aryl bromide
5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 1
(0.22 g, 1.1 mmol) and K2CO3 (0.63 g, 4.6 mmol) were suspended
in 8 mL DMF under nitrogen atmosphere. A suspension of aryl bro-
mide in 7 mL DMF was added to the suspension. The mixture was
stirred overnight at room temperature and was diluted with demi-
water (60 mL) and extracted with ethylacetate (3  45 mL). The
combined organic layers were washed with demiwater
(2  40 mL), 0.1 M aqueous HCl (40 mL), brine (2  20 mL), dried
over MgSO4, filtered and concentrated in vacuo. The product was
obtained after purification using column chromatography.
4.1.5. Synthetic procedure 4: saponification of the acetonide
5 M KOH (0.16 mL, 0.80 mmol) was added to a solution of 2,2-
dimethyl-5-((4-(alkyloxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-
one (0.15 g, 0.40 mmol) in 10 mL THF. The reaction mixture was
heated till 60 C and stirred overnight affording an orange suspen-
sion. The reaction mixture was concentrated in vacuo yielding the
product as potassium salt.
4.1.6. Synthetic procedure 5: hydrolysis of acetonide
5 M KOH (1.2 mL, 6 mmol) was added to a colorless solution of
acetonide (0.60 mmol) in 10 mL THF. The reaction mixture was
stirred for 24 h at 62 C. The reaction mixture was diluted and acid-
ified with 1 N aqueous HCl (2.6 mL) and extracted with ethylace-
tate (2  40 mL). The combined organic layers were washed with
water (50 mL), brine (2  30 mL), dried over MgSO4, filtered and
concentrated in vacuo.
4.1.7. (4-(Pentyloxy)phenyl)methanol (2a)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromopentane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
purified using column chromatography with heptane/EtOAc 5:1
(v/v) as an eluent. Yield 73%. Light orange solid. Rf = 0.41 (hep-
tane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.40–7.18 (m, 2H),
6.97–6.79 (m, 2H), 4.59 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.87 (s, 1H),
1.86–1.72 (m, 2H), 1.46–1.34 (m, 4H), 0.94 (t, J = 7.0, 3H). 13C
NMR (50 MHz, CDCl3) d 158.47, 133.10, 128.80, 114.73, 68.24,
65.20, 29.14, 28.38, 22.65, 14.20. MS (APPI): m/z 194.2 [M+].
4.1.8. 1-(Bromomethyl)-4-(pentyloxy)benzene (3a)
The product was obtained from (4-(pentyloxy)phenyl)methanol
2a using synthetic procedure 2. The product was obtained in high
purity and no further purification was required. Yield 97%. Yellow
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7.38–7.22 (m, 2H), 6.94–6.74 (m, 2H), 4.51 (s, 2H), 3.94 (t, J = 6.2,
2H), 1.91–1.65 (m, 2H), 1.59–1.21 (m, 4H), 0.94 (t, J = 7.1, 3H).
13C NMR (50 MHz, CDCl3) d 159.47, 130.60, 129.88, 114.94, 68.26,
34.30, 29.11, 28.38, 22.65, 14.22. MS (ESI): m/z 177.1 [MBr]+.
4.1.9. 2,2-Dimethyl-5-((4-(pentyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (12a)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(pentyl-
oxy)benzene 3a using synthetic procedure 3. The product was
crystallized from iso-propanol. Yield 70%. White solid. Rf = 0.6
(heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3) d 7.50–7.32 (m,
3H), 6.90 (d, J = 8.3, 2H), 6.65 (d, J = 8.5, 1H), 6.54 (d, J = 8.2, 1H),
5.18 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.81–1.70 (m, 8H), 1.46 - 1.40
(m, 4H), 0.93 (t, J = 7.1, 3H). 13C NMR (50 MHz, CDCl3) d 160.69,
159.10, 157.99, 136.40, 128.53, 128.26, 114.82, 109.57, 107.62,
105.41, 105.22, 104.17, 70.89, 68.23, 29.17, 28.41, 25.86, 22.67,
14.23. MS (APPI): m/z 370.2 [M+].
4.1.10. Potassium 2-hydroxy-6-((4-
(pentyloxy)benzyl)oxy)benzoate (23a)
The product was obtained from 2,2-dimethyl-5-((4-(pentyl-
oxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-one 12a using syn-
thetic procedure 4. Yield quantitatively determined from the final
yield of product in excess of KOH. Orange gum. Rf = 0.16 (hep-
tane/EtOAc 1:1 containing 1% acetic acid). The product was more
than 95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
D2O) d 7.15 (d, J = 8.5, 2H), 6.89 (t, J = 8.3, 1H), 6.68 (d, J = 8.5,
2H), 6.34 (d, J = 8.3, 1H), 6.27 (d, J = 8.3, 1H), 4.91 (s, 2H), 3.68 (t,
J = 6.5, 2H), 1.50–1.47 (m, 2H), 1.14–1.11 (m, 4H), 0.70 (t, J = 7.0,
3H).13C NMR (50 MHz, D2O) d 195.90, 159.11, 158.08, 157.85,
131.54, 129.50, 128.81, 114.48, 111.31, 109.15, 105.52, 70.26,
68.25, 28.21, 27.56, 21.89, 13.38. HRMS: m/z [MH] calcd for
C19H21O5 329.13945, found 329.13995.
4.1.11. (4-(Heptyloxy)phenyl)methanol (2b)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
crystallized from heptane. Yield 87%. Colorless to white crystal.
Rf = 0.44 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.49–
7.16 (m, 2H), 6.99–6.79 (m, 2H), 4.59 (s, 2H), 3.95 (t, J = 6.6, 2H),
1.83 (s, 1H), 1.81–1.71 (m, 2H), 1.55–1.19 (m, 8H), 0.89 (t, J = 6.4,
3H).13C NMR (50 MHz, CDCl3) d 158.97, 133.09, 128.81, 114.75,
68.27, 65.22, 31.98, 29.46, 29.26, 26.20, 22.80, 14.28. MS (APPI):
m/z 222.2 [M+].
4.1.12. 1-(Bromomethyl)-4-(heptyloxy)benzene (3b)
The product was obtained from (4-(heptyloxy)phenyl)methanol
2b using synthetic procedure 2. The product was obtained in high
purity and no further purification was required. Yield 97%. Yellow
oil. Rf = 0.71 (heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3) d
7.37–7.27 (m, 2H), 6.91–6.75 (m, 2H), 4.51 (s, 2H), 3.95 (t, J = 6.5,
2H), 1.91–1.68 (m, 2H), 1.57–1.18 (m, 8H), 0.91 (t, J = 6.5, 3H).13C
NMR (50 MHz, CDCl3) d 159.47, 130.60, 129.87, 114.94, 68.27,
34.30, 31.98, 29.42, 29.25, 26.19, 22.81, 14.29. MS (ESI): m/z
205.1 [MBr]+.
4.1.13. 5-((4-(Heptyloxy)benzyl)oxy)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (12b)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(heptyl-
oxy)benzene 3b using synthetic procedure 3. The product was
purified using column chromatography with heptane/EtOAc 11:1
(v/v) as an eluent. Yield 78%. White solid. Rf = 0.41 (heptane/EtOAc3:1).1H NMR (200 MHz, CDCl3) d 7.50–7.32 (m, 3H), 6.90 (d, J = 8.6,
2H), 6.90 (d, J = 8.4, 1H), 6.65 (d, J = 8.4, 1H), 5.18 (s, 2H), 3.94 (t,
J = 6.5, 2H), 1.85–1.65 (m, 8H), 1.40–1.30 (m, 8H), 0.89 (t, J = 6.6,
3H). 13C NMR (50 MHz, CDCl3) d 160.68, 159.11, 158.23, 157.99,
136.40, 128.53, 128.25, 114.82, 109.57, 107.61, 105.41, 104.17,
70.88, 68.25, 31.99, 29.48, 29.27, 26.21, 25.85, 22.82, 14.29. MS
(APPI): m/z 398.2 [M+].
4.1.14. Potassium 2-((4-(heptyloxy)benzyl)oxy)-6-
hydroxybenzoate (23b)
The product was obtained from 5-((4-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 12b using synthetic
procedure 4. Yield quantitatively determined from the final yield
of product in excess of KOH. Orange solid. Rf = 0.49 (heptane/EtOAc
2:1 containing 1% acetic acid). The product was more than 95%
pure as judged from TLC and NMR. 1H NMR (200 MHz, D2O) d
6.93 (m, 2H), 6.60 (m, 1H), 6.42 (m, 2H), 6.18 (m, 1H), 5.94 (m,
1H), 4.74 (s, 2H), 3.38 (m, 2H), 1.31–1.06 (m, 10H), 0.68 (t,
J = 6.6, 3H). 13C NMR (50 MHz, CD3OD) d 202.2, 179.61, 161.89,
161.16, 160.88, 133.19, 131.99, 130.65, 116.15, 111.26, 106.62,
105.29, 72.48, 69.85, 33.85, 31.30, 31.08, 28.01, 24.53, 15.27.
HRMS: m/z [MH]calcd for C21H25O5357.17075, found
357.17109.
4.1.15. (4-(Nonyloxy)phenyl)methanol (2c)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromononane, and 4-hydroxy-
benzaldehyde using synthetic procedure 1. The product was
crystallized from heptane. Yield 73%. White crystal. Rf = 0.44 (hep-
tane:ethylacetate 1:1).1H NMR (200 MHz, CDCl3) d 7.35–7.20 (m,
2H), 6.95–6.82 (m, 2H), 4.60 (s, 2H), 3.95 (t, J = 6.6, 2H), 1.85–
1.74 (m, 2H), 1.71 (s, 1H), 1.42–1.29 (m, 12H), 0.89 (t, J = 7.0,
3H).13C NMR (50 MHz, CDCl3) d 158.99, 133.09, 128.82, 114.76,
68.28, 65.27, 32.08, 29.74, 29.61, 29.47, 26.24, 22.87, 14.31. MS
(APPI): m/z 250.2 [M+].
4.1.16. 1-(Bromomethyl)-4-(nonyloxy)benzene (3c)
The product was obtained from (4-(nonyloxy)phenyl)methanol
2c using synthetic procedure 2. The product was obtained in high
purity and no further purification was required. Yield 94%. Light
yellow oil. Rf = 0.74 (heptane/EtOAc 1:1).1H NMR (200 MHz, CDCl3)
d 7.39–7.20 (m, 2H), 6.94–6.76 (m, 2H), 4.50 (s, 2H), 3.95 (t, J = 6.5,
2H), 1.88–1.66 (m, 2H), 1.54–1.14 (m, 12H), 0.89 (t, J = 6.4, 3H).13C
NMR (50 MHz, CDCl3) d 159.48, 130.61, 129.88, 114.96, 68.29,
34.31, 32.09, 29.74, 29.59, 29.47, 29.42, 26.23, 22.88, 14.32. MS
(ESI): m/z 233.1 [MBr]+.
4.1.17. 2,2-Dimethyl-5-((4-(nonyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (12c)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-(nonyl-
oxy)benzene 3c using synthetic procedure 3. The product was puri-
fied using column chromatography with heptane/EtOAc 15:1 (v/v)
as an eluent. Yield 85%. White solid. Rf = 0.48 (heptane/EtOAc 3:1).
1H NMR (200 MHz, CDCl3) d 7.53–7.29 (m, 3H), 6.90 (d, J = 8.4, 2H),
6.65 (d, J = 8.4, 1H), 6.54 (d, J = 8.4, 1H), 5.18 (s, 2H), 3.94 (t, J = 6.5,
2H), 1.88–1.64 (m, 8H), 1.36 (d, J = 30.5, 12H), 0.88 (t, J = 6.2,
3H).13C NMR (50 MHz, CDCl3) d 202.3, 160.67, 159.09, 158.20,
157.98, 136.39, 128.52, 128.24, 114.81, 109.56, 107.60, 105.40,
102.26, 70.87, 68.24, 32.08, 29.74, 29.61, 29.47, 26.25, 25.85,
22.87, 14.35, 14.31. MS (APPI): m/z 426.2 [M+].
4.1.18. Potassium 2-hydroxy-6-((4-
(nonyloxy)benzyl)oxy)benzoate (23c)
The product was obtained from 2,2-dimethyl-5-((4-(nonyl-
oxy)benzyl)oxy)-4H-benzo[d][1,3]dioxin-4-one 12c using syn-
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yield of product in excess of KOH. Rf = 0.18 (heptane/EtOAc 1:1
containing 1% acetic acid). The product was more than 95% pure
as judged from TLC and NMR. 1H NMR (200 MHz, D2O) d 6.95 (d,
J = 8.3, 2H), 6.57 (t, J = 8.5, 1H), 6.43 (d, J = 8.3, 2H), 6.16 (d,
J = 8.5, 1H), 5.91 (d, J = 8.5, 1H), 4.75 (s, 2H), 3.38 (m, 2H), 1.34
(m, 2H), 1.06 (m, 12H), 0.71 (t, J = 7.0, 3H).13C NMR (50 MHz, CD3-
OD) d 202.2, 164.24, 160.76, 156.88, 133.10, 131.98, 130.67,
116.19, 111.48, 109.33, 106.36, 72.41, 69.89, 61.77, 33.83, 31.47,
31.31, 31.18, 28.10, 27.95, 24.52, 14.22. HRMS: m/z [MH] calcd
for C23H29O5 385.20205, found 385.20248.
4.1.19. (4-((3,7-Dimethyloctyl)oxy)phenyl)methanol (2d)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-1-bromo-3,7-dimethyloctane,
and 4-hydroxybenzaldehyde using synthetic procedure 1. The
product was used for the next reaction step without further purifi-
cation. Yield 92%. Yellow oil. Rf = 0.48 (heptane/EtOAc 1:1). 1H
NMR (200 MHz, CDCl3) d 7.27 (d, J = 8.6, 2H), 6.88 (d, J = 8.6, 2H),
4.59 (s, 2H), 3.98 (t, J = 6.5, 2H), 1.88–1.46 (m, 5H), 1.32–1.14 (m,
6H), 0.93 (d, J = 6.2, 3H),0.87 (d, J = 6.5, 6H).13C NMR (50 MHz,
CDCl3) d 158.98, 133.10, 128.82, 114.77, 66.59, 65.27, 39.45,
37.49, 36.40, 30.06, 28.17, 24.86, 22.91, 22.81, 19.86. MS (APPI):
m/z 264.1 [M+].
4.1.20. 1-(Bromomethyl)-4-((3,7-dimethyloctyl)oxy)benzene
(3d)
The product was obtained from (4-((3,7-dimethyloc-
tyl)oxy)phenyl)methanol 2d using synthetic procedure 2. The
product was used for the next reaction step without further purifi-
cation. Yield quantitative. Light yellow oil. Rf = 0.75 (heptane/
EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.30 (d, J = 8.6, 2H), 6.85
(d, J = 8.6, 2H), 4.49 (s, 2H), 3.98 (t, J = 6.5, 2H), 1.87–1.46 (m,
4H), 1.32–1.10 (m, 6H), 0.93 (d, J = 6.2, 3H), 0.87 (d, J = 6.4,
6H).13C NMR (50 MHz, CDCl3) d 159.46, 130.60, 129.88, 114.95,
66.59, 39.45, 37.47, 36.35, 34.30, 30.04, 28.18, 24.86, 22.92,
22.82, 19.85. MS (ESI): m/z 247.1 [M–Br]+.
4.1.21. 5-((4-((3,7-Dimethyloctyl)oxy)benzyl)oxy)-2,2-dimethyl-
4H-benzo[d][1,3]dioxin-4-one (12d)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-4-((3,7-dime-
thyloctyl)oxy)benzene 3d using synthetic procedure 3. The product
was purified using column chromatography with heptane/EtOAc
19:1 (v/v) as eluent. Yield 68%. White solid. Rf = 0.35 (heptane/
EtOAc 4:1). 1H NMR (200 MHz, CDCl3) d 7.46–7.26 (m, 3H), 6.92
(d, J = 8.6, 2H), 6.65 (d, J = 8.5, 1H), 6.54 (d, J = 8.5, 1 H), 5.18 (s,
2H), 3.98 (t, J = 6.5, 2H), 1.84–1.5 (m, 10H), 1.32–1.14 (m, 6H),
0.93 (d, J = 6.2, 3H), 0.87 (d, J = 6.4, 6H).13C NMR (50 MHz, CDCl3)
d 160.69, 159.10, 158.23, 157.99, 136.40, 128.53, 128.25, 114.82,
109.57, 107.61, 105.41, 70.89, 66.56, 39.45, 37.49, 36.40, 30.05,
28.17, 25.85, 24.85, 22.91, 22.81, 19.86. MS (APPI): m/z 440.4 [M+].
4.1.22. Potassium 2-((4-((3,7-dimethyloctyl)oxy)benzyl)oxy)-6-
hydroxybenzoate (23d)
The product was obtained from 5-((4-((3,7-dimethyloc-
tyl)oxy)benzyl)oxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one
12d using synthetic procedure 4. The compound is racemic at its
asymmetric carbon. Yield quantitatively determined from the final
yield of product in excess of KOH. Orange solid. Rf = 0.54 (heptane/
EtOAc 1:1 containing 1% acetic acid). The product was more than
95% pure as judged from TLC and NMR. 1H NMR (200 MHz, CD3OD)
d 7.42 (d, J = 8.7, 2H), 7.05 (t, J = 8.2, 1H), 6.95–6.85 (m, 2H), 6.43–
6.38 (m, 2H), 5.03 (s, 2H), 3.99 (t, J = 6.7 2H), 1.92–1.48 (m, 4H),
1.40–1.16 (m, 6H), 0.95 (d, J = 6.2, 3H), 0.89 (d, J = 6.5, 6H).13C
NMR (50 MHz, CD3OD) d 202.3, 164.42, 161.42, 160.86, 132.74,132.06, 130.69, 116.17, 111.76, 105.95, 72.47, 68.11, 41.28, 39.28,
38.27, 31.89, 29.99, 26.67, 23.95, 23.86, 20.90. HRMS: m/z [MH]
calcd for C24H31O5 399.2177, found 399.21844.
4.1.23. (3-(Heptyloxy)phenyl)methanol (4b)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 3-hydroxy-
benzaldehyde using synthetic procedure 1. The product was used
for the next reaction step without further purification. Yield 94%.
Brown solid. Rf = 0.48 (heptane/EtOAc 1:1). 1H NMR (200 MHz,
CDCl3) d 7.26–7.18 (m, 1H), 6.96–6.75 (m, 3H), 4.64 (s, 2H), 3.95
(t, J = 6.5, 2H), 1.88–1.67 (m, 3H), 1.55–1.17 (m, 8H), 0.89 (t,
J = 6.5, 3H).13C NMR (50 MHz, CDCl3) d 159.62, 142.67, 129.74,
119.09, 114.01, 113.09, 68.18, 65.48, 31.99, 29.49, 29.27, 26.22,
22.82, 14.34. MS (APPI): m/z 222.2 [M+].
4.1.24. 1-(Bromomethyl)-3-(heptyloxy)benzene (5b)
The product was obtained from (3-(heptyloxy)phenyl)methanol
4b using synthetic procedure 2. Therefore product was used for the
next reaction step without further purification. Yield 86%. Brown
solid. Rf = 0.71 (heptane/EtOAc 1:1). 1H NMR (200 MHz,
CDCl3)7.32–6.27 (m, 4H), 4.76 (s, 2H), 3.92 (t, J = 6.4, 2H), 1.72-
1.65(m, 2H), 1.34–1.15 (m, 8H), 0.89 (t, J = 6.5, 3H).13C NMR
(50 MHz, CDCl3) d 159.41, 129.63, 119.81, 114.36, 105.23, 68.05,
32.65, 32.01, 29.53, 29.36, 26.24, 22.84, 14.31. MS (ESI): m/z
285.0 [M+].
4.1.25. 5-((3-(Heptyloxy)benzyl)oxy)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (13b)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-3-(heptyl-
oxy)benzene 5b using synthetic procedure 3. The product was
purified using column chromatography with heptane/EtOAc 16:1
(v/v) as eluent. Yield 58%. White solid. Rf = 0.29 (heptane/EtOAc
5:1).1H NMR (200 MHz, CDCl3) d 7.42–7.35 (m, 2H), 7.25 (d,
J = 7.5, 1H), 7.04 (d, J = 7.5, 1H), 6.83 (d, J = 7.9, 1H), 6.70–6.49 (m,
2H), 5.22 (s, 2H), 3.99 (t, J = 6.4, 2H), 1.87–1.68 (m, 2H) 1.56 (s, 6H),
1.42– 1.12 (m, 8H), 0.89 (t, J = 6.5, 3H). 13C NMR (50 MHz, CDCl3) d
160.53, 159.77, 158.23, 158.01, 138.02, 136.48, 129.73, 118.57,
114.61, 112.43, 109.67, 107.36, 105.46, 70.74, 68.19, 32.00, 29.50,
29.29, 26.26, 25.85, 22.82, 14.30. MS (APPI): m/z 399.2 [M+H]+.
4.1.26. 2-((3-(Heptyloxy)benzyl)oxy)-6-hydroxybenzoic acid
(24b)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 13b using synthetic
procedure 5. Yield quantitative. Yellow oil. Rf = 0.42 (heptane/
EtOAc 1:1 containing 1% acetic acid). The product was more than
95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
DMSO-d6) d 7.26–7.19 (m, 2H), 7.08 (d, J = 7.5, 1H), 7.04 (d,
J = 7.5, 1H), 6.79 (d, J = 8.11H), 6.31 (d, J = 8.2, 2H), 5.04 (s, 2H),
3.95 (t, J = 6.4, 2H), 1.73 - 1.63 (m, 2H), 1.36–1.18 (m, 8H), 0.87
(t, J = 7.0, 3H).13C NMR (50 MHz, DMSO-d6) d 170.28, 164.46,
159.34, 158.66, 139.68, 130.82, 129.05, 118.77, 113.03, 110.05,
109.85, 102.77, 69.61, 67.26, 31.26, 28.75, 28.48, 25.55, 22.07,
13.96. HRMS: m/z [MH]calcd for C21H25O5 357.17075, found
357.17114.
4.1.27. (3-(Nonyloxy)phenyl)methanol (4c)
The product was obtained using Williamson ether synthesis fol-
lowed by aldehyde reduction of 1-bromoheptane, and 3-hydroxy-
benzaldehyde using synthetic procedure 1. The product was used
for the next reaction step without further purification. Yield 89%.
Rf = 0.54 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.22
(t, J = 7.8, 1H), 6.89 (s, 1H), 6.85–6.72 (m, 2H), 4.59 (s, 2H), 3.92
(t, J = 6.5, 2H), 2.32 (s, 1H), 1.79–1.69 (m, 2H), 1.42–1.28 (m,
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142.67, 129.62, 119.04, 113.88, 113.02, 68.11, 65.25, 32.05, 29.72,
29.58, 29.44, 26.22, 22.84, 14.26. MS (APPI): m/z250.2 [M+].
4.1.28. 1-(Bromomethyl)-3-(nonyloxy)benzene (5c)
The product was obtained from (3-(nonyloxy)phenyl)methanol
4c using synthetic procedure 2. Therefore the product was used for
the next reaction step without further purification. Yield 78%. Yel-
low oil. Rf = 0.71 (heptane/EtOAc 1:1).1H NMR (500 MHz, CDCl3) d
7.22 (t, J = 7.8, 1H), 6.96–6.92 (m, 2H), 6.84–6.81 (m, 1H), 4.46 (s,
2H), 3.95 (t, J = 7.0, 2H), 1.87–1.75 (m, 2H), 1.47–1.28 (m, 12H),
0.89 (t, J = 6.8, 3H). 13C NMR (50 MHz, CDCl3) d 159.33, 139.04,
129.73, 121,03, 115.03, 114.67, 68.02, 33.55, 31.86, 29.52, 29.38,
29.24, 26.02, 22.65, 14.09. MS (ESI): m/z 313.0 [M+].
4.1.29. 2,2-Dimethyl-5-((3-(nonyloxy)benzyl)oxy)-4H-
benzo[d][1,3]dioxin-4-one (13c)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-(bromomethyl)-3-(nonyl-
oxy)benzene 5c using synthetic procedure 3. The product was puri-
fied using column chromatography with heptane/EtOAc 16:1 (v/v)
as eluent. Yield 88%. Yellow oil. Rf = 0.29 (heptane/EtOAc 5:1). 1H
NMR (500 MHz, CDCl3) d 7.41–7.35 (m, 2H), 7.25–7.20 (m, 2H),
7.04 (d, J = 7.0, 1H), 6.82 (d, J = 6.9, 1H), 6.59 (d, J = 8.0, 1H), 5.21
(s, 2H), 3.99 (t, J = 6.0, 2H), 1.89–1.62 (m, 8H), 1.51–1.13 (m,
12H), 0.87 (d, J = 6.3, 3H).13C NMR (50 MHz, CDCl3) d 160.46,
159.71, 157.95, 137.97, 136.45, 129.66, 118.51, 114.55, 112.37,
109.62, 107.30, 105.39, 103.97, 70.68, 68.13, 32.04, 29.71, 29.60,
29.43, 26.26, 25.79, 22.83, 14.28. MS (ESI): m/z 427.3 [M+H]+.
4.1.30. 2-Hydroxy-6-((3-(nonyloxy)benzyl)oxy)benzoic acid
(24c)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 13c using synthetic
procedure 5. The product was obtained in high purity and no fur-
ther purification was required. Yield 58%. Yellow oil. Rf = 0.60 (hep-
tane/EtOAc 1:1 containing 1% acetic acid). The product was more
than 95% pure as judged from TLC and NMR. 1H NMR (200 MHz,
CD3OD) d 7.27–7.20 (m, 2H), 7.11–7.01 (m, 2H), 6.81 (d, J = 7.8,
1H), 6.49 (d, J = 7.5, 2H), 5.16 (s, 2H), 3.97 (t, J = 6.2, 2H), 1.75–
1.71 (m, 2H), 1.41–1.23 (m, 12H), 0.90 (t, J = 6.5, 3H).13C NMR
(50 MHz, CD3OD) d 185.96, 161.65, 156.96, 141.16, 131.25,
121.03, 115.76, 115.03, 107.29, 94.05, 72.58, 69.81, 33.92, 31.56,
31.43, 31.30, 28.07, 24.59, 15.30. HRMS: m/z [MH] calcd for
C23H29O5 385.20205, found 385.20261.
4.1.31. 2,2-Dimethyl-5-(nonyloxy)-4H-benzo[d][1,3]dioxin-4-
one (11)
The product was obtained from 5-hydroxy-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one 1, and 1-bromononane using synthetic
procedure 3. The product was purified using column chromatogra-
phy with heptane as eluent followed by heptane/EtOAc 50:1 (v/v)
as eluent until the starting material was completely removed from
the column and the product was obtained by eluting the column
with EtOAc as eluent. Yield 53%. Light yellow solid. Rf = 0.64 (hep-
tane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d 7.40 (t, J = 8.4, 1H),
6.59 (d, J = 8.1, 1H), 6.51 (d, J = 8.2, 1H) 4.06 (t, J = 6.7, 2H), 1.95–
1.81 (m, 2H), 1.69 (s, 6H), 1.50–1.26 (m, 12H), 0.85 (t, J = 6.6,
3H).13C NMR (50 MHz, CDCl3) d 161.30, 158.20, 157.96, 136.41,
109.03, 106.62, 105.28, 103.67, 69.60, 32.07, 29.69, 29.55, 29.46,
29.14, 26.03, 25.84, 22.86, 14.31. MS (APPI): m/z 321.0 [M+H]+.
4.1.32. 2-Hydroxy-6-(nonyloxy)benzoic acid (22)
The product was obtained from 5-((3-(heptyloxy)benzyl)oxy)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 11 using synthetic
procedure 5. The product was obtained in high purity and nofurther purification was required. Yield quantitative. Light brown
solid. Rf = 0.60 (heptane/EtOAc 1:1 containing 1% acetic acid). The
product was more than 95% pure as judged from TLC and NMR.
1H NMR (200 MHz, DMSO-d6) d 7.02 (t, J = 8.2, 1H), 6.28 (d,
J = 8.0, 1H), 6.24 (d, J = 8.1, 1H), 3.87 (t, J = 6.5, 2H), 1.68–1.58 (m,
2H), 1.40–1.17 (m, 12H), 0.86 (t, J = 6.5, 3H).13C NMR (50 MHz,
DMSO-d6) d 164.31, 160.21, 131.19, 110.51, 109.82, 103.07,
69.00, 31.74, 29.48, 29.34, 29.14, 25.92, 22.54, 14.40. HRMS: m/z
[MH] calcd for C16H23O4 279.16018, found 279.16061.
4.1.33. 1-(4-Bromophenyl)decan-1-one (7)
The product was obtained using Friedel–Craft acylation of bro-
mobenzene 6 with decanoylchloride. AlCl3 (0.81 g, 6.1 mmol) was
added slowly to a solution of bromobenzene (0.54 mL, 5.1 mmol)
and decanoylchloride (1.2 mL, 5.8 mmol) in 20 mL CH2Cl2 in a
50 mL flask at 0 C. AlCl3 slowly dissolved in the mixture and the
reaction mixture was stirred for 1 hour at 60 C. The reaction mix-
ture was poured into ice-water (25 mL) and extracted with CH2Cl2
(2  30 mL). The combined organic layers were dried over brine
and concentrated in vacuo. The product was dissolved in CH2Cl2
and washed with 2 N aqueous HCl (2  15 mL) and dried over
brine (15 mL) and concentrated in vacuo. The product was crystal-
lized from heptane in a yield 62% (0.49 mg, 1.5 mmol) as a white
solid. Rf = 0.69 (heptane/EtOAc 1:1). 1H NMR (200 MHz, CDCl3) d
7.89–7.75 (m, 2H), 7.65–7.53 (m, 2H), 2.92 (t, J = 7.5, 2H), 1.75–
1.64 (m, 2H), 1.32–1.27 (m, 12H), 0.87 (t, J = 6.4, 3H).13C NMR
(50 MHz, CDCl3) d 199.72, 136.01, 132.06, 129.82, 128.19, 38.81,
32.08, 29.67 (2C), 29.54, 29.49, 24.50, 22.88, 14.32. MS (APPI): m/
z 311.2 [M+].
4.1.34. 1-Bromo-4-decylbenzene (8)
The product was obtained using a Wolff–Kishner reaction to re-
duce 1-(4-bromophenyl)decan-1-one 7. 1-(4-Bromophenyl)decan-
1-one 7 (1.3 g, 4.2 mmol), hydrazine monohydrate (1.2 mL,
16 mmol) and KOH (1.8 g, 32 mmol) were dissolved in 25 mL of
1-octanol to yield a green suspension in a two-necked 50 mL flask.
The reaction mixture was stirred at reflux at 135 C for 23=4 h to give
an almost colorless solution. The reaction mixture was then cooled
to room temperature and diluted with ether (50 mL), washed with
1 N aqueous HCl (50 mL), 2 N aqueous HCl (20 mL), brine (2 times,
30 mL), dried over MgSO4, filtered, concentrated in vacuo. 1-Octa-
nol was removed by vacuum distillation to yield about 2.7 g of the
crude product. The product was purified using column chromatog-
raphy with heptane as eluent. Yield 40%. Colorless oil. Rf = 0.61
(100% heptane). 1H NMR (500 MHz, CDCl3) d 7.37 (d, J = 8.3, 2H),
7.03 (d, J = 8.1, 2H), 2.54 (t, J = 7.7, 2H), 1.60–1.54 (m, 2H), 1.28–
1.25 (m, 14H), 0.88 (t, J = 6.8, 3H).13C NMR (50 MHz, CDCl3) d
142.05, 131.46, 130.37, 119.47, 35.59, 32.14, 31.56, 29.85, 29.82,
29.71, 29.57, 29.43, 22.93, 14.34. MS (APPI): m/z 296.2 [M+].
4.1.35. ((4-Decylphenyl)ethynyl)trimethylsilane
Into a dried 10–20 mL microwave vial, PdCl2(PPh3) (52 mg,
74 lmol), CuI (18 mg, 95 lmol), and PPh3 (80 mg, 0.30 mmol) were
suspended in CH3CN (2 mL) under nitrogen atmosphere. Subse-
quently, 1-bromo-4-decylbenzene 8 (0.46 g, 1.5 mmol), diethyl
amine (Et2NH) (2.4 mL, 23 mmol), and trimethylsilyl acetylene
(TMSA) (0.24 mL, 1.7 mmol), were added to the mixture. The mix-
ture was heated at 120 C for 35 min via microwave irradiation
(95 W). The reaction mixture was diluted with EtOAc (50 mL)
and washed with water (3  50 mL). The water layer was washed
with EtOAc (2  50 mL). The combined organic phases were ex-
tracted with brine (1  50 mL) and dried over Mg2SO4. The solvent
was evaporated under reduced pressure and the residue was puri-
fied by column chromatography with heptane as eluent. Yield 65%.
Brown oil. Rf = 0.41 (100% heptane). 1H NMR (500 MHz, CDCl3) d
7.37 (d, J = 8.0, 2H), 7.10 (d, J = 7.9, 2H), 2.58 (t, J = 7.6, 2H), 1.58–
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9H);13C NMR (50 MHz, CDCl3) d 143.89, 132.08, 128.52, 120.44,
105.63, 93.45, 36.11, 32.12, 31.42, 29.82, 29.69 (2C), 29.55, 29.42,
22.91, 14.34, 0.26. MS (APPI): m/z 314.2 [M+].
4.1.36. 1-Decyl-4-ethynylbenzene (9)
((4-Decylphenyl)ethynyl)trimethylsilane (0.29 g, 0.91 mmol)
was dissolved in THF (5 mL) and the solution was cooled to 0 C.
Tetra butyl ammonium fluoride (TBAF) (1.4 mL, 1.4 mmol) in THF
(1 M, 2.6 mL) was added dropwise and the reaction mixture was
stirred for 10 min. The reaction mixture was diluted with EtOAc
(50 mL), extracted with water (4  50 mL) and washed with brine
(2  50 mL). The organic phase was dried over MgSO4 and filtered.
The solvent was evaporated and the product was used without fur-
ther purification. Yield 93%. Brown oil. Rf = 0.45 (100% heptane). 1H
NMR (500 MHz, CDCl3) d 7.40 (d, J = 8.0, 2H), 7.13 (d, J = 7.8, 2H),
3.02 (s, 1H), 2.59 (t, J = 7.6, 2H), 1.59–1.55 (m, 2H), 1.29–1.26 (m,
14H), 0.88 (t, J = 6.8, 2H).13C NMR (50 MHz, CDCl3) d 144.22,
132.25, 128.63, 119.41, 105.22, 92.67, 36.12, 32.12, 31.45, 29.82,
29.79, 29.69, 29.55, 29.46, 22.91, 14.34. MS (APPI): m/z 242.2 [M+].
4.1.37. Benzyl 2,4-bis(benzyloxy)-6-((4-
decylphenyl)ethynyl)benzoate
The product was obtained using Sonogashira coupling reaction
of 2,4-bis(benzyloxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate
10, and 1-decyl-4-ethynylbenzene 9. Distilled diethylamine
(0.11 mL, 1.05 mmol) and 1-decyl-4-ethynylbenzene 9 (0.18 g,
0.74 mmol) were subsequently added to a solution of the triflate
10 (0.36 g, 0.63 mmol), CuI (9.0 mg, 47 lmol), and PdCl2(PPh3)2
(18 mg, 0.026 mmol) in degassed anhydrous acetonitrile (1.0 mL)
under nitrogen atmosphere. The mixture was subjected to micro-
wave irradiation for 35 min at 120 C (70 W). The reaction mixture
was diluted with ether (50 mL) and washed with demi water
(2  30 mL), brine (2  50 mL), dried over MgSO4 and filtered.
The solvent was evaporated under reduced pressure, and the resi-
due was purified by column chromatography with heptanes/EtOAc
5:1 (v/v) as eluent. Yield 80%. Brown oil. Rf = 0.40 (heptane/EtOAc
1:1). 1H NMR (500 MHz, CDCl3) d 7.43–7.27 (m, 15H), 7.22 (d,
J = 8.0, 2H), 7.12 (d, J = 7.9, 2H), 6.75 (s, 1H), 6.56 (s, 1H), 5.37 (s,
2H), 5.06 (s, 2H), 5.04 (s, 2H), 2.60 (t, J = 7.5, 2H), 1.60- 1.55 (m,
2H), 1.30- 1.26 (m, 14H), 0.88 (t, J = 6.6, 3H).13C NMR (50 MHz,
CDCl3) d 166.91, 160.54, 157.24, 144.06, 136.47, 136.38, 136.09,
131.89, 128.89, 128.76, 128.61, 128.48, 128.44, 128.17, 128.12,
127.75, 127.30, 123.86, 120.06, 119.89, 109.67, 101.97, 93.47,
86.28, 70.80, 70.53, 67.30, 36.15, 32.12, 31.47, 29.81, 29.71,
29.55, 29.46, 22.91, 14.34. MS (APPI): m/z 665.2 [M+H+].
4.1.38. 2-(4-Decylphenethyl)-4,6-dihydroxybenzoic acid (20)
Benzyl 2,4-bis(benzyloxy)-6-((4-decylphenyl)ethynyl)benzoate
(0.28 g, 0.42 mmol) was dissolved in EtOAc (due to low solubility
in MeOH) and added to 10 mol% Pd/C (10%) (45 mg, 42 nmol).
The suspension was shaken with 3 atm H2-pressure in a Parr appa-
ratus at 45 C for 24 h. Subsequently, the mixture was filtered
through Celite. The solvent was evaporated under reduced pres-
sure and the residue was purified by column chromatography with
heptane/EtOAc 9:1 (v/v) as eluent, followed by EtOAc as eluent to
obtain the desired product. Yield 72%. White solid. Rf = 0.40 (hep-
tane/EtOAc 1:1 + acetic acid). The product was more then 95% pure
as judged from TLC and NMR. 1H NMR (200 MHz, CD3OD) d 7.12–
7.02 (m, 4H), 6.18 (d, J = 2.4 Hz, 1H); 6.16 (d, J = 2.4 Hz, 1H),
3.18–3.10 (m, 2H), 2.83–2.75 (m, 2H), 2.62–2.48 (m, 2H), 1.60–
1.50 (m, 2H), 1.28–1.20 (m, 14H), 0.89 (t, J = 6.5, 3H).13C NMR
(50 MHz, CD3OD) d 167.82, 164.57, 150.02, 142.23, 141.60,
130.15, 112.86, 106.44, 102.82, 41.15, 40.02, 37.41, 33.93, 33.67,
31.59, 31.47 (2C), 31.31, 31.19, 24.59, 15.30. HRMS: m/z [MH]
calcd for C25H33O4 397.23843, found 397.2388.4.1.39. 2-(Benzo[d]oxazol-2-yl)phenol (26)
Salicylic acid (0.138 g, 1.0 mmol) was mixed with 2-aminophe-
nol (0.11 g, 1.0 mmol) and 3 mL of polyphosphoric acid was added
to the mixture. The mixture was heated in oil bath at 180 C under
N2 for 6.5 h. The reaction mixture was cooled to room temperature
and subsequently poured into 150 mL demi water. The mixture
was extracted with ethylacetate (2  30 mL). The combined organ-
ic layers were washed with demiwater (2  40 mL), brine
(1  40 mL), dried with MgSO4, filtered and concentrated in vacuo.
The product was obtained after crystallization or purification using
column chromatography with heptane/EtOAc 50:1 (v/v) as eluent.
Yield 47%. Colorless to white crystals. Rf = 0.69 (heptane/EtOAc
1:1). The product was more than 95% pure as judged from TLC
and NMR. 1H NMR (200 MHz, DMSO) d 8.04 (dd, J = 7.9, 1.7, 1H),
7.83-7.89 (m, 2H), 7.53–7.58 (m, 1H), 7.45–7.50 (m, 2H), 7.06–
7.16 (m, 2H).13C NMR (50 MHz, DMSO) 158.17, 151.40, 149.24,
139.90, 134.41, 128.04, 126.31, 125.77, 120.43, 119.64, 117.63,
111.50, 110.84. HRMS: m/z [M+H]+ calcd for C13H10O2N1
212.07061, found 212.07051.
4.2. Enzyme activity studies
4.2.1. Human 5-LOX inhibition screening UV assay
Enzyme inhibition was measured by the residual enzyme activ-
ity after 10 min incubation with the inhibitor at room temperature.
The enzyme activity was determined by conversion of lipoxyge-
nase substrate linoleic acid into hydroperoxy-octadecadienoate
(HPOD). The conversion rate was followed by UV absorbance of
the conjugated diene at 234 nm (e = 25000 M1 cm1) over a peri-
od of 20 min. The UV absorbance increase over time was used to
determine the enzyme activity.
Tris buffer (50 mM) pH 7.5 containing 2 mM EDTA and 2 mM
CaCl2 was used as an assay buffer for human 5-LOX experiments.
The human 5-LOX enzyme was diluted 1:4000 with the assay buf-
fer. The inhibitor (100 mM in DMSO) was diluted with the assay
buffer to 1 mM. The substrate, linoleic acid was diluted with EtOH
to 20 mM. Subsequently, 1 mL of enzyme solution (1:4000) was
mixed with 100 lL ATP (2 mM), 100 lL inhibitor (1 mM) and
790 lL Tris buffer and incubated for 10 min. After that the linoleic
acid solution (10 lL, 20 mM) was added to a mixture and the con-
version rate of the substrate was measured after 10 s mixing of the
enzyme with the substrate. The reaction rate in the absence of the
inhibitor was used as positive control. In the positive control
experiment, the assay buffer was supplemented with a small
amount of DMSO (3 lL of DMSO in 1.5 mL) in order to replace
the DMSO inhibitor solution, which was also pre-incubated for
10 min.
4.2.2. COX-2 inhibition screening assay
The COX-2 activity was measured spectrophotometrically by
measuring the formation of oxidized N,N,N0,N0-tetramethyl-p-
phenylenediamine (TMPD). Tris buffer (0.1 M) pH 8.0 was used
as an assay buffer for COX-2 experiments. The COX-2 enzyme
was diluted 1:1000 with the assay buffer. Hematin (7.5 mM in
DMSO) was diluted with assay buffer to 330 lM. The inhibitor
was diluted to 1.1 mM in DMSO. The substrate, arachidonic acid
was diluted by adding 50 lL KOH 0.1 M and 800 lL H2O into
150 lL of a 22 mM arachidonic acid solution in EtOH. The colori-
metric substrate TMPD (2.64 mM in H2O) was prepared freshly
prior to the experiment. The substrate, linoleic acid was diluted
with EtOH to 20 mM. Subsequently, in a 96 wells plate, 150 lL as-
say buffer, 10 lL hematin 330 lM, 10 lL COX-2 enzyme (1:1000)
was added. 10 lL inhibitor solution (1.1 mM in DMSO) was added
to the inhibitor well and 10 lL of DMSO was added to the positive
control wells. The plate was incubated for 5 min at room tempera-
ture. 20 lL of freshly prepared TMPD was added followed by the
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excluded from the negative control wells. The plate was incubated
for another 5 min at room temperature. The absorbance was mea-
sured at 550 nm, and the calculations were performed with Excel
2010. The experiments were performed in triplicate, and the pre-
sented results were the average of three measurements with the
standard deviation.
4.2.3. Michaelis Menten enzyme kinetics
The enzyme kinetics of human 5-LOX were also studied by the
formation of the conjugated diene product at 234 nm
(e = 25000 M1 cm1) using the same experimental setup as for
the concentration dependent and the inhibitor screening. Enzyme
kinetics were performed against linoleic acid and ATP to get a com-
plete indication about the regulation of human 5-LOX enzyme
activity.
In the kinetic study of the human 5-LOX against ATP, the ATP
concentration was varied between 12.5–200 lM while the con-
centration of linoleic acid was fixed (100 lM). In the kinetic
study of the human 5-LOX against the linoleic acid, substrate
concentration was varied between 37.5–300 lM. The enzyme
activity was measured in the absence or presence of fixed con-
centrations of activator 23a (0 lM, 12.5 lM, and 25 lM) or
inhibitor 23d (0 lM, 25 lM, and 50 lM). The reaction velocities
(v), which are the concentration changes over time, were plotted
against the substrate concentrations in Michaelis–Menten plots
and the Km and Vmax and the apparent values (K
app
m and K
app
max)
in the presence of the activator were derived. The results from
the non-linear curve fitting were in line with the results from
Lineweaver–Burk plot.
The slopes and y-intercepts from the Lineweaver–Burk plot of
h-5-LOX activation was derived and then re-plotted as 1/Dslope
or 1/Dy intercept versus 1/[activator]. From these plots a, b and
KA values were derived as described by Leskovac44 for non-essen-
tial activation. According to this method in the re-plot of 1/Dy
intercept versus 1/[activator] the y intercept corresponds to b
(Vmax/(b  1)), whereas in the re-plot of 1/Dslope versus 1/[activa-
tor] the y intercept correspond to bVmax/Km(b  a). The x intersec-
tion point of two lines from the plot of 1/Dy intercept and 1/Dslope
is b/aKA, which can be employed to derive the KA value if a and b
are known. All the experiments were performed in triplicate and
the average triplicate values and their standard deviations are plot-
ted. Calculations were performed with Excel 2010.
4.3. Docking studies
4.3.1. Protein and ligand structures
Structures of compounds 23a, 23b, 23c, and 23d were built
using Omega2 from OpenEye53 We fixed the rotatable bonds be-
tween the benzyl ring and the carboxylic acid group on all mole-
cules using AutoDockTools to dock structures that kept a planar
geometry for the benzyl ring and carboxylic acid.54
4.3.2. Docking and scoring
The receptor structure was prepared for docking using the pre-
pare_receptor4.py script from AutoDockTools. Compounds were
docked using smina55 with the default vina scoring function and
the argument ‘–num_modes = 40’. The docked poses were rescored
using the ‘–score_only’ command in smina and then reranked. The
top ranked poses were used for further analysis.
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APPENDIX C  SCRIPT FOR COMPUTING RESIDUE OVERLAPS IN MDS 
 
The following Python script was used to compute the overlaps of the p53 residues as shown in 
Figure 2.2. 
 
#Python for computing the fractional overlap of the p53 residues. 
#Part of the Supplemental information for: 
#Baumgartner, MP and Camacho, CJ. "The atomistic induced-fit binding 
mechanism of p53 to MDM2"  
 
#by Matthew Baumgartner 
#1-11-16 
 
 
 
import sys 
import os 
import argparse 
import math 
 
#control how much debugging information is printed 
DEBUG = 2 
 
def main(): 
     
    parser = argparse.ArgumentParser(description = 'Compute the overlap of 
md frames to an input structure (ex. smisp)') 
    parser.add_argument('-s', dest = 'residues', type = str, help = 'residues 
to check overlap of') 
    parser.add_argument('-l', dest = 'frame_list',  help = 'list of frames') 
    parser.add_argument('-ot', dest = 'outtext', help = 'output text file') 
    parser.add_argument('-o', dest = 'outfile',  help = 'output pdb file') 
    parser.add_argument('-start', dest = 'start', default = 0, type = float, 
help = 'optional, choose a starting from to start at') 
    parser.add_argument('-end', dest = 'end', default = -1, type = float, 
help = 'optional, choose a starting from to end at') 
    parser.add_argument('--redo', dest = 'redo', action = 'store_const', 
const = True, default = False, help = 'If specified, ignore any saved results 
and recompute (Default: False)') 
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    args = parser.parse_args() 
     
    resfile = args.residues 
    frame_list = args.frame_list 
    outfile = args.outtext 
    phe_outfile = args.outfile  
    start = int(args.start) 
    end = int(args.end) 
    REDO = args.redo 
    
#https://www.rbvi.ucsf.edu/chimera/docs/UsersGuide/midas/vdwtables.html#all
atom 
    vdw = {'C' : 1.7, 
       'N' : 1.625, 
       'O' : 1.48, 
       'S' : 1.782, 
       'H' : 1.00, 
       'P' : 1.871, 
       'F' : 1.56, 
       'Cl' : 1.735, 
       'CL' : 1.735, 
       'Br' : 1.978, 
       'BR' : 1.978, 
       'I' : 2.094} 
     
    if not REDO: 
        if os.path.exists(outfile): 
            print 'Output file:', outfile, 'already exists, non-
recomputing!\nRun with --redo to force recompute' 
            sys.exit() 
         
 
    res_atoms = [ map(float,[ line[30:38], line[38:46], line[46:54]]) for 
line in open(resfile).readlines() if (line.startswith('ATOM') or 
line.startswith('HETATM')) ] 
     
    #proceed each atom name with the resid to avoid collisions 
    res_atom_names = [ line[12:16].strip() + '_' + line[22:26].strip() for 
line in open(resfile).readlines() if (line.startswith('ATOM') or 
line.startswith('HETATM')) ]  
     
    #Get the atom tyes from the last column 
    res_atom_type = [ line[76:80].strip().strip('-+0123456789') for line in 
open(resfile).readlines() if (line.startswith('ATOM') or 
line.startswith('HETATM')) ] 
     
    #read in text file that lists the absolute paths of the pdb files of the 
frames. I used mdpocket from fpocket to split the simulation and create the 
input file 
    frames = [ line.strip() for line in open(frame_list).readlines() ] 
     
    #the frames in which an atom is over lapped 
    frame_overlaps = { nm : [] for nm in res_atom_names } 
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    for frame_id, frame in enumerate(frames): 
         
        #check to see if you are inside the range you want to be 
        if frame_id < start: 
            continue 
        if end != -1: 
            if frame_id >= end: 
                continue 
         
         
        if frame_id > 0: 
            if DEBUG > 2: 
                print 'frame:', frame_id, 'frame:', frame 
             
            for line in open(frame).xreadlines(): 
                if line.startswith('ATOM'): 
                    atom_name = line[12:16].strip() 
                    if not atom_name.startswith('H'): #skip hydrogens 
                        traj_coor = map(float, [line[30:38], line[38:46], 
line[46:54]]) 
                         
                        for i,res_coor in enumerate(res_atoms): 
                            res_name = res_atom_names[i] 
                            res_vdw = vdw[res_atom_type[i]] #vdw of the first 
letter (element) 
                             
                            #distance 
                            dist = math.sqrt((res_coor[0] - traj_coor[0])**2 
+ (res_coor[1] - traj_coor[1])**2 + (res_coor[2] - traj_coor[2])**2) 
                             
                            #if it is closer than the vdw 
                            if dist < res_vdw: 
                                #get the residue number of the overlapping 
atom 
                                traj_resid = int(line[22:26].strip()) 
                                 
                                #if you haven't added one already 
                                if len(frame_overlaps[res_name]) < frame_id: 
 
                                    
frame_overlaps[res_name].append(traj_resid) 
                                 
#                                break 
                     
            #if you didn't find any overlapping atoms, add a 0 to the list 
            for res_name in res_atom_names: 
                if DEBUG > 2: 
                    print res_name, 'overlap len:', 
len(frame_overlaps[res_name]) 
                if len(frame_overlaps[res_name]) < frame_id: 
                    frame_overlaps[res_name].append(0) 
                     
         
    atom_names = [] 
    lists = [] 
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     for res_name, overlapped in frame_overlaps.iteritems(): 
        if DEBUG > 2: 
            print res_name, ':',  overlapped    
            print len(overlapped) 
        atom_names.append(res_name) 
        lists.append(overlapped) 
         
         
    fout = open(outfile, 'w') 
      
    if start == 0 and end == -1: 
     
        #print the header 
        header = 'Frame\t' + '\t'.join(atom_names) + '\n' 
        fout.write(header) 
         
        for i in range(len(lists[0])): # 
            str_line = str(i) 
             
            for lst in lists: 
                str_line += '\t' + str(lst[i]) 
                 
            fout.write(str_line + '\n') 
        fout.close() 
         
        if DEBUG > 2: 
            print outfile, 'written' 
             
             
         
    #write out the residue again but put the perc overlapped in the b factor 
field 
    name_perc = {} 
    if DEBUG > 2: 
        print 'Calculating the percent overlapped' 
    for i,lst in enumerate(lists): 
        non_zero = len([ x for x in lst if x != 0 ]) 
        perc_overlapped = float(non_zero) / len(lst) 
        if DEBUG > 2: 
            print atom_names[i], perc_overlapped 
        name_perc[atom_names[i]] = perc_overlapped 
         
     
    output = [] 
     
    for line in open(resfile).readlines(): 
        if not (line.startswith('ATOM') or line.startswith('HETATM')): 
            output.append(line) 
        elif line[76:80].strip().strip('-+0123456789').startswith('H'): 
            output.append(line) 
        else: 
            atom_name = line[12:16].strip() + '_' + line[22:26].strip() 
            b_fac = '  ' + '%03.2f' % round(name_perc[atom_name],2) 
         
            new_line = line[:60] + b_fac + line[66:] 
            output.append(new_line) 
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    fout = open(phe_outfile, 'w') 
    fout.write(''.join(output)) 
    fout.close() 
     
    print phe_outfile, 'written' 
         
         
         
         
         
if __name__ == '__main__': 
    main() 
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